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ABSTRACT  
Human induced pluripotent stem cells (hiPSCs) hold great promise in regenerative 
medicine as they have the potential to differentiate into any specialized cell type and 
retain unlimited self-renewal capacity in vitro. The use of hiPSC-derived 
lymphocytes for adoptive cell transfer therapies is appealing as it provides a 
potentially indefinite cell source and a platform for genetically modifying cells. 
Natural killer (NK) cell-based therapy has shown promising results in the treatment 
of haematological malignancies and the unlimited derivation of NK cells from 
hiPSCs could overcome the current obstacle of insufficient NK cell numbers for 
cellular anti-cancer immunotherapy. In this study, we initially used a two-stage 
culture system to differentiate human pluripotent stem cells (hPSCs) into NK cells. 
First, haematopoietic stem cells (HSCs) were derived by co-culture with murine OP9 
stromal cells. The CD34-expressing fraction was enriched with magnetic activated 
cell sorting (MACS) and phenotypically characterised by cell surface marker 
expression. Colony forming unit (CFU) assay confirmed that hPSC-derived CD34+ 
cells had multi-lineage differentiation potential. Subsequently, HSCs were co-
cultured with murine EL08.1D2 feeder cells and under feeder-free conditions with 
GBGM medium to generate NK like cells. Interestingly, we observed a 100-fold 
lower cell expansion of hiPSC-derived CD34+ cells in NK cell differentiation 
conditions compared to umbilical cord blood (UCB)-derived CD34+ cells. Despite 
this observation the phenotype of hiPSC-derived NK like cells was comparable to 
UCB CD34+-derived NK cells and freshly isolated peripheral blood natural killer cells 
(PBNKs). As an alternative to the two-stage culture system, we aimed to drive NK 
cell differentiation by overexpressing the NK cell-specific transcription factor E4bp4 
during in vitro derivation. Our data suggest that the overexpression of E4bp4 does 
not improve the efficiency of hiPSC-derived NK like cell differentiation, nor can 
E4bp4 alone induce the NK cell-specific transcriptional network in fibroblasts. 
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Chapter 1 Introduction 
Immunotherapy aims to activate the body’s own immune system to fight cancer cells 
and to obtain long-lasting response in cancer patients. In addition to conventional 
therapies such as surgery, radio- and chemo-therapy, new approaches to hinder the 
reoccurrence of cancer cells need to be addressed. In recent years enormous 
advances have been made in fighting cancer by the exploitation of different 
components of the immune system.  
NK (natural killer) cells have originally been described as CD56 positive, CD3 
negative lymphocytes of the innate immune system, which recognise and kill virus-
infected and tumour cells without prior sensitisation to antigens (Kiessling, Klein et 
al. 1975). NK cells comprise 5-15% of mononuclear cells in peripheral blood. 
Circulating NK cells have been divided into two main subsets: CD56bright and 
CD56dim  based on the intensity of CD56 expression (Lanier, Phillips et al. 1986) 
(Figure 1.1). Each subset has distinct phenotypic properties. The majority (~90%) of 
circulating NK cells have low CD56 expression (CD56dim) and express CD16 (Fcƴ 
Receptor III) whereas the CD56bright CD16- population mainly secretes cytokines to 
support the adaptive immunity. However, recent findings suggest that the functional 
and phenotypic diversity of mature NK cells is much broader than expected so far.  
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Figure 1.1 Flow cytometric analysis of CD56bright and CD56dim natural killer 
(NK) cells. CD56bright NK cells comprise of between 5-15% of human peripheral 
blood NK cells and are CD16− or CD16dim. The majority (around 90%) of NK cells is 
CD56dim and expresses CD16. (Cooper, Fehniger et al. 2001). 
 
 Tissue-specific NK cells 1.1
 
A significantly large number of NK cells is found in the spleen, liver, gut, and uterus 
(Freud and Caligiuri 2006) (Shi, Ljunggren et al. 2011). Recent studies of NK cell 
populations from various organs have identified distinct, tissue-specific populations 
of NK cells. 
The gastrointestinal tract harbours a unique range of lymphocytes responsible for 
specific immunological requirements in the intestine. Intestinal lymphocytes include 
conventional single-positive CD4+ and CD8+ T cells, as well as unique populations 
of double positive and double-negative T cells (Tait Wojno and Artis 2012). 
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Intestinal NK cells, from mice and humans, include a distinct subset of cells known 
as NK22 cells that is identified by the expression of NKp46 which is known to have 
a role in tissue remodelling (Cella, Fuchs et al. 2009). Neither human nor murine 
mucosal NK22 cells produce IFN-ƴ or perforins and exhibit reduced cytotoxicity 
(Colonna 2009). Additionally, they express the mucosa-homing chemokine receptor 
CCR6 and TF Rorƴt consistent with their localisation (Cella, Fuchs et al. 2009) 
(Williams 2006). 
Pulmonary NK cells play a major role in pathology of several respiratory conditions, 
including influenza, asthma, tuberculosis, and others. The maintenance of NK cells 
in the mucosal layers of lungs is dependent on IL-15, produced by the alveolar 
macrophages, as shown in murine models, or by human bronchial epithelial cells, 
as shown in vitro  (Allavena, Giardina et al. 1997) (Ge, Nishioka et al. 2004). 
Several reports have shown that pulmonary NK cells are recruited from the 
periphery to the lungs upon infection; however, evidence of tissue-specific 
pulmonary NK cells, phenotypically distinct from those found in the blood, is also 
accumulating (Wang, Li et al. 2012). In murine, 70% of lung NK cells express low 
levels of CD27 and high levels of CD11b and are capable of producing high levels 
of IFN-ƴ. They also express higher levels of inhibitory CD94/NKG2A and Ly49 
receptors, which facilitate steady-state tolerance of the lung NK cells to daily 
exposure to non-pathogenic agents (Wang, Li et al. 2012). In humans, less is known 
about pulmonary NK cells, although NK cells isolated from pleural effusion of 
Mycobacterium tuberculosis-infected patients were CD56brightCD16-perforinlow and 
capable of producing high levels of IFN-ƴ (Schierloh, Yokobori et al. 2005). 
 
The liver also hosts significant populations of NKR-expressing lymphoid cells 
including CD8+ T as well as classical NK cells, reflecting its requirement to fight 
hepatotrophic infections, as well as malignancy and metastases. Hepatic NK cells 
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also known as “pit” cells comprise 30-50% of the lymphocyte compartment (Norris, 
Collins et al. 1998). Human liver-specific NK cells are mainly CD56brightCD16- and 
express high levels of CD94/NKG2A and decreased KIR (Moroso, Metselaar et al. 
2010). 
 
In the uterus, NK cells play a critical role in pregnancy, as well as protecting the 
non-pregnant uterus against infection and malignancy. Uterine immune cell 
populations are mainly composed of macrophages and T cells but also include 
significant populations of NK cells (Bulmer and Lash 2005). uNK (uterine) cells are 
granular cytotoxic cells that are crucial in supporting angiogenesis during 
placentation (Chazara, Xiong et al. 2011). Phenotypically, uNK cells are CD56bright, 
CD16-, and CD94+ and contain high numbers of cytolytic granules. Compared with 
PBNK cells, uNK cells include significantly higher proportions of (killer-
immunoglobin like receptors) KIR2D-double-positive cells that recognize non-
classical HLA-C (human leukocyte antigen) molecules expressed by trophoblast 
cells (Male, Sharkey et al. 2011). In general, the uNKR repertoire does not differ 
significantly between pregnant and non-pregnant stages, with the exception of 
CD161, which is lower in dNK cells (so called during pregnancy), and CD69, shown 
to be lower in uNK cells (Male, Sharkey et al. 2011). dNK cells are potent producers 
of IFN-ƴ, which is required for spiral artery remodelling during implantation (Moffett-
King 2002). uNK cells are also prominent producers of tissue-remodelling factors, 
such as vascular endothelial growth factor C, placental growth factor, TGF-β1, Ang 
1, and Ang 2 (Lash, Schiessl et al. 2006).  
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 Target recognition by NK cells 1.2
 
Unlike B and T cells, NK cells belong to the innate immune system and do not 
express somatically rearranged receptors specific for antigens. NK cell-specific 
receptors are germ line-encoded and include a variety of activating and inhibitory 
receptors. The most significant receptors are the killer-immunoglobin like receptors 
(KIR) that recognise human leukocyte antigen (HLA) class I proteins (HLA-A, -B and 
–C) (Vilches and Parham 2002). KIRs also play a pivotal role in the education 
process of NK cells where cells are primed to distinguish between self and non-self. 
Only after NK cells have contact with self-HLA molecules do they become 
functionally competent in a process called licensing (Fernandez, Treiner et al. 2005) 
(Kim, Poursine-Laurent et al. 2005). Individuals can have up to 15 KIR genes and 
the intracellular domain can either transmit an inhibitory or activating signal. Another 
inhibitory receptor expressed on NK cells is the heterodimer CD94/NKG2A with its 
counterpart NKG2C as an activating receptor, both recognizing HLA-E (Bryceson, 
March et al. 2006). 
Most receptors bind their ligand through Ig domains, except for NKG2 homo- and 
heterodimers which have C-type lectin-binding domains. Inhibitory receptors have 
intracellular domains with multiple immune-receptor tyrosine-based inhibitory motifs 
(ITIMs) and many activating receptors possess intracellular domains containing 
immune-receptor tyrosine-based activation motifs (ITAMs). NKG2D and 2B4 
receptors signal via tyrosine residues of the tyrosine-x-x-methionine (YxxM) and 
immune-receptor tyrosine-based switch motifs (ITSMs), respectively. DNAM-1 
signalling involves phosphorylation of Ser329 by protein kinase C. 
To contribute to the first line of defence, NK cells are poised ready to attack infected 
or malignant cells. This immediate response capacity of NK cells may present a 
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danger to healthy cells in the event of inappropriate NK cell activation, and 
consequently the process of NK cell activation is tightly regulated. Part of this 
regulation is inherent in the type of receptors that NK cells use to recognize and 
respond to target cells. Two suggested hypotheses of NK cell activation are the 
‘missing self’ and ‘induced self’ theories as described in Figure 1.2 (Ljunggren and 
Karre 1990) (Watzl 2003). 
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Figure 1.2 Target cell recognition by NK cells. (A) When the NK cell interacts 
with a normal (self) cell, activating signals might be triggered. However, the NK cell 
will not lyse the cell because it expresses self-MHC class I alleles. (B) Cells can 
lose the expression of MHC class I molecules because of viral infection or 
cancerous transformation. Consequently, the MHC-binding inhibitory receptor at the 
surface of the NK cell is not engaged and no inhibitory signals are transmitted. This 
process is known as the missing-self theory and results in killing of the target cell. 
(C) If the NK cell engages with allogeneic (non-self) cells, which express foreign 
MHC class I alleles, the target cell will be lysed because of insufficient inhibitory 
receptor binding (Kumar and McNerney 2005). 
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 NK cell receptor repertoire 1.3
1.3.1 Activating and Inhibitory receptors 
NK cell activation programs result from the integration of multiple inhibitory (table 
1.1) and activating (table 1.2) signals that vary depending on the nature of the 
interacting cells. These signals involve ITAM (immunoreceptor tyrosine-based 
activation motif)-bearing molecules and other stimulatory receptors and adhesion 
molecules, as well as (intracellular immunoreceptor tyrosine-based inhibitory motifs) 
ITIM. Inhibitory receptors signal through ITIM located in the cytoplasmic tail of these 
receptors. Commonly, Src homology 2 domain containing phosphatases (SHP1 or 
2) are recruited after phosphorylation of a tyrosine residue (Tomasello, Blery et al. 
2000). How inhibitory signals interfere with activating signals remains unclear, but 
recent reports suggest that ITIM-mediated signalling result in both 
dephosphorylation and specific phosphorylation of intracellular components. One 
recent report implicated b-arrestin 2 in the inhibition of NK cell activation, through 
the recruitment of SHP1 and SHP2 (Yu, Su et al. 2008). Another report suggested 
that a common point of NK cell activation signalling could be targeted, in which a 
SHP1 phosphorylation site (Vav1) could be de-phosphorylated during inhibitory 
signalling. This report showed that inhibitory signalling can prevent not only NK cell-
mediated cytotoxicity, but also interfere with adhesion of NK cells to target cells 
(Bryceson, Ljunggren et al. 2009). In contrast, Long and Peterson (Peterson and 
Long 2008) have described the specific phosphorylation of a tyrosine adapter, Crk, 
as a result of ITIM engagement. Therefore, it is now clear that while ITIM signalling 
prevents intracellular phosphorylation, it is likely to involve more complex signalling 
than originally thought.  
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Receptor Ligands 
KIR2DL1 HLA-C2 
KIR2DL2/3 HLA-C1 
KIR2DL5 ? 
KIR3DL1 HLA-Bw4 
KIR3DL2 HLA-A3, -A11 
CD94-NKG2A HLA-E 
LILR MHC class1, UL-18 
LAIR1 Collagen 
SIGLEC-3/-7/-9 Sialic acid 
KLRG1 Cadherins 
NKR-P1A (KLRB1) CLEC2D (LLTI) 
Table 1.1 NK cell inhibitory receptors. 
 
Activating receptors on the cell surface of NK cells recognize ligands expressed on 
tumour-transformed or virally infected cells. The natural cytotoxicity receptors (NCR) 
bind to viral ligands, heat-shock associated proteins or tumour antigens and include 
NKp30, NKp44 and NKp46 (Pende, Parolini et al. 1999; Mandelboim, Lieberman et 
al. 2001; Baychelier, Sennepin et al. 2013). NKG2D is another essential activating 
receptor expressed on all NK cells and recognizes the major histocompatibility 
complex class I chain-related genes A and B (MICA and MICB) and UL16 binding 
protein family members 1-6 (ULBP1—6) (Cosman, Mullberg et al. 2001). Some 
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activating receptors signal through immunoreceptor tyrosine-based activating motifs 
(ITAMs), although these are not contained in the receptors’ cytoplasmic tails but 
rather in associated molecules. After phosphorylation of a tyrosine residue in the 
tail, the Src homology 2 domain containing kinases (Syk or ZAP70) are recruited 
leading to a signal cascade which results in de-granulation and transcription of 
cytokine and chemokine genes (Tomasello, Blery et al. 2000). 
 
Receptor Ligands 
KIR2DL4 HLA-G 
KIR2DS1 HLA-C2 
KIR2DS2 HLA-C1 
KIR2DS3 unknown 
KIR2DS4 unknown 
KIR2DS5 unkown 
KIR3DS1 HLA-Bw4 
CD94-NKG2C HLA-E 
CD94-NKG2D MIC-A/-B, ULBP 1/2/3/4 
CD94-NKG2E HLA-E 
CD160 HLA-C 
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NKp30 BAT-3, HSPG, B7-H6, CMV-pp65 
NKp44 Viral HA 
NKp46 Viral HA, HSPG 
NKp80 AICL 
DNAM-1 PVR, CD122, Nectin 2 
2B4 act/inh CD48 
CD16 IgG 
Table 1.2 NK cell activating receptors.  
 
A third activation/inhibition signalling pathway results from stimulation of the CD244 
(2B4) receptor. This cytoplasmic tail of this receptor contains an immunoreceptor 
tyrosine-based switch motif, which recruit Src homology 2 domain containing 
adapter proteins SAP or ERT (Veillette 2006). Recruitment of SAP results in 
activation of NK cell function, wherein recruitment of ERT inhibits NK cell function. 
A family of molecules that bind nectin and nectin-like proteins has recently emerged 
and have been shown to function as an important regulator of NK cell functions. 
These molecules include CD226, T cell immunoreceptor with immunoglobulin and 
ITIM domains (TIGIT), CD96, and cytotoxic and regulatory T cell molecule 
(CRTAM). 
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1.3.2 DNAM-1 receptor 
DNAM-1 receptor, also known as CD226, is a member of the Ig-superfamily and is 
constitutively expressed on approximately 50% of NK cells (Shibuya, Campbell et 
al. 1996). The ligands for this co-stimulatory activating receptor are CD155 (also 
referred to as Polio virus receptor, PVR or Necl-5) and CD112 (Nectin-2), and these 
ligands can be upregulated on some tumour cells, implicating DNAM-1 in some NK 
cell-mediated anti-tumour responses (Bottino, Castriconi et al. 2003) (Tahara-
Hanaoka, Shibuya et al. 2004) (Masson, Jarry et al. 2001). In addition, DNAM-1 has 
been shown to be involved in the lysis of tumour cells that do not express ligands for 
NK cell-activating receptors, this therefore broadens the scope of tumours 
susceptible to NK cell-mediated responses, and suggests this receptor is more than 
just co-stimulatory (Gilfillan, Chan et al. 2008).   
In humans, CD96 expression is confined chiefly to NK cells, CD8+ T cells and CD4+ 
T cells (Wang, O'Farrell et al. 1992). CD96 shares sequence similarity with CD226 
and competes for binding to CD155 (Martinet and Smyth 2015). A recent study has 
found that CD96 competed with CD226 for CD155 binding and limited NK cell 
function by direct inhibition. As a result, CD96−/− mice displayed hyper-
inflammatory responses to the bacterial product lipopolysaccharide (LPS) and 
resistance to carcinogenesis and experimental lung metastases. Their data 
provided the first description of the ability of CD96 to negatively control cytokine 
responses by NK cells (Chan, Martinet et al. 2014). Blocking CD96 may have 
applications in pathologies in which NK cells are important.  
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1.3.3 TIGIT  
It was recently shown that a new inhibitory receptor, named T-cell immunoglobulin 
and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT), is 
expressed mainly on T cells and NK cells (Yu, Harden et al. 2009) (Boles, Vermi et 
al. 2009) (Stanietsky, Simic et al. 2009). Poliovirus receptor (PVR, also known as 
CD155) is identified as the physical ligand of TIGIT, and TIGIT/PVR engagement 
suppresses T-cell activation through regulation of IL-10 secretion by dendritic cells 
(Yu, Harden et al. 2009). TIGIT also has an intrinsic inhibitory function to T cells 
independent of antigen-presenting cells (Joller, Hafler et al. 2011) (Lozano, 
Dominguez-Villar et al. 2012). Additionally, the activation of TIGIT signaling can 
downregulate IFN-γ secretion and cytotoxicity in both human and mouse NK cells 
(Stanietsky, Simic et al. 2009) (Stanietsky, Rovis et al. 2013). Recently, it was 
reported that TIGIT alleviates liver injury through negatively regulating NK-cell 
activation in murine acute viral hepatitis and also that TIGIT is a safeguard molecule 
to improve liver regeneration through negatively regulating NK–hepatocyte crosstalk 
(Bi, Zhang et al. 2014) (Bi, Zheng et al. 2014). Furthermore, regulatory T cells, also 
through expression of the co-inhibitory molecule TIGIT, selectively inhibit pro-
inflammatory Th1 and Th17 cell responses (Joller, Lozano et al. 2014). 
1.3.4 Cytotoxic and regulatory T cell molecule (CRTAM) 
CRTAM was discovered in 2000 using a cDNA library generated from NK and T 
cells (Kennedy, Vicari et al. 2000). The structure of CRTAM has some similarity to 
CD226 as it contains two extracellular immunoglobulin-like domains. Only one 
CRTAM ligand has so far been described, the nectin-like family member 2 (NECL2; 
also known as CADM1 and TSLC1). Unlike CD226 and CD96, CRTAM is not 
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expressed by resting NK cells but expression of this receptor is rapidly and 
transiently upregulated following NK cell activation (Arase, Takeuchi et al. 2005). 
CRTAM has been shown to enhance NK cell adhesion and cytotoxicity and to 
trigger the rejection of NECL2-expressing targets in vivo (Boles, Barchet et al. 
2005). The generation of Crtam−/− mice revealed that CRTAM has a pivotal role in 
CD8+ T cell retention within peripheral lymph nodes by favouring interactions with 
NECL2-expressing CD8α+ dendritic cells (DCs) (Takeuchi, Itoh et al. 2009). CRTAM 
is also involved in stabilizing the conjugation between CD4+ T cells and DCs. A 
recent study revealed that CRTAM interacts with the cell polarity regulator SCRIB to 
maintain T cell polarity after the early phase of T cell activation (Yeh, Sidhu et al. 
2008).  
 NK cell effector functions 1.4
 
Conventional NK cells have been classified as members of the group 1 innate 
lymphoid cells (ILCs). Group 1 ILCs are defined by their ability to secrete IFN-γ in 
contrast to group 2 ILCs which secrete IL-13 and group 3 ILCs which produce IL-17 
or IL-22 (Spits, Artis et al. 2013). ILCs are a growing family of immune cells that 
mirror the phenotypes and functions of T cells. NK cells can be considered the 
innate counterparts of cytotoxic CD8+ T cells, whereas ILC1s, ILC2s, and ILC3s 
may represent the innate counterparts of CD4+Thelper1 (TH1), TH2, and TH17 
cells. However, in contrast to T cells, ILCs do not express antigen receptors or 
undergo clonal selection and expansion when stimulated (Spits, Artis et al. 2013). 
Instead, ILCs react promptly to signals from infected or injured tissues and produce 
an array of secreted proteins, termed cytokines that direct the developing immune-
response into one that is adapted to the original insult (Figure 1.3). 
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Figure 1.3 Effector functions of innate lymphoid cells (ILCs). (Eberl, Colonna et 
al. 2015). 
 
Innate lymphoid cells (ILCs) differentiate from haematopoietic stem cells, via an 
ID2+ precursor cell, under the influence of cytokines such as interleukin‑7 (IL‑7), IL‑
15, IL‑23, IL‑25 and IL‑33. These signals induce the expression of transcription 
factors that promote the differentiation of the various ILC subsets (group 1, 2 and 3 
ILCs) and induce their expression of signature cytokines. The cytokines secreted by 
ILCs promote important physiological responses, such as wound healing, tumour 
surveillance and protection against infections. However, ILC-derived cytokines can 
also promote immunopathology in diseases such as asthma and inflammatory 
bowel diseases (IBDs) (Walker, Barlow et al. 2013). 
NK cells have four major effector functions: (1) the secretion of cytokines, (2) the 
release of perforins and granzyme, (3) killing through apoptotic pathways using 
FasL and TRAIL and antibody-dependent cellular cytotoxicity (ADCC) via the 
expression of FcγRIIIA (CD16) on their cell surface.  
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1.4.1 Secretion of cytokines  
An essential function of NK cells especially early in viral infections, is to release 
antiviral cytokines, such as IFN-γ and TNF-α (Alter, Malenfant et al. 2004), as 
immune-defensive agents that additionally serve to activate resident inflammatory 
cells and recruit other cells (Biron, Nguyen et al. 1999). These NK cell-sourced 
cytokines also regulate dendritic cells, T cells, and B cells (Vivier, Tomasello et al. 
2008) and regulate TNF-mediated apoptosis of the NK cells and neighbouring cells 
to delimit immune responses (Ross and Caligiuri 1997). Thus, cytokine production 
by NK cells influences both innate and adaptive immune responses (Degli-Esposti 
and Smyth 2005). Parenthetically, the uncontrolled release of TNF and other pro 
inflammatory cytokines in acute and chronic inflammatory disease is a major cause 
of ongoing tissue damage, pain, and fatality in these conditions (Bradley 2008). 
Uncontrolled cytokine release by NK cells and other cells together with defective 
granule release and target cell killing are concomitant features of hemophagocytosis 
and lymphohistocytosis in humans and in mouse models (Haddad, Wu et al. 2001) 
(Ishii, Ueda et al. 2005). Cytokine secretion is therefore central to immunity and to 
immunopathologies. Despite their importance, little is known about how cytokines 
are secreted by NK cells.  
1.4.2 Release of perforin and granzyme  
NK cells are renowned for their ability to kill virally infected or transformed host cells 
by release of cytotoxic granules containing granzymes and perforin. As a subset of 
cytotoxic lymphocytes, NK cells recognize and destroy malignant and virally infected 
cells (Cerwenka and Lanier 2001) (Lanier 2008). NK cells respond to signals 
generated by activating and inhibitory receptors on their surfaces to constrain killing 
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to appropriate target cells. Upon making contact with an appropriate target, NK cells 
release the membrane-disrupting protein, perforin, and proteolytic serine proteases, 
the granzymes, from secretory granules (Trapani and Smyth 2002).   
1.4.3 Killing through apoptotic pathways using FasL and TRAIL 
NK cells also use FasL and TRAIL to lyse different cells. FasL is constitutively 
expressed or induced upon interaction with target cells and induces Ca2+ 
independent, Fas (CD95/Apo1)-mediated apoptosis. Additionally, TRAIL transduces 
apoptotic signals upon binding their soluble ligand, the TNF-related apoptosis-
inducing ligand (TRAIL). Fas ligand (FasL)-mediated cytotoxicity is initiated by NK 
cells through ligation of their activating receptors. FasL-mediated cytotoxicity is 
specifically directed against Fas- expressing target cells and is initiated by ligation of 
surface-bound homotrimeric FasL to the Fas receptor expressed on the target cell 
surface. This initiates the recruitment of “death domain” containing proteins, 
resulting in activation of the caspase cascade (Ashkenazi and Dixit 1998). The 
apoptotic cell presents with DNA fragmentation, nuclear membrane and cytoskeletal 
breakdown, plasma membrane blebbing, and the formation of membrane- enclosed 
apoptotic bodies, which are rapidly phagocytosed by neighbouring cells such as 
macrophages (Smyth and Trapani 1995) (Steller 1998). In addition, because 
cytotoxic lymphocytes, including NK cells, express Fas, the Fas/FasL apoptotic 
pathway may also play an important role in downregulating the immune response. 
This occurs by inducing FasL-mediated apoptosis in NK cells after the upregulation 
of FasL, leading to activation induced cell death (AICD) (Lynch, Ramsdell et al. 
1995). The upregulation of both FasL mRNA expression and cytotoxicity have been 
shown to involve activation through the CD16 (FcγRIIIA) receptor in the presence of 
interleukin IL-2 stimulation (Ortaldo, Mason et al. 1995). 
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TRAIL, was first described as a cytokine capable of inducing apoptosis in a wide 
variety of cancer cells while sparing normal cells. However, its main role seems to 
be regulation of the immune response (Corazza, Brumatti et al. 2004). The role of 
endogenous TRAIL in tumour immune surveillance is not fully understood yet. A few 
in vitro studies have clearly shown that NK cells are able to kill cancer cells using 
TRAIL (Takeda, Smyth et al. 2001) (Cretney, Takeda et al. 2002).  
 
 Human NK Cell Development 1.5
 
NK cells have a short half-life of less than 10 days. They are continuously 
replenished through differentiation from haematopoietic stem cells in the bone 
marrow (BM) and specific subtypes reside in the liver, uterus and to lesser extend in 
the lymph nodes and thymus (Yu, Freud et al. 2013). NK cells primarily develop in 
the bone marrow, thymus and lymph nodes and the resident and recruited NK cells 
play an important role in immunosurveillance and homeostasis of mucosal surfaces 
(Vivier, Tomasello et al. 2008; Colonna 2009). The development of NK cells occurs 
in a series of maturation steps that result in the acquisition of specific functionality. 
The schematic representation of human NK cell development is summarised in 
Figure 1.4.   
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Figure 1.4 Schematic overview of human NK cell development. Memory NK 
cells are displayed as a possible terminal stage of maturation (stage 6). (Yu, Freud 
et al. 2013). 
 
Human NK cells develop from BM-derived HSCs via a common lymphoid progenitor 
which has the potential to differentiate into all lymphocyte lineages (Blom and Spits 
2006). Human HSCs are defined as CD34+CD38dim/-CD45RA-CD10- and CLPs as 
CD34+CD38+CD45RA+CD10+ within the BM-derived haematopoietic progenitor cell 
(HPC) pool (Galy, Travis et al. 1995). An important step in human NK cell 
development is the acquisition of IL-15 receptor β chain (CD122). IL-15 promotes 
NK cell development, maturation and survival (Becknell and Caligiuri 2005). Both 
stage 2 and 3 precursor cells respond to IL-15 and can give rise to mature NK cells 
in vitro. In the late stages of NK cell development, acquisition of functional receptors 
occurs. CD56, CD94, NKp46 and NKG2D are upregulated in the first maturation 
steps, followed by KIRs and CD16 (Freud and Caligiuri 2006) (Grzywacz, Kataria et 
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al. 2006). Mature NK cell subsets (stage 4 and 5) differ in their surface marker 
expression and functionality and have been characterised as CD56dim and CD56bright 
(Cooper, Fehniger et al. 2001). Studies suggest that CD56bright NK cells are 
precursors to CD56dim NK cells (Caligiuri 2008) (Huntington, Legrand et al. 2009). 
CD56bright NK cells are more prevalent in umbilical cord blood and neonatal tissues 
whereas the CD56dim NK cell population increases later in life and exhibits shorter 
telomers (Romagnani, Juelke et al. 2007). Although NK cells are classified as cells 
of the innate immune system, it is believed that they can exhibit memory function. In 
humans, memory NK cells could be described as the final stage of NK cell 
maturation, although the origin within the stages of NK cell differentiation is not clear 
yet (Romee, Schneider et al. 2012). Recently it has been demonstrated that mature 
NK cells possess characteristics of immunological memory, including antigen-
specific response - similar to B and T cells – and antigen-independent memory 
induced by exposure to a specific cytokine milieu. Antigen-specific NK cell memory 
was first demonstrated in the setting of hapten-induced contact hypersensitivity in 
RAG2-deficient mice, lacking B and T cells (O'Leary, Goodarzi et al. 2006) (Paust, 
Gill et al. 2010). In these studies it was shown that NK cells were responsible for the 
secondary response and that a subset of hepatic NK cells mediated the response. 
Importantly, antigen-specificity of NK cells has further been demonstrated for the 
germline-encoded activating receptor Ly49H, which uniquely recognises the MCMV-
encoded glycoprotein m157 and receptor-ligand interaction results in the activation 
and proliferation of Ly49H+ NK cells (Arase, Mocarski et al. 2002) (Smith, Heusel et 
al. 2002) (Brown, Dokun et al. 2001). The adoptive transfer of Ly49 H+ NK cells into 
mice lacking the receptor revealed expansion of this specific NK cell subset within 1 
week following MCMV infection and a pool of memory NK cells persisted in both 
lymphoid and non-lymphoid tissues several months after infection (Sun, Beilke et al. 
2009). Although the evidence supporting the generation of NK cell memory is 
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continuously growing, a lot of questions regarding mechanisms remain unanswered. 
Addressing questions about involved receptors/ligands, influence of epigenetic 
setup or if memory NK cells remain tissue-resident or continue circulating will help 
to utilize NK cells for successful immunotherapy. 
1.5.1 Transcriptional control of ILC development 
The commitment of the NK cell lineage and further maturation requires the 
expression of a range of specific transcription factors (TFs) including PU.1, T-bet, 
Ets-1, TOX and E4BP4 (also known as NFIL3) (Colucci, Samson et al. 2001; 
Gascoyne, Long et al. 2009; Aliahmad, de la Torre et al. 2010; Gordon, Chaix et al. 
2012; Ramirez, Chandler et al. 2012). The transcriptional network that regulates 
differentiation of distinct ILC groups from a common CLP progenitor is summarised 
in figure 1.5. NK cells, including conventional NK (cNK) and thymic NK (tNK) cells, 
are characterised as cytotoxic ILC1 and are defined by IFNƴ production and their 
requirement of T-bet and Eomes TFs (Klose, Flach et al. 2014) (Gordon, Chaix et 
al. 2012).  
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Figure 1.5 Schematic overview of transcriptional control in ILC development. 
(1) Expression of EBF1 and Pax5 in CLPs induces B cell differentiation (2) Nfil3 
(E4bp4) and Id2/Id3 expression leads to NK cell precursors. T-bet and Eomes 
expression is required for further NK cell maturation. (3) The expression of Notch 
and GATA-3 induces a multipotent ILC/T progenitor which further matures to a NK/T 
progenitor regulated by TCF-1 expression. (5) The induction of a common 
progenitor to all helper like ILCs (CHILPs) is regulated by Nfil3 and Id2 expression. 
(Lim and McKenzie 2015) 
 
The TF Id2 is highly expressed in NKPs and CHILPs but not in HSCs and CLPs, 
which indicates that Id2 is important for the initiation of ILC development (Klose, 
Flach et al. 2014) (Carotta, Pang et al. 2011). Eomes and Id2 are regulated by the 
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expression of E4bp4 and it is suggested that E4bp4 acts both up- and downstream 
of IL-15, forming a feedback loop that drives commitment to the NK cell lineage 
(Male, Nisoli et al. 2014). T-bet and Eomes act at later stages in NK cell 
development and promote cell maturation and function (Gordon, Chaix et al. 2012) 
(Seillet, Huntington et al. 2014). 
Furthermore, the cytokine milieu has a significant role in NK cell development. IL-15 
is pivotal not only for NK cell survival and proliferation, but also for NK cell 
differentiation, in combination with Flt3L, SCF and IL-7 (Freud and Caligiuri 2006). 
IL-21 has been shown to regulate KIR expression in later stages of NK cell 
development (Sivori, Cantoni et al. 2003).  
 NK cells and Immunotherapy 1.6
 
First immunotherapy studies with NK cells focused on the activation and expansion 
of autologous NK cells. A study from 2011 (Parkhurst, Riley et al. 2011) used 
autologous PBMC, depleted of CD3 T lymphocytes, and expanded them on a 
feeder layer of autologous PBMC in the presence of IL-2. Eight patients with renal 
cancer or advanced melanoma received an average of 4.7×1010 (± 2.1×1010) NK 
cells after chemotherapy with Cytoxan/Fludarabine, followed by administration of IL-
2 (720,000 IU/kg every 8h). In this study no clinical responses were detected, but 
the transferred NK cells stayed present in the PB and were able to mediate ADCC 
with rituximab or anti HER2/neu antibodies. The important conclusion of this study 
was that even treatment with lympho-depleting chemotherapy, extensive ex vivo NK 
cell expansion and high doses of IL-2 will not necessarily result in a clinically 
relevant anti-tumour response. In general, information from this and other studies 
resulted in the following important findings: IL-2 can be administered to patients in a 
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safe manner daily up to 3 times/week and it increases the level of circulating 
lymphocytes with significant higher NK cells numbers.  
Further research revealed that autologous NK cells are unlikely to kill tumours 
because of the inhibitory signals resulting from KIR-self-MHC interaction. These 
findings led to the use of allogeneic NK cell for immunotherapies and several 
studies have since been conducted. Miller et al. (Miller, Soignier et al. 2005) infused 
patients with renal cell carcinoma or leukemia (prior treatment with 
cyclophosphamide and fludarabine) with CD3-depleted lymphocytes containing 20-
42% CD56+ NK cells from an MHC haplotype-mismatched relative, followed by IL-2 
injections (1.75 x 106 IU/m2 for 3 weeks or 10 MU 3 times per week). They observed 
that 5 out of 19 patients with acute myeloid leukemia (AML) obtained a remission, 
but no response was detected in patients with renal cancer which lead to the 
assertion that response to NK cell infusion might be dependent on disease. The 
infusions were well tolerated except for occasional fever and rigors. Another study 
treated 10 children with good/intermediate prognosis AML with KIR-HLA-
mismatched allogeneic NK cell infusions (CD3 depleted), after front line 
chemotherapy (Rubnitz, Inaba et al. 2010). The NK cell infusions were well tolerated 
and NK cells could be detected in all patients after infusion, with 3 children having 
cells detected up to 1 month. The promising outcome of this study was that all 
patients remained in remission for at least 2 years. Although the study included only 
a small cohort of patients, it suggests that KIR-HLA mismatching is beneficial. In 
another study from Curti et al. (Curti, Ruggeri et al. 2011), older AML patients were 
transfused with allogeneic KIR-mismatched NK cells after treatment with 
cyclophosphamide and fludarabine (Cy/Flu). Three of six patients were in complete 
remission and remained disease-free at 34,32 and 18 months. One patient had a 
transient response only. Recent results of clinical studies are summarised in table 
1.3. 
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Table 1.3 Overview of recent NK cell clinical trials with in vitro activated NK 
cells. (Koehl, Kalberer et al. 2016) 
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1.6.1 Challenges of NK cell immunotherapy 
So far, adoptive NK cell therapy has shown promising results in the treatment of 
haematological diseases, mainly in AML patients, but treatment of other cancers 
has been challenging and there has not yet been a clinical breakthrough for NK cell 
therapy. The obstacles for successful NK cell immunotherapy include low NK cell 
expansion and activation status and the risk of graft versus host disease (GVDH) by 
residual T- or B cells. Furthermore, the suppressive milieu within the tumour 
environment and the activation of suppressive T lymphocytes (Tregs) followed by 
IL-2 administration has been shown to suppress NK cell activity (Sim, Martin-Orozco 
et al. 2014). Methods therefore have to be found to (1) improve the anti-tumour 
cytolytic properties of the derived NK cells and (2) to generate large numbers of NK 
cells to promote clinical efficacy. 
1.6.2 NK cell engineering 
To enhance the anti-tumour activity of lymphocytes and to direct them specifically to 
tumour cells, transgene chimeric antigen receptors (CAR) can be expressed on their 
cell surface. This approach has shown great promise in T cell-therapies against CLL 
cells (Grupp, Kalos et al. 2013). Although the focus currently lies on CAR-
transduced T cell therapy, NK cells could be useful as an alternative lymphocyte 
source for CAR-directed therapies. The disadvantage of NK cells is the low number 
in PBMCs that can be isolated and low transfection and expansion efficiencies. 
However, a number of studies have used the NK cell line, NK-92, transduced with 
CARs directed towards CS1-expressing multiple myeloma (MM) cells (Chu, Deng et 
al. 2014), CD19 and CD20 (Boissel, Betancur-Boissel et al. 2013). Another report 
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shows the expression of the chimeric receptor CD4ζ in hiPSC-derived NK cells 
targeting HIV-infected cells (Ni, Knorr et al. 2014). 
1.6.3 NK cell sources for immunotherapy 
1.6.3.1 Peripheral blood-derived NK cells 
NK cells for immunotherapy can be derived from various sources. Because large 
numbers of functional NK cells are needed for adoptive cell transfer, several 
expansion methods have been described in the literature using either cytokines or 
artificial antigen-presenting cells (aAPCs) (Cheng, Chen et al. 2013; Shah, Martin-
Antonio et al. 2013). Further sources are the NK cell line NK-92, which is an IL-2 
dependent cell line derived from a 50 year old male with rapidly progressive non-
Hodgkin's lymphoma (Gong, Maki et al. 1994). 
1.6.3.2 Cord blood-derived NK cells 
The differentiation of NK cells from haematopoietic stem cells is an alluring option. 
High numbers of clinically appropriate NK cells can be generated from either 
umbilical cord blood (UCB) or mobilized PB-CD34+ cells in cytokine-dependent 
differentiation protocols (Grzywacz, Kataria et al. 2006; Spanholtz, Preijers et al. 
2011). Derived NK cells show high expression of activating NK cell receptors and 
cytolytic activity against K562 cells. Stromal cell-based in vitro differentiation 
methods include the co-culture on mouse fetal liver cell lines EL08.1D2 or AFT024 
and cells are cultured for a period of 4-6 weeks (Pinho, Marques et al. 2012; 
Luevano, Domogala et al. 2014). 
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1.6.3.3 HPSC-derived NK cells 
 
The in vitro derivation of large numbers of functional lymphocytes from hPSC 
sources has huge potential for immunotherapy. In contrast to umbilical cord blood 
HSCs, hiPSCs can be expanded indefinitely whilst remaining their pluripotent 
characteristics. This further provides a platform for genetically modifying cells before 
differentiating them into the lineage of interest. In contrast, the ex vivo manipulation 
of UCB-derived CD34+ cells is less efficient and limited. In addition, NK cell therapy 
with UCB-derived NK cells is dependent on cord blood donations with the desired 
tissue type. NK cells generated from hPSCs could overcome this limitation by 
establishing a cell database covering all MHC classes and providing an off-the-shelf 
cell therapy. 
 
 
  
46 
 
 Stem cells  1.7
 
Mammalian development starts with the fertilization of an oocyte with a 
spermatocyte. This fusion results in a cell called zygote, which undergoes numerous 
cell divisions to give rise to any specialised cell type within the organism. The 
process of cell type specialisation is called differentiation. The Waddington model 
describes the developmental potential of differentiating cells with the metaphor of a 
ball rolling down a mountain (Figure 1.6). 
 
 
 
Figure 1.6 The developmental potential and epigenetic states of cells at 
different stages of development.  (Hochedlinger and Plath 2009) A modification of 
C. H. Waddington's epigenetic landscape model, showing cell populations with 
different developmental potentials (left) and their respective epigenetic states (right). 
Developmental restrictions can be illustrated as marbles rolling down a landscape 
into one of several valleys (cell fates). Coloured marbles correspond to different 
differentiation states (purple, totipotent; blue, pluripotent; red, multipotent; green, 
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unipotent). Examples of reprogramming processes are shown by dashed arrows. 
Adapted from (Hochedlinger and Plath 2009). 
The ball in the above figure represents a stem cell which rolls down a mountain and 
can take different routes, which represent different lineages during differentiation. At 
the very top of the mountain, the ball has the opportunity to take any route downhill. 
The further the ball rolls down a specific route, the more difficult it becomes to go 
back uphill or cross to a different route. This model represents the differentiation 
potential of stem cells at different stages in development: totipotent, pluripotent and 
multipotent. 
Totipotent stem cells are defined as cells that can give rise to a whole organism – 
including both, embryo proper and extraembryonic tissue. After numerous cell 
divisions, the blastocyst is formed at day five of human development. Cells of the 
inner cell mass (ICM) at this stage are defined as pluripotent stem cells (PSCs), 
which have the ability to differentiate into cells of all three germ layers including 
ectoderm, mesoderm and endoderm. As cell divisions continue during early 
development, cells become more specialized and less plastic. Multipotent stem cells 
can give rise to a certain lineage of cell types – for example haematopoietic stem 
cells, from which the whole haematopoietic system within an organism is formed.  
1.7.1 Embryonic stem cells 
In 1998 the first human PSCs, embryonic stem cells (ESCs), were derived from 
cells of the inner cell mass of early stage blastocysts (Thomson, Itskovitz-Eldor et 
al. 1998). Since then, a variety of protocols has been established showing the 
differentiation potential of these cells to all three lineages including cardiomyocytes, 
neurons and haematopoietic progenitors (Lerou and Daley 2005). 
48 
 
Human ES cells have major clinical potential in tissue repair, disease modelling and 
drug screening and the interest in hESCs for regenerative medicine research 
increased significantly. However, the use of hESCs is highly controversial because 
cells are derived from human pre-implantation embryos. Most hESC lines are 
established from spare embryos from in vitro fertilisation (IVF) but the production of 
embryos specifically for therapeutic cloning via somatic cell nuclear transfer is under 
discussion.  This procedure aims to derive hESCs – genetically identical to the 
patient - by transfer of a patient’s somatic cell-nucleus to an unfertilized egg. These 
cells could be used as an unlimited cell source for a variety of somatic cells for 
autologous cell transplantation (de Wert and Mummery 2003). The moral aspects of 
hESC research, regarding the conditions and restrictions of isolation and use, have 
to be considered by researchers and are subject to governmental regulations. Laws 
for governing stem cell research vary in different countries, with the UK being the 
first to pass a law. The European Science Foundation reports on the scientific, 
ethical and legal issues in human stem cell research within the European Union. 
1.7.2 Induced pluripotent stem cells 
To overcome the ethical and logistical issues related to hESCs, research focussed 
on identifying factors required for maintaining the pluripotent state of cells. In 2006 a 
major breakthrough was achieved when the first induced pluripotent stem cells 
(iPSCs) were generated by Kazutoshi Takahashi and Shinya Yamanaka who 
discovered the crucial role of the core transcriptional network of pluripotency in 
murine cells (Takahashi and Yamanaka 2006). This study showed that the over-
expression of the four transcription factors Oct4, Sox2, Klf4 and c-Myc by retrovirus-
mediated transduction in murine fibroblasts generated cells with most properties of 
PSCs (Takahashi and Yamanaka 2006). One year later, human iPSCs (hiPSCs) 
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were obtained by using the same four transcription factors (Takahashi, Tanabe et 
al. 2007).  
1.7.3 Reprogramming methods 
Since the use of retrovirus for generation of first induced pluripotent stem cells, 
many other methods have been generated and they can be divided into two 
categories: integrative and integration-free. Integrative methods include retrovirus 
and lentivirus and using this system the transgenes are integrated in the host 
genome of the cells. The advantage of integrative system is that the reprogramming 
efficiency is much higher. Due to the integration of transgenes into the host system 
this can potentially affect the genetic stability of the cells and poses a risk for 
tumourigenesis as some of the reprogramming factors are oncogenes such as c-
myc. 
Non-integrative methods include use of Sendai virus, RNA, protein and episomal 
plasmid based methods. Sendai virus has the advantageous property that it is an 
RNA virus that does not enter the nucleus and is therefore diluted out of cells after 
infection. Cells are reprogrammed in ~25 days at an efficiency of 0.1% for blood 
cells and 1% for fibroblasts. One disadvantage of Sendai-based reprogramming is 
that it takes ~10 passages for the virus to be completely lost from recently 
reprogrammed iPSCs and cells may need to be cultured at a higher temperature 
(39°C) to inactivate the virus. 
The ability to express reprogramming factors as mRNA offers another method to 
make integration-free iPSCs (Warren, Manos et al. 2010). Warren and colleagues 
were able to reprogram human fibroblasts at an efficiency of 1.4% within 20 days 
and the efficiency increased to 4.4% in hypoxic conditions. Although reprogramming 
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factor mRNAs are commercially available, this method suffers from the fact that it is 
labour intensive, requires addition of mRNA daily for 7 days, and has not been 
validated in cells other than fibroblasts. 
Expression of reprogramming factors as proteins would be an ideal method to 
generate integration-free iPSCs. Unfortunately, it has been technically challenging 
to synthesize large amounts of bioactive proteins that can cross the plasma 
membrane. The low efficiency, technical challenges, and lack of published studies 
in non-fibroblast cell types suggest that much work needs to be done before protein 
reprogramming is a viable method (Kim, Kim et al. 2009).Transient expression of 
reprogramming factors as episomal plasmids would allow for the generation of 
footprint-free iPSCs. Yu et al. (Yu, Vodyanik et al. 2007) used oriP/Epsein-Bar 
nuclear antigen-1 based episomal vectors (oriP/EBNA1) with an overall low 
reprogramming efficiency. Okita et al. (Okita, Matsumura et al. 2011) improved the 
reprogramming efficiency by introducing small hairpin p53 suggesting a link 
between reprogramming efficiency and tumour generation (Marion, Strati et al. 
2009). In addition C-Myc was replaced with L-Myc. In our lab a systematic 
evaluation of different methods for generating hiPSCs was performed with the aim 
of developing a feeder- and xeno-free method suitable for scale up and clinical 
translation (Goh, Caxaria et al. 2013).  The reprogramming efficiency of three 
different primary fibroblast lines - two derived from patients with rapid onset 
Parkinsonism dystonia and one from an elderly healthy volunteer - was 4 fold higher 
with the episomal plasmid method when compared to the retroviral method and over 
50 fold higher than the mRNA method. Additionally, with the plasmid reprogramming 
protocol, commercially available, fully defined, xeno-free media and supplements 
could be used, without significantly impacting the reprogramming efficiency. The 
data suggests that the non-viral, episomal plasmid method is most efficient and 
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robust at reprogramming patient-derived human fibroblasts and it is currently 
transferred into a GMP environment for clinical use. 
1.7.4 Reprogramming cocktail 
Since the initial report of reprogramming, different combinations of factors have 
been used to reprogram somatic cells. Thomson et al. tested whether Oct4, Sox2, 
Nanog and Lin-28 are sufficient to induce pluripotency and showed successful 
reprogramming of human fibroblasts without c-Myc (Yu, Vodyanik et al. 2007). A 
potential tumour risk associated with some of the reprogramming factors - Lin-28 
and c-Myc – is a main challenge for clinical applications of hiPSC technology. Other 
studies replaced some of the transcription factors with chemicals and/or small 
molecules such as valproic acid and RepSox to improve the reprogramming 
efficiency (Huangfu, Osafune et al. 2008; Shi, Do et al. 2008). Furthermore, it has 
been demonstrated that the somatic cell type can greatly influence the efficiency of 
iPSC derivation and it was suggested that the subsequent differentiation of these 
cells can be influenced by their epigenetic memory (Kim, Doi et al. 2010). 
1.7.5 Clinical application 
Overall, human iPSCs have gained incredible interest in regenerative medicine as 
they offer an indefinite supply of patient-specific cells that can be differentiated into 
any somatic cell type, offering immunologically compatible cells for transplantation 
and cell replacement therapies (Figure 1.7). Many differentiation studies have been 
conducted to gain better insight into the kinetics, characteristics and potential of 
differentiated cell types. In addition to conventional differentiation approaches, 
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recent studies showed that the over-expression of cell-specific TFs can change the 
cell identity of somatic cells in a process termed direct lineage-conversion or 
transdifferentiation which bypasses the intermediate pluripotent state (Pereira, 
Chang et al. 2013). This principle has been shown with various somatic cell types 
including human fibroblasts to multi-lineage blood progenitors (Szabo, Rampalli et 
al. 2010) and Alzheimer’s disease fibroblasts into neurons (Qiang, Fujita et al. 
2011). These findings demonstrate an alternative approach to reprogramming to the 
pluripotent state, but also sacrifice the unlimited cell source provided by pluripotent 
stem cells. 
 
 
Figure 1.7 Application of hiPSC technology. HiPSCs have the potential to be 
used to model and treat human disease. Patient-specific iPSCs can be derived by 
ectopic co-expression of transcription factors in cells isolated from a skin biopsy can 
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be used in one of two pathways. In cases in which the disease-causing mutation is 
known gene targeting could be used to repair the DNA sequence (right). The gene-
corrected patient-specific iPSCs would then undergo directed differentiation into the 
affected neuronal subtype and be transplanted into the patient’s brain. Alternatively, 
directed differentiation of the patient-specific iPSCs will allow the patient’s disease 
to be modelled in vitro, and potential drugs can be screened, aiding in the discovery 
of novel therapeutic compounds (Robinton and Daley 2012). 
 
Several clinical trials are underway utilising embryonic stem cells as well as induced 
pluripotent stem cells in regenerative medicine. HPSC – based therapy moved into 
clinic surprisingly quickly and only twelve years after the first hPSCs have been 
isolated, the first patient has been treated with hESC-derived cells. There are 
several clinical trials (table 1.4) ongoing and their outcome will give valuable 
information about the safety and efficacy of PSC-based therapies.  
 
Disease type 
Cell 
source 
Institution Country Start date 
Finish 
date 
Subject 
Spinal cord 
injury 
hESC 
Geron 
Asterias 
USA 
USA 
Oct 2010 
March 2015 
July 
2013 
June 
2018 
5 
13 
Immunotherapy 
vaccine for lung 
cancer 
hESC Asterias UK Not defined 
Not 
defined 
Not 
defined 
Geographic 
atrophy 
secondary to 
myopic macular 
degeneration 
hESC Ocata USA April 2014 
April 
2015 
Not 
defined 
Stargardt 
macular 
degeneration of 
hESC Ocata USA July 2012 
Dec 
2030 
13 
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retina UK Nov 2011 Dec 
2015 
16 
Dry macular 
degeneration of 
retina 
hESC 
 
 
hiPSC 
Ocata 
Cell cure 
Neurosc. 
RIKEN 
CBD 
USA 
Israel 
 
Japan 
July 2012 
April 2015 
 
Oct 2013 
Dec 
2030 
Aug 
2017 
 
Not 
defined 
13 
15 
 
6 
Wet macular 
degeneration of 
retina 
hESC 
The 
London 
Project to 
cure 
blindness 
UK Aug 2015 
Oct 
2016 
3 
Dry macular 
degeneration 
hiPSC 
The 
London 
Project to 
cure 
blindness 
UK April 2016 
Not 
defined 
3 
Diabetes type I hESC ViaCyte USA Sep 2014 
Aug 
2017 
40 
Heart failure hESC APHP France June 2013 
June 
2017 
6 
 
Table 1.4 Clinical trials with hPSCs. (Ilic, Devito et al. 2015) 
 
1.7.6 Challenges of hiPSC based therapy 
Despite the great enthusiasm about the potential of hPSCs, there are still many 
challenges that need to be addressed. One big issue is the ability of hPSCs to 
induce tumour formation within the recipient. Consequently, it is essential to verify 
that no cells with pluripotent potential are present in hiPSC-derived engraftments. 
Contradictory reports are published regarding the immunogenicity of patient-specific 
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hiPSCs. Zhao et al. (Zhao, Zhang et al. 2011) reported in their study that teratomas 
– formed from “self” hiPSCs – which triggered an immune response in mice. This 
result was unexpected because it was believed that these cells would not cause any 
immune response due to self-tolerance and triggered a debate on safe use of hiPS-
derived cells. However, two recent reports on using in vitro differentiated cells from 
syngeneic hiPSCs showed no evidence of immune rejection of tissue derived from 
either hESCs or hiPSCs (Araki, Uda et al. 2013; Guha, Morgan et al. 2013). In a 
further study hESCs have been differentiated into retinal pigment epithelium (RPE) 
and these cells transplanted into patients with Stargardt's macular dystrophy and 
dry age-related macular degeneration - the leading cause of blindness in developed 
countries (Schwartz, Hubschman et al. 2012; Schwartz, Regillo et al. 2014). 22 
months after transplantation, the hESC-derived RPE cells showed no signs of 
rejection or tumourigenicity, which gives a positive outlook on the safe use of 
pluripotent cells in cell transplantation therapy.  
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 Research proposal 1.8
 
The overall aim of this study was to explore the in vitro generation of NK cells from 
hPSCs and to compare the phenotype of generated cells to UCB CD34+-derived 
and peripheral blood NK cells.  
Our hypotheses were that hiPSC-derived NK cells (1) can be generated in numbers 
comparable to the numbers derived from UCB CD34+ cells (2) are phenotypically 
similar to UCB-derived and PBNKs and (3) are functionally active and capable of 
effectively lysing target cells. HiPSCs could represent an unlimited source of NK 
cells enabling administration of high cell doses for immunotherapy and supporting 
the development of a well characterized repository of potentially “off the shelf” cells. 
1.8.1 Aim 1 - To generate and characterize haematopoietic progenitors from 
hESCs and hiPSCs.  
We hypothesised that haematopoietic progenitors can be efficiently differentiated 
from various episomal plasmid-derived hiPSC lines. These cells (a) show a similar 
immunophenotype compared to UCB-derived HSCs, (b) show differentiation 
potential into the myeloid lineages of the haematopoietic system and (c) can 
generate NK cells in in vitro differentiation protocols. 
Objectives:  
• To establish and compare protocols for HSC derivation including the co-
culture with murine stromal cells, embryoid body formation and 2D culture 
methods. 
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• To compare the differentiation efficiencies of hPSC-derived CD34+ cell 
populations from different donors. 
• To characterize the cell surface marker expression using flow cytometry. 
• To assess the myeloid and erythroid differentiation potential using colony 
forming unit (CFU) assay and compare results in colony numbers to UCB-
derived CD34+ cells. 
1.8.2 Aim 2 - To establish a robust in vitro differentiation protocol for NK cell 
derivation from hPSC-derived haematopoietic progenitors.  
We hypothesised that hPSC-derived haematopoietic progenitor cells can be 
efficiently differentiated to NK lymphocytes. These cells (a) can be generated by 
adopting protocols used for NK cell generation from UCB-derived CD34+ cells, 
including EL08.1D2 co-culture and a serum- and feeder free method using GBGM 
medium which is novel for NK cell derivation from hPSCs, (b) can be generated in 
numbers comparable to NK cells derived from UCB-derived CD34+ cells, (c) are 
phenotypically similar to UCB-derived and peripheral blood NK (PBNK) cells and 
express a similar receptor repertoire compared to UCB-derived and peripheral blood 
NK cells and (c) are functionally active and capable of effectively lysing target cells. 
 
Objectives: 
• To compare the efficiencies of NK cell derivation methods, including co-
culture with EL08.1D2 murine fetal liver cells and a clinically applicable 
protocol using GBGM medium supplemented with a cytokines cocktail. 
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• To characterize the cell surface marker expression of hPSC-derived NK cells 
using flow cytometry. 
• To determine the cytolytic efficacy in vitro with degranulation experiments 
using K562 cells as a target. 
1.8.3 Aim 3 - To explore transcription factor – driven NK cell differentiation 
by overexpression of E4bp4. 
We hypothesised that the overexpression of human E4bp4 in cord blood and 
hiPSC-derived CD34+ cells will increase NK cell numbers with improved cytotoxic 
effect in NK cell differentiation with GBGM medium. Furthermore, we aimed to 
investigate if the overexpression of E4bp4 in fibroblasts can activate the NK cell 
specific gene expression network and directly convert fibroblasts to NK cells. 
Objectives: 
• To produce functional lentivirus and determine titer. 
• To assess the efficiency of lentiviral transduction in UCB- and hiPSC-derived 
CD34+ cells and to test if upregulation is stable during differentiation. 
• To investigate if cell expansion and phenotype is altered by E4bp4 
overexpression using multi-colour flow cytometry. 
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Chapter 2 Materials & Methods 
 Cell culture 2.1
 
All tissue culture was performed in category 2 safety cabinets under sterile 
conditions. All media were sterile filtered and supplemented with 1mg/ml 
Penicillin/Streptomycin. Solutions were pre-warmed at room temperature prior to 
use. 
Cell 
line 
Species 
Derived 
from 
Received 
from 
Age of 
patient 
Pathological 
defect in 
patient 
Passage 
used 
OP9 Mouse Newborn 
mouse 
calvaria 
ATCC - - 22-28 
EL08.
1D2 
Mouse Murine 
embryonic 
liver 
Coll-
aboration 
- - - 
HEK 
293T 
Human Human 
embryonic 
kidney 
ATCC - - 8-12 
Jurkat 
cells 
Human Peripheral 
blood 
In house 14 T cell 
leukaemia 
- 
K562 
cells 
Human Peripheral 
blood 
In house 53 CML - 
H1 
ESC 
Human Inner cell 
mass 
Coll-
aboration 
Pre-
implantation 
- 63-70 
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BJ 
iPSC 
Human Fibroblast
s 
Derived in 
our lab (Goh, 
Caxaria et 
al. 2013) 
Newborn - 
30-50 
JOM 
iPSC 
Human Fibroblast
s 
Derived in 
our lab (Goh, 
Caxaria et 
al. 2013) 
89 years - 
30-50 
MMC 
iPSC 
Human Fibroblast
s 
Derived in 
our lab (Goh, 
Caxaria et 
al. 2013) 
31 years Rapid onset 
Parkinsonism 
Dystonia 
30-50 
HPS1 
iPSC 
Human Fibroblast
s 
Derived in 
our lab 
4 years Hermansky 
Pudlak 
Syndrome 
Type 1 
30-50 
PB3 
iPSC 
Human PBMCs Derived in 
our lab 
Unknown CEP290 
30-50 
Table 2.1 Cell lines.  
 
2.1.1 Human pluripotent stem cells 
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) 
were maintained in a pluripotent state by passaging them on geltrex (Thermo Fisher 
Scientific, # A1413302) - coated tissue culture plates in mTESR1 medium (Stem 
Cell Technologies, #05850) at 37°C/5% CO2. Tissue culture plates were coated with 
geltrex (1% final concentration) for at least one hour before use or alternatively 
stored at 4°C for up to one week. For passaging, gentle cell dissociation reagent 
(Stem Cell Technologies, # 07174) was used. Briefly cells were washed once with 
PBS and 1ml of gentle dissociation medium was added and cells were incubated at 
room temperature until the edges of the colonies began to curl (up to five minutes). 
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The enzyme was aspirated and fresh mTESR1 medium was added. Cells were 
scraped off the plate in small clumps using a 5 ml short glass pipette (Corning). 
Disaggregated colonies were transferred immediately to geltrex-coated plates. The 
split ratio was adjusted depending on the growth characteristics of the cells. The 
cells were split at a 1:2-1:20 ratio. The media was changed every 1 -2 days.  
2.1.1.1 Cryopreservation of hPSCs 
Cells were cryopreserved using bambanker freezing medium (Anachem, 
#95016585). Cells were collected in small clumps as described above and spun 
down for 5 minutes at 200x g. The cell pellet was resuspended in 100µl mTESR1. 
50µl were transferred in each cryovial and 500µl of bambanker freezing medium 
was added. Cells were immediately transferred to -80°C in a Mr. Frosty to achieve a 
rate of cooling of -1°C/minute. For long term storage, cells were transferred into a 
liquid nitrogen tank after a minimum of 24 hours. 
2.1.1.2 Thawing hPSCs 
Cryopreserved stem cells were thawed in a 37°C water bath until a small fraction 
was still frozen. 6ml of pre-warmed mTESR1 medium was added drop-by-drop and 
cells were spun down for 5 minutes at 200x g. The medium was aspirated and cells 
were resuspended in fresh mTESR1 and transferred to pre-coated geltrex plate.  
2.1.2 OP9 feeder cells 
Murine bone marrow OP9 cells were purchased from ATCC® (Catalog number 
ATCC® CRL-2749™). The OP9 cell line was established from newborn op/op mouse 
calvaria. The cells do not produce functional macrophage colony-stimulating factor 
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(M-CSF) due to an osteopetrotic mutation in the gene encoding M-CSF. The 
presence of M-CSF had inhibitory effects on the differentiation of stem cells to blood 
cells other than macrophages. 
OP9 cells were maintained on gelatine-coated tissue culture flasks in α-MEM 
without ribonucleosides and deoxyribonucleosides made fresh from powder with 
sodium bicarbonate. This was supplemented with 20% defined FBS HyClone to 
make the complete growth medium and cells were cultured at 37°C/5% CO2. For 
passaging, medium was discarded and cells were washed twice with PBS. TryPLE 
(Thermo Fisher Scientific, 12605010) was added and cells were incubated at 37°C 
for approximately 5 minutes. Cells were resuspended with medium and centrifuged 
for 5 minutes at 400x g. The supernatant was discarded and cells were transferred 
into a new flask with fresh medium. Cells were passaged every 4 days using a split 
ratio of 1:4 and medium was renewed every 2-3 days. For cryopreservation, cells 
were resuspended in complete growth medium supplemented with 5% DMSO. 
2.1.3 EL08.1D2 feeder cells 
The murine foetal liver cell line EL08.1D2 was maintained on gelatine-coated tissue 
culture plates and flasks at 32°C/5% CO2. The complete growth medium contained 
42.5% α-MEM, 50% Myelocult (StemCell Technologies M5300), 7.5% FBS, 2mM 
Glutamax, 10-6M Hydrocortisone and 50µM 2-Mercaptoethanol. For passaging, the 
medium was discarded and cells washed twice with PBS. TryPLE was added and 
cells were incubated at 37°C for approximately 5 minutes. Cells were resuspended 
with medium and centrifuged for 5 minutes at 400x g. The supernatant was 
discarded and cells transferred into a new flask with fresh medium. Cells were 
passaged every 4 days using a split ratio of 1:4 and medium was renewed every 2-3 
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days. For cryopreservation cells were resuspended in complete growth medium 
supplemented with 5% DMSO. 
2.1.4 Isolation of human mononuclear cells from peripheral blood and 
umbilical cord blood 
Umbilical cord blood (UCB) samples were received from the Anthony Nolan institute 
and peripheral blood samples were obtained from healthy donors in the laboratory. 
Blood samples were diluted 1:1 with PBS and 35ml was slowly added on top of 15 
ml Ficoll - without mixing the two phases. After centrifugation at 400 x g for 30 
minutes at RT, without break, the mononuclear cell layer was transferred with a 
Pasteur pipette into a new tube. The cell suspension was topped up to 50 ml with 
PBS and centrifuged at 400 x g for 10 minutes at RT. The wash step was repeated 
twice and mononuclear cell numbers were determined using a haematocytometer. 
The isolated PBMCs were frozen down in αMEM/20% FBS/7%DMSO. 
2.1.5 Magnetic activated cell sorting (MACS) 
CD34+ cells were enriched using the CD34 micro beads kit from Miltenyi Biotec (Cat 
# 130-046-702). Depending on the number of total cells the volumes of reagents 
and size of separation columns had to be adjusted. The following protocol was used 
for a total cell number of up to 108. Cells were resuspended in 300µl MACS Buffer 
containing 0.5% BSA in PBS with 2 mM EDTA (Ethylenediaminetetraacetic acid). 
For magnetic labelling, the cells were incubated for 30 minutess at 4°C with FcR 
blocking reagent and CD34 MicroBeads. Cells were washed and resuspended in 
500µl buffer. Columns were placed in the magnetic field of a suitable MACS 
separator and rinsed with buffer. The labelled cell suspension was applied onto the 
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column and washed 3 times with MACS buffer. Flow-through of unlabelled cells was 
collected and kept on ice. The column was transferred onto a 15 ml tube, and 
magnetically labelled cells were flushed out by adding 1ml of buffer and firmly 
pushing the plunger into the column. Aliquots of CD34+ cells were further processed 
for flow cytometry, RNA isolation and CFU assay. The remaining cells were either 
used fresh for NK cell differentiation or cryopreserved in α-MEM/20% FBS/7% 
DMSO. 
NK cells were isolated from PBMCs using the NK cell isolation kit from Miltenyi 
Biotec (Cat # 130-092-657). In brief, up to 107 PBMCs were resuspended in 40µl 
MACS buffer and cells were incubated with 10 µl of NK cell biotin-antibody cocktail 
for 5 minutes at 4°C. 30 µl of MACS buffer and 20 µl of NK cell microbread cocktail 
were added, mixed well and incubated for an additional 10 minutes at 4°C. The 
volume was adjusted to 500 µl with MACS buffer and the flow through which 
represented the NK cell fraction was collected after magnetic sorting. 
2.1.6 Co-culture with OP9 feeder cells 
OP9 cells were plated on gelatine-coated tissue culture flasks at a density of 4x103-
1x104 cells/cm2 in complete growth medium (see OP9 maintenance). A complete 
medium change was performed on day 2 and half medium change on day 4 of 
culture. Cells were overgrown an additional 4 days to form a dense monolayer 
embedded in extracellular matrix. On day 0 of differentiation 1.7x104 hPSCs/cm2 
were added as small clumps onto the overgrown OP9 layer in differentiation 
medium containing α-MEM without ribonucleosides and deoxyribonucleosides made 
fresh from powder, supplemented with 20% defined FBS HyClone and 100µM 
monothioglycerol. A full medium change was performed on day 1 and half medium 
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changes on day 4 and day 6. Cells were collected on day 9 to 12 by aspirating the 
medium and incubating with 1mg/ml Collagenase IV solution for 30 minutes at 37°C 
to digest the collagen-rich matrix. The collagen solution was aspirated and cells 
were incubated with TryPLE for 15 minutes at 37°C. Cells were collected with 
complete growth medium and passed through a 0.4µm cell strainer to obtain a 
single cell suspension. After centrifugation at 300xg for 5 minutes the cell pellet was 
resuspended in complete growth medium and a cell count was performed using a 
haematocytometer. An aliquot was kept on ice for Flow Cytometry analysis and 
remaining cells were prepared for MACS. 
2.1.7 Serum- and feeder free differentiation with cytokines 
The differentiation with STEM™diff™ APEL™ medium from StemCell Technologies 
is based on the published protocols (Ng, Davis et al. 2008) (Chadwick, Wang et al. 
2003). On day 0, approximately 2 days after passaging the pluripotent stem cells, 
small colonies were present on geltrex-coated plates and medium was changed 
from mTESR1 to APEL™ medium supplemented with 30ng/ml VEGF, 30ng/ml 
BMP4, 40ng/ml SCF and 50ng/ml Activin A, named APEL A. On day 4 medium was 
changed to APEL™ medium supplemented with 300ng/ml SCF, 300ng/ml Flt3L, 
10ng/ml IL3, 10ng/ml IL6, 50ng/ml G-CSF and 25ng/ml BMP4, named APEL B. 
Media changes were performed on day 7 and day 10 with APEL B and cells were 
harvested on day 13 by incubating with Accutase for 10mins at 37°C. An aliquot 
was kept on ice for Flow Cytometry analysis and remaining cells were prepared for 
MACS. 
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2.1.8 Embryoid body formation 
For embryoid body (EB) formation, pluripotent stem cells were collected in small 
clumps using cell dissociation reagent and were collected in a 15ml tube. After 
aggregated cells settled to the bottom of the tube by gravitation, the medium was 
discarded and cells were transferred to a low-adhesion suspension plate in fresh 
mTESR1, incubated overnight at 37°C/5% CO2. The following day EBs have been 
formed and medium was changed to APELTM supplemented with 20ng/ml VEGF, 
20ng/ml BMP4 and 40ng/ml SCF to induce haematopoietic mesoderm 
differentiation. Medium changes were performed on day 4, day 6 and cells were 
harvested on day 13. 
2.1.9 Spin embryoid body formation 
In order to generate spin EBs the pluripotent cells were collected as single cells 
using Accutase. After centrifugation at 200x g for 5 min cells were resuspended at a 
concentration of 3x104 cells/ml in APELTM medium supplemented with 20ng/ml 
VEGF, 20ng/ml BMP4 and 40ng/ml SCF. 100µl of this cell suspension were 
transferred to each of the inner 60 wells of a round-bottomed 96-well plate, giving a 
final concentration of 3000 pluripotent cells/well. PBS was added to the outer 36 
wells of each plate to humidify the EBs during differentiation. Cells were aggregated 
at the bottom of the wells by centrifugation at 480x g for 4 min which initiated the 
formation of spin EBs. The plates were placed in an incubator at 37°C/5% CO2 and 
the presence of EBs was checked the following day. Medium changes were 
performed on day 4, day 6 and cells were harvested on day 13. 
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2.1.10 NK cell differentiation 
2.1.10.1 EL08.1D2 co-culture 
CD34+ cells isolated from cord blood samples or hiPSC-generated CD34+ cells were 
co-cultured on a monolayer of irradiated EL08.1D2 murine feeder cells in 96-well 
plates. 500 CD34+ cells were plated per well with the following cocktail of cytokines: 
IL-3 (week one), IL-15, IL-7, SCF in weeks 1-3 and IL-15 only for week 4 and 5. 
Fresh medium was added weekly and cells were collected at different time points 
during differentiation for cell counts and flow cytometry analysis. 
2.1.10.2 Feeder-free NK cell differentiation with cytokines 
CD34+ cells  isolated from cord blood samples or hiPSC-generated CD34+ cells 
were cultured at a density of 1x105 cells/ml in GBGM (Glycostem basal growth 
medium) expansion medium (GBGM, 10% Human serum AB, 1x LDC (low-dose 
cytokine) supplemented with 25 ng/ml SCF, 25 ng/ml Flt3L, 25ng/ml TPO, 25 ng/ml 
IL-7 and 20 µg/ml Clivarin). After 10 days of expansion, suspension cells were 
collected and re-plated in GBGM differentiation medium I (GBGM, 10% Human 
serum AB, 1x LDC mix, 25 ng/ml SCF, 25 ng/ml Flt3L, 20 ng/ml IL-15, 25 ng/ml IL-7 
and 20 µg/ml Clivarin) at a density of at least 1x106 cells/ml. On day 14 of 
differentiation, cells were re-plated in GBGM differentiation medium (GBGM 2% 
Human serum AB, 1x LDC mix, 20 ng/ml SCF, 20 ng/ml IL-15, 20 ng/ml IL-7 and 
1000 U/ml IL-2) at a density of at least 2-3x106 cells/ml. Cell culture medium was 
refreshed every 2-3 days by replacing 500 µl with fresh medium. 1x LDC mix 
contained: 10 pg/ml GM-CSF, 250 pg/ml G-CSF and 50 pg/ml IL-6. Cells at different 
time points during differentiation were collected for cell counts, RNA extraction and 
flow cytometry analysis. 
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 Phenotypic analysis by flow cytometry 2.2
Cells were prepared as a single cell suspension in PBS/0.1% FBS and were 
labelled with a combination of the following fluorochrome-conjugated monoclonal 
antibodies (mABs): CD16-APC, CD34-APC, CD43-FITC, CD45-PE, CD56-PE, 
CD94-PerCPCy5.5, CD133-PE, NKp46-APC and NKG2D-APC all obtained from BD 
Biosciences and CD117-PerCPCy5.5 from Beckman Coulter. Tra-1-60 and Tra-1-81 
antibodies were non-conjugated mouse monoclonal IgM antibodies obtained from 
Santa Cruz Biotechnology used in combination with an AlexaFluor®488 goat anti-
mouse IgG (Thermofischer Scientific). Samples were analysed using a BD 
FACSVerseTM flow cytometer with BD FACSuiteTM and FlowJo software. Control 
staining with appropriate isotype controls was performed using APC mouse IgG1 κ, 
FITC mouse IgG1 κ and PE mouse IgG1 κ. 
Antibody Specificity Clone Fluorochrome Company Catalogue 
number 
TRA-1-85 Mouse anti-
human 
TRA-1-85 PE BD 
Pharmingen 
563021 
CD3 Mouse anti-
human 
SK7 APC-Cy7 BD 
Pharmingen 
557832 
CD4 Mouse anti-
human 
SJ25C1 APC-Cy7 BD 
Pharmingen 
557791 
CD14 Mouse anti-
human 
HCD14 PerCP-Cy5.5 BioLegend 325621 
CD16 Mouse anti-
human 
VEP13 VioGreen Miltenyi Biotec 130-098-095 
CD16 Mouse anti-
human 
3G8 APC-Cy7 BioLegend 302017 
CD34 Mouse anti-
human 
581 APC BD 
Pharmingen 
555824 
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CD43 Mouse anti-
human 
1G10 FITC BD 
Pharmingen 
555475 
CD45 Mouse anti-
human 
HI30 PE BD 
Pharmingen 
555483 
CD45 Mouse anti-
human 
5B1 VioBlue Miltenyi Biotec 130-098-136 
CD56 Mouse anti-
human 
B159 PE-Cy7 BD 
Pharmingen 
557747 
CD73 Mouse anti-
human  
AD2 PE-Cy7 BD 
Pharmingen 
561258 
CD90 Mouse anti-
human 
5E10 PE-Cy7 BD 
Pharmingen 
561558 
CD94 Mouse anti-
human 
DX22 APC BioLegend 305508 
CD133 Mouse anti-
human 
AC133 PE Miltenyi Biotec 130-080-801 
NKp30 
(CD337) 
Mouse anti-
human 
P30-15 APC BioLegend 325209 
NKp46 
(CD335) 
Mouse anti-
human 
9E2 VioBright FITC Miltenyi Biotec 130-104-567 
NKp44 
(CD336) 
Mouse anti-
human 
P44-8 PE BioLegend 325107 
NKG2A 
(CD159a) 
Mouse anti-
human 
131411 PE R&D Systems FAB1059P 
NKG2C 
(CD159c) 
Mouse anti-
human 
134591 FITC R&D Systems FAB138G 
NKG2D 
(CD314) 
Mouse anti-
human 
1D11 PerCP-Cy5.5 BioLegend 320817 
CD107a Mouse anti-
human 
H4A3 PE BD 
Pharmingen 
555801 
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Pan KIR2D Mouse anti-
human 
NKVFS1 VioBlue Miletnyi Biotec 130-099-042 
IgG2a, к Mouse G155-178 PE BD 
Pharmingen 
556653 
IgG1, к Mouse MOPC-21 APC-Cy7 BD 
Pharmingen 
557873 
IgG1, к Mouse MOPC-21 PE BioLegend 400111 
IgG1, к Mouse MOPC-21 APC BioLegend 400119 
IgG1, к Mouse MOPC-21 FITC BD 
Pharmingen 
555909 
IgG1, к Mouse MOPC-21 PerCP/Cy5.5 BioLegend 400149 
IgG1 Mouse IS5-21F5 VioBlue Miltenyi Biotec 130-094-670 
IgG1 Mouse IS5-21F5 VioBright FITC Miltenyi Biotec 130-104-562 
IgG2a Mouse S43.10 VioBlue Miltenyi Biotec 130-098-898 
IgM Mouse IS5-20C4 VioGreen Miltenyi Biotec 130-100-010 
IgG1, к Mouse MOPC-21 PE-Cy7 BD 
Pharmingen 
557872 
Table 2.2 Antibodies used for Flow cytometry. 
 
 Colony forming unit assay 2.3
Colony forming unit (CFU) assays were performed using the StemMACS HSC-CFU 
media obtained from Miltenyi Biotec. The medium is based on methylcellulose in 
IMDM (1%), supplemented with FBS (30%) and the following cytokines: stem cell 
factor (SCF – 50ng/ml), GM-CSF (20ng/ml), G-CSF (20ng/ml), IL-3 (20ng/ml), IL-6 
(20ng/ml) and Erythropoietin (Epo- 3U/ml). It supports the clonal progeny of a 
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single-cell to differentiate and grow in distinct colonies including BFU-E, CFU-E, 
CFU-GEMM, CFU-G, CFU-M and CFU-GM. 2x103 CD34+ cells were added to 2ml 
StemMACS HSC-CFU media, vortexed vigorously until the cells were well 
suspended and let tubes sit for 10mins to allow air bubbles to rise. 1ml of the cell 
suspension was plated in a well of a 12-well plate at a final density of 1x103 
cells/well. The outer wells were filled with PBS to avoid evaporation. Cells were 
incubated at 37°C/5% CO2 for 12-14 days. 
 CD107a degranulation assay 2.4
NK cells were incubated with K562 cells in a 1:1 effector: target ratio for 2 hours at 
37°C/5% CO2 in RPMI/10% FCS. Cells were labelled with a CD107a-PE conjugated 
antibody from BD and expression was determined via flow cytometry. 
 Molecular Biology 2.5
Name Purpose Company Catalogue number 
TRIzol® reagent RNA isolation Life technologies 015596-018 
SuperScript®III 
First-Strand 
cDNA synthesis Life technologies 
18080-051 
Fast SYBR® 
Green master 
mix 
qPCR  Thermo Scientific 4385612 
 
Table 2.3 Reagents used in Molecular Biology 
 
2.5.1 RNA isolation 
Cells for RNA isolation were collected as described in passaging of 
adherent/suspension cells and pelleted by centrifugation. Supernatant was removed 
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and cell pellets stored at -80˚C until RNA extraction. For homogenization, pelleted 
cells were resuspended in 1ml TRIzol® reagent and incubated at RT for 5 minutes. 
0.2ml of chloroform was added per 1ml TRIzol® reagent. Samples were shaken 
vigorously by hand for 15 seconds. Samples were incubated for 2-3 minutes at RT 
and centrifuged at 12,000xg for 15 minutes at 4˚C. The aqueous phase was 
transferred into a new tube and RNA precipitated by the addition of 0.5mL of 100% 
isopropanol. After incubation at RT for 10 minutes, samples were centrifuged at 
12,000xg for 10 minutes at 4˚C. The supernatant was removed and the gel-like RNA 
pellet was washed with 75% ethanol, by vortexing briefly and centrifugation at 7,500 
x g for 5 minutes at 4˚C. After 2-3 washes, the RNA pellet was air-dried for 10-15 
minutes at RT and resuspended in 20-50 µl of nuclease-free water. RNA 
absorbance was measured using nanodrop.  
2.5.2 cDNA Synthesis 
cDNA was synthesised with the “SuperScript® III First-Strand Synthesis System for 
RT-PCR”. 2µg per RNA sample, 1µl oligo(dT)20 (50 µM) and  1µl dNTP mix (10mM) 
were mixed in a PCR tube and nuclease-free water was added to bring the final 
volume to 10µl. The mix was incubated at 65˚C for 5 minutes and placed on ice for 
at least 1 minute. The following cDNA synthesis mix was prepared per reaction: 
 
10x RT buffer 2 µl 
25 mM MgCl2 4 µl 
0.1 M DTT 2 µl 
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RNaseOUT
TM
 (40 
U/µl) 
1 µl 
SuperScript® III RT 
(200 U/µl) 
1 µl 
Table 2.4 cDNA Synthesis Mix. 
 
10µl of cDNA synthesis mix were added to each RNA/primer sample, mixed, 
incubated for 50 minutes at 50˚C and the reaction terminated at 85˚C for 5 minutes. 
The samples were either kept on ice for qPCR analysis or were stored at -20˚C. 
2.5.3 qRT-PCR 
In each well of a 96-well plate 11µl SYBR® Green master mix plus 0.5µl of forward 
and 0.5µl of reverse primer were added and mixed with 8µl cDNA sample. The list 
of primers is listed below in table 2.5. All standards were measured in duplicates 
and all samples were run in triplicates. Analysis of qPCR data was performed in 
Microsoft Excel, using the relative standard curve method with GAPDH as an 
endogenous control by calculating 2^-delta, delta CT method. Melting curves were 
checked after each run to confirm specificity. 
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Gene Orientation Sequence Product 
length (bp) 
Brachyury 
(T) 
forward ATGATGGAGGAACCCGGAGA 482 
 reverse ACTGCATCTTTCGGGACCTG  
AFP forward TTTGGGACCCGAACTTTCCA 551 
 reverse TTTGCCAATGCTTGGCTCTC  
FoxA2 forward GGTGTCTGAGGAGTCGGAGA 519 
 reverse AGTTCATGTTGGCGTAGGGG  
Nestin forward AGCGTTGGAACAGAGGTTGG 302 
 reverse CCTCTGGGGTCCTAGGGAAT  
Otx2 forward ATTGCTAGAGCAGCCCTCAC 473 
 reverse CATACCTGCACCCTCGACTC  
Tie2 (TEK) forward AGTACGTGGTCCGAGCTAGA 554 
 reverse CACAGCTGGTTCTTCCCTCA  
Lyve1 forward GACAGTACCTACTCGGTGGC 458 
 reverse AGGCATCGCACGGTAGTTTT  
CD10 forward GACCTCGTTGACTGGTGGAC 500 
 reverse TCTGTGGTGTTGGCAAGTCT  
PU.1 forward AGCTTCGCCGAGAACAACTT 483 
 reverse GGTCATCTTCTTGCGGTTGC  
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Klf4 forward TACCAAGAGCTCATGCCACC 432 
 reverse CTTCCCTCATCGGGAAGACAG  
E4bp4 forward AAGCTCCGGATCAAAGCCAA 224 
 reverse TGATGCCAGTGCTCCGATTT  
Ets1 forward AAGAGACCACAGACTTTGAGGGAAG 307 
 reverse CTGCACATTCCATATCTGAGACAC  
Eomes forward TCGGCAGGCGCATGTTT 367 
 reverse TTCAAGTCCTCCACGCCATC  
Id2 forward GCAGCACGTCATCGACTACA 465 
 reverse ACCTTCCAACTGCAGAAAGGG  
Tbet forward GACGGCGGATGTTCCCAT 493 
 reverse TTCTCCCGGAATCCTTTGGC  
Tox forward AAGGGCCAAAATCCAAACGC 329 
 reverse TGCATGGCAGTTAGGTGAGG  
CD56 forward GAACGACGAGGCTGAGTACAT 304 
 reverse GCCAGCCTGTCCTTTCTGTC  
IL-15RB forward TGGCACTTCCCAGTTCACAT 307 
 reverse GCGAAGGTTCTCAAAGGGCT  
Table 2.5 List of primers. 
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2.5.4 Protein extraction 
Cellular proteins were extracted and solubilised in RIPA (Radio-Immunoprecipitation 
Assay) Buffer (Sigma, R 0278). Adherent cells were washed twice with PBS, the 
appropriate volume of RIPA Buffer (1ml for 0.5 to 5 x 107 cells) was added and cells 
incubated on ice for five minutes. Cells were scrapped off and the lysate clarified by 
centrifugation at 8,000xg for 10 minutes at 4°C to pellet the cell debris. The 
supernatant containing soluble protein was carefully transferred into a new tube for 
analysis or stored at -80°C. Suspension cells were centrifuged at 400xg for 5 
minutes and the cell pellet washed with PBS twice to remove contaminants. The cell 
pellet was resuspended in the appropriate volume of RIPA Buffer (1ml per 0.5 to 5 x 
107 cells) and cells were incubated on ice for 5 minutes. The lysates were clarified 
by centrifugation at 8,000xg for 10 minutes at 4°C and the supernatant was carefully 
transferred into a new tube for analysis or stored at -80°C. 
2.5.5 BCA assay 
The total protein in the sample lysates was quantified by BCA protein assays 
(Pierce TM Protein Assay Kit, Thermo Fisher Scientific, #23225). A set of protein 
standards was prepared with bovine serum albumin (BSA) according to table 2.6. 
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Vial Volume of diluent 
(RIPA buffer) [µl] 
Volume and source of 
BSA [µl] 
Final BSA 
concentration [µg/ml] 
A 0 300 of stock 2000 
B 125 375 of stock 1500 
C 325 325 of stock 1000 
D 175 175 of vial B dilution 750 
E 325 325 of vial C dilution 500 
F 325 325 of vial E dilution 250 
G 325 325 of vial F dilution 125 
H 400 100 of vial G dilution 25 
I 400 0 0 = blank 
Table 2.6 List of standards used in BCA assay. 
 
The working reagent was prepared by mixing 50 parts of BCA Reagent A with 1 part 
of BCA Reagent B (50:1, Reagent A:B). 25 µl of each standard and sample were 
pipetted as triplicates in a 96-well flat-bottomed microplate. 200 µl of the working 
reagent were added per well, mixed and incubated at 37°C for 30 minutes. After the 
plate was cooled down to RT, the absorbance was measured at 562 nm on a plate 
reader and protein concentration of unknown samples was determined by plotting 
the standard curve of BSA standards in Microsoft Excel. 
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2.5.6 Western Blotting 
20µl of protein sample were mixed with 10µl loading dye mix (containing 7.5µl LDS 
sample buffer and 2.5µl DTT reducing agent) and heated to 80°C for 10 minutes. 
The samples were loaded on a 10% Bis-Tris Protein Gel (Thermo Fisher Scientific, 
NuPAGETM NovexTM, #NP0301BOX) and run at 200V, 85mA for 40 to 50 minutes, 
including the protein standard ladder (Novex Sharp pre-stained protein standards, 
Invitrogen, #LC5800). The gel was removed from the gel tank, placed face down in 
its plastic housing and the gel casing was cracked open using a spatula. For the 
transfer, 3 sponges and 3 whatman paper (cut to gel-size) were soaked in transfer 
buffer and put into the transfer cassette. The gel was placed on top, a piece of 
Nitrocellulose membrane and 3x whatman paper plus 3x sponges were put on top 
before placing the cassette into the wet transfer system.  The transfer is run at 25V, 
125mA and 15W on ice for 1h 30 minutes.  
The membrane was stained with Ponceau S for 20 seconds and washed with 
TBS/tween for 40 minutes (buffer changed 4 times). The membrane was blocked 
with blocking buffer for 1 hour at RT and incubated with the primary antibody 
overnight at 4°C. The next day, the membrane was washed with TBS/tween for 40 
minutes (buffer changed 4 times) and incubated with the secondary antibody for 1-2 
hours at RT. The membrane was washed with TBS/tween for 40 minutes (buffer 
changed 4 times), incubated with enhanced chemiluminescence (ECL) and the 
bands were visualised on x-ray film. 
2.5.6.1 Buffer 
Running buffer:   50ml 20x stock MOPS + 950 ml DI water, fill the middle part 
of the tank between two gels and 500µl antioxidant was 
added 
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Transfer buffer: 50ml 20x transfer buffer (Bicine, Bis Tris, EDTA) + 200ml 
methanol + 750 ml DI water and 200 µl antioxidant. 
TBS/tween:  50ml 20x stock (20 mM Tris, 127 mM NaCl, HCl until pH 7.4-
7.8) + 950 ml DI water + 2% Tween 20 
Blocking buffer: 5% skimmed milk powder in TBS/Tween 
2.5.6.2 Antibodies 
Primary:  E4BP4/NFIL3 (D5K80) Rabbit mAb, #14312 Cell Signaling 
Technology ®, working concentration: 1:1000 in blocking buffer 
GAPDH (14C10) Rabbit mAb, #2118 Cell Signaling Technology ®, 
working concentration: 1:1000 in blocking buffer 
Secondary:  Polyclonal goat anti-rabbit antibody HRP conjugated (Dako, #P0448), 
working concentration: 1:2000 in blocking buffer 
2.5.7 Cloning 
The E4BP4 plasmid was received from a collaborator. For the isolation of high-copy 
plasmid DNA from E. coli cultures, the following Mini-prep kit was used: 
NucleoSpin® plasmid, Macherey-Nagel, #740588.250. In brief, 2 ml of a saturated 
E. coli LB culture were pelleted, cells resuspended in 250 µl buffer A1 and cells 
lysed by the addition of 250 µl buffer A2. After 5 minutes of incubation at RT, the 
tubes were inverted gently – to avoid shearing of genomic DNA – and the lysate 
clarified by centrifugation at 11000xg for 5 minutes. Plasmid DNA was bound on a 
NucleoSpin® column by centrifugation at 11000 xg for 1 minute and the silica 
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membrane was washed with buffer A4. The Plasmid DNA was eluted by adding 50 
µl AE buffer and centrifugation at 11000xg for 1 minute at RT. Concentration was 
determined by Nanodrop analysis.For high-copy plasmid DNA purification of culture 
volumes of 400 ml, the following Maxiprep kit was used: Midiprep (NucleoBond® 
Xtra Midi, #740410.100). 
2.5.8 Restriction digest 
10x NEB buffer 
5 µg DNA 
5 µl enzyme 
Up to 100 µl dH2O  
1 hour at 37 °C and heat inactivated depending on manufacturing guidelines. 
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Name of enzyme Buffer Restriction site Catalogue number 
SalI 3.1 5’ G˅TCGAC 3’ 
3’ CAGCT˄G 5’ 
R3138 
MluI 3.1 5’ A˅CGCGT 3’ 
3’ TGCGC˄A 5’ 
R0198 
PspXI CutSmart 5’ C˅TCGAG 3’ 
3’ CTCGA˄G 5’ 
R0656 
BstBI CutSmart 5’ TT˅CGAA 3’ 
3’ AAGC˄TT 5’ 
R0519 
SmaI CutSmart 5’ GGG˅CCC 3’ 
3’ CCC˄GGG 5’ 
R0141 
NotI CutSmart 5’ GC˅GGCCGC 3’ 
3’ CGCCGG˄CG 5’ 
R3189 
Table 2.7 List of restriction enzymes. 
2.5.9 Quick ligation 
Quick ligation buffer   10 µl 
Cut pCCL.EF1α.eGFP plasmid 2 µl 
Cut IRES.E4bp4 plasmid  2 µl 
H2O     up to 20 µl 
Quick ligase    1 µl, Mix, 5 minutes at RT and on ice 
82 
 
2.5.10 PCR protocol for cloning 
HiFid buffer (5x) 20 µl 
dNTPs   2 µl 
Phusion  1 µl 
Primer OL163  2 µl 
Primer OL166  2 µl 
DNA (400 ng)  0.59 µl  
dH2O   72.41 µl 
2.5.11 Sequencing 
Samples were sent for Sanger sequencing by Source Bioscience and the list of 
sequencing primers can be found below in table 2.8. 
Name Sequence 
OL60 3’ GAATGCTCGTCAAGAAGACAGGGCCGGTTTC 5’ 
OL163 5’GGCAACTCGAGTGCCACCATGCAGCTGAGAAAAATGCAGA3’ 
OL166 5’ CCGATCCTCCAGCAACTCCCCGAGAA 3’ 
MP5860 5’ GTTACTGGCCGAAGCCGCTTGGAATAAGG 3’ 
E4bp4 5’ GGCAACTCGAGTGCCACCATGCAGCTGAGAAAAATGCAGA 3’ 
Table 2.8 List of sequencing primers. 
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 Lentivirus work 2.6
2.6.1 Transformation 
2µl of ligation were added to 25µl of C2987 competent cells and kept on ice for 20-
30 minutes. Cells were heat-shocked at 42°C for 30 seconds and put on ice for 5 
minutes. 475µl of super optimal broth (SOC) medium was added and the tube 
incubated at 37°C for 1 hour, shaking. Cells were plated on LB Agar plates + 
Kanamycin (final concentration 50µg/ml) and incubated at 37 °C overnight. 
2.6.2 Transient transfection 
2.5µl PEI were mixed with 47.5µl IMDM, incubated at RT for 5 minutes and 1µg of 
plasmid DNA was added. After an incubation of 15 minutes at RT, the mix was 
added drop wise to HEK 293T cells and incubated at 37°C. The transfection was left 
for 24-48 hours. 
2.6.3 Preparation of Lentiviral particles 
On day 1 of lentivirus preparation, 10x106 HEK 293T cells were plated in each 15 
cm dish with DMEM/10% FCS. The following day a mix of the 3rd generation 
packaging plasmids was prepared with constitution below in table 2.9. 
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Plasmid Concentration 
[ng/µl] 
Per 1 plate [µg] 
KGP3R 2046 2,3 
RTR2 1952 1,2 
VSVG 2327 2,5 
pCCL.EF1a.E4BP4.IRES.eGFP 4139 24 
DMEM - 1,6 ml 
Table 2.9 Mix 1 of third generation lentivirus production. 
 
The mix in tube 2 constituted 60µl of PEI plus 1,5ml DMEM. The mix 1 was sterile 
filtered into tube 2 with a 0.45 µm filter, mixed well and incubated at RT for 20 
minutes. 3 ml of the transfection mix was added drop wise per 15 cm dish. On day 3 
the medium in each plate was replaced with 15ml fresh DMEM/10% FCS and the 
supernatant harvested on day 4 and 5 of transfection. The viral supernatant was 
centrifuged at 400xg for 5 minutes, sterile filtered with a 0.45µm filter and ultra-
centrifuged at 25,000 RPM for 1.5 hrs at 4°C. After centrifugation the supernatant 
was poured off and the pellet gently resuspended in the remaining supernatant. 
Virus was aliquoted in 20 µl aliquots and stored at -80°C. 
2.6.4 Determination of lentiviral titer 
On day 1 of virus titration, 8 x 104 HEK 293T cells were plated in each well of a 12-
well plate with DMEM/10% FCS. On day 2 the medium was replaced with 500µl 
DMEM/10% FCS per well and a serial dilution of virus was prepared: 1:5, 1:25, 
1:125, 1:625 and 1:3125. HEK 293T cells were transduced with 25µl of dilutions 1-
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5, leaving one well untransduced as a control. On day 4 the medium was topped up 
with 500µl DMEM/10% FCS per well and GFP expression was determined by FACS 
on day 5.  
2.6.5 hiPSC transduction 
hiPSCs were passaged in small colonies in 6-well plates. Two days before 
transduction, an approximate cell number was determined by single cell dissociation 
of one well using Accutase. Lentiviral particels were added drop wise onto the cells 
in a small amount of medium (1ml / well of a 6-well plate). The cells were incubated 
at 37°C / 5% CO2 and 1 ml of fresh mTESR1 was added the following day. On day 
3 the transduction efficiency was determined by GFP expression analysis using flow 
cytometry and a full medium change was performed. Cells were either used for 
differentiation experiments directly or were expanded in their pluripotent state using 
mTESR1. 
2.6.6 Statistical analysis 
Statistical comparisons were performed with GraphPad Prism software using one-
way analysis of variance (one-way ANOVA) followed by non-parametric test. 
Results are presented as Mean±SD and p values of <0.05 (*) were considered 
statistically significant. 
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Chapter 3 Generation and characterisation of 
haematopoietic progenitors from hPSCs 
 Introduction 3.1
 
The in vitro derivation of haematopoietic progenitors and mature blood cells from 
hiPSCs holds great promise for basic research and clinical applications. It provides 
an in vitro platform to study the generation of blood progenitors and gain better 
understanding of related disease development. Furthermore, the potential use of 
hPSCs as an alternative cell-source for stem cell transplantations and 
immunotherapies is an alluring goal in regenerative medicine. In recent years, great 
progress has been made to identify the underlying mechanisms of haematopoietic 
lineage specification and various protocols for in vitro derivation have been 
developed. 
3.1.1 Haematopoietic stem cell specification in vivo 
The key to successful modelling of haematopoietic development in vitro is a detailed 
understanding of what happens in vivo. Studies of mouse ESC differentiation and 
embryogenesis revealed key pathways of the early development of haematopoietic 
progenitors in vivo. Gastrulation is the first important step in development of blood 
precursors. This step is defined by the formation of the primitive streak (PS) in 
which epiblast cells migrate into and give rise to the mesoderm and definitive 
endoderm (Kinder, Tsang et al. 1999). During embryogenesis, endothelial and 
haematopoietic progenitor cells develop in parallel from a common precursor called 
haemangioblast, which is defined as aggregates of yolk sac mesenchyme (Choi, 
Kennedy et al. 1998). A subset of cells with haemato-endothelial potential (KDR+) 
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migrates into the yolk sac, where the first blood progenitors are formed (Yamaguchi, 
Dumont et al. 1993). It has been shown that BMP4, Nodal, WNT3 and FGF2 are the 
most important factors for mesoderm induction (Conlon, Lyons et al. 1994; Winnier, 
Blessing et al. 1995; Liu, Wakamiya et al. 1999; Saxton and Pawson 1999). In the 
mouse embryo, the first haematopoietic stem cells (HSCs), which are capable of 
reconstituting the entire haematopoietic system of adult mice are identified within 
the aorta-gonado-mesonephros (AGM) region, umbilical arteries and placenta by 
E10.5-11 and it is estimated that this region contains only around 1 HSC at E11.5 
(Medvinsky and Dzierzak 1996; Kumaravelu, Hook et al. 2002; Ottersbach and 
Dzierzak 2005). Studies in mice revealed, that within the AGM, haematopoietic cells 
were found to bud off from a unique population of endothelial cells on the ventral 
wall of the dorsal aorta, defined as the hemogenic endothelium (HE) through a 
transition of endothelial to haematopoietic cells (Choi, Kennedy et al. 1998; Chen, 
Yokomizo et al. 2009; Boisset, van Cappellen et al. 2010). Subsequent studies 
showed that other embryonic and extraembryonic sites possess hemogenic 
potential such as the placenta or head vasculature (Gekas, Dieterlen-Lievre et al. 
2005; Li, Lan et al. 2012). The expansion of HSCs occurs in the fetal liver and cells 
later migrate to the bone marrow, which represents the site of adult haematopoiesis 
(Cumano and Godin 2007). 
3.1.2 In vitro HSC differentiation from pluripotent stem cells 
To fully understand the early steps of human haematopoiesis and the dissimilarity to 
the mouse model, in vitro modelling with hPSCs serves as a powerful system. Three 
major approaches for the in vitro derivation of human HSCs have been described in 
the literature: (1) the co-culture with mouse stromal cell lines, (2) embryoid body 
(EB) formation and (3) 2D culture protocols.  
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Different murine stromal cell lines have been compared for their efficiency to induce 
haematopoietic differentiation, including S17, M210-B4 and MS-5 cell lines 
(Vodyanik, Bork et al. 2005) (Ni, Knorr et al. 2011) (Woll, Martin et al. 2005). The 
co-culture on OP9 stromal cells appeared most efficient for HSC derivation and 
differentiation into myeloid, erythroid and lymphoid lineages (Vodyanik, Bork et al. 
2005; Choi, Vodyanik et al. 2011). The OP9 cell line was established from newborn 
op/op mouse calvaria. The cells do not produce functional macrophage colony-
stimulating factor (M-CSF) due to an osteopetrotic mutation in the gene encoding M-
CSF. The presence of M-CSF had inhibitory effects on the differentiation of PSCs to 
blood progenitors other than macrophages (Nakano 1996). Studies suggest that 
CD34+CD43+ and CD34+CD45+ cell populations contain more haematopoietic 
progenitors compared to CD34+CD43- and CD34+CD45- (Woll, Martin et al. 2005) 
(Knorr, Ni et al. 2013). 
EB formation mimics the differentiation within a compact structure like the embryo 
proper in in vitro culture conditions. PSCs differentiate randomly into multiple cell 
types and differentiation can be forced into a specific lineage by adding cytokines 
and small molecules. Haematopoietic development has been significantly enhanced 
by the addition of bone morphogenetic protein-4 (BMP-4) and the haematopoietic 
cytokines  stem cell factor (SCF), Fms-related tyrosine kinase 3 ligand (Flt3L), 
interleukin-3 (IL-3), interleukin-6 (IL-6) and granulocyte colony-stimulating factor (G-
CSF) (Chadwick, Wang et al. 2003). In order to perform a uniform differentiation of 
PSCs, a variation of the EB protocol has been developed using an animal product-
free medium, denoted APEL (Albumin Polyvinylalcohol Essential Lipids) or the more 
economical variant, BPEL (Bovine Serum Albumin Polyvinylalcohol Essential Lipids) 
in combination with the spin EB methodology (Ng, Davis et al. 2008; Knorr, Ni et al. 
2013). A variation of the EB protocol uses BPEL medium in combination with SCF, 
BMP-4 and VEGF only (Knorr, Ni et al. 2013).  
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Protocols for deriving haematopoietic progenitors in 2D cultures have been explored 
using media and cytokines similar to the EB formation protocols. These protocols 
are serum- and feeder free and cells are grown as a monolayer culture with regular 
media changes supplemented with cytokines (Chicha, Feki et al. 2011; Niwa, Heike 
et al. 2011; Salvagiotto, Burton et al. 2011). A haematopoietic differentiation 
protocol using STEMdiff APEL medium from Stemcell Technologies has been 
published based on the protocols of EB formation (Chadwick, Wang et al. 2003; Ng, 
Davis et al. 2008).  
3.1.3 Challenges and obstacles of hiPSC-derived HSC derivation 
Although there has been a lot of progress in the research field in recent years, the 
differentiation efficiencies remain low and generation of hiPSC-derived HSCs with 
engraftment and long-term reconstitution potential remain a big challenge in the field 
(Wang, Menendez et al. 2005; Narayan, Chase et al. 2006; Tian, Woll et al. 2006; 
Ledran, Krassowska et al. 2008; Tian, Hexum et al. 2009; Risueno, Sachlos et al. 
2012). Data suggest that the current protocols are limited and new approaches for 
overcoming these obstacles are required. Recent studies investigate the effect of 
over-expression of haematopoietic key transcription factors on reconstitution 
efficiency of hiPSC-derived HSCs. Ran et al. showed that the over-expression of 
RUNX1a enhances haematopoietic lineage commitment in hiPSC-derived 
differentiation cultures and improves multilineage reconstitution in vivo (Ran, Shia et 
al. 2013). Direct TF-driven approaches demonstrate that the over-expression of key 
transcriptional regulators can induce haematopoietic lineages from hiPSCs. Elcheva 
et al. (Elcheva, Brok-Volchanskaya et al. 2014) reported in their study that the 
haemato-endothelial program can be induced in hiPSCs by the expression of a set 
of transcriptional regulators: ETV2 and GATA2 for the pan-myeloid and GATA2 and 
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TAL1 for the erythro-megakaryocytic lineage. In another study, the direct-
programming which circumvents the transition through a pluripotent intermediate of 
endothelial to haematopoietic cells is reported (Sandler, Lis et al. 2014). By over-
expressing the transcription factors FOSB, GFI1, RUNX1 and SPI1 in endothelial 
cells, this group demonstrated the derivation of multipotent blood progenitor cells 
which successfully engrafted into immune-deficient mice; producing both myeloid 
and lymphoid cells. A recent study describes a combined approach of morphogen-
driven and transcription factor-mediated differentiation of hPSCs that results in 
HSCs with engraftment potential (Sugimura, Jha et al. 2017). In this study, cells with 
engraftment, self-renewal and multi-lineage differentiation potential have been 
generated from hPSCs. A set of seven transcription factors – RUNX1, ERG, LCOR, 
HOXA5, HOXA9, HOXA10 and SPI1 - has been identified by in vivo screening. This 
set of TFs facilitates the differentiation of in vitro-hPSC-derived haemogenic 
endothelial cells to HSCs that engraft myeloid, B and T cells in primary and 
secondary mouse recipients. RNA sequencing analysis of engrafted cells revealed a 
strong correlation to haemogenic endothelium, engrafted cord blood HSCs and 
fresh cord blood CD34+ cells suggesting the activation of transcription factor 
networks that reflect the capacity for engraftment and reconstitution in transplant 
recipients (Sugimura, Jha et al. 2017).  
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 Results 3.2
3.2.1 Haematopoietic stem cell progenitors derived with co-culture on 
murine OP9 stromal cells 
All hiPSC lines used in this study have been derived by episomal plasmid 
reprogramming in our lab and have been extensively characterised (Goh, Caxaria et 
al. 2013), see table 2.1. In order to establish a robust and reproducible protocol for 
the differentiation of hPSCs into HSCs, we adapted the protocol from Choi et al. and 
Vodyanik et al. and their differentiation studies on hPSCs to HSCs and myeloid 
progenitors (Vodyanik, Bork et al. 2005; Choi, Vodyanik et al. 2011). In this study, 
we aimed to compare the differentiation potential of the hESC line H1, hiPSC line 
derived from the newborn foreskin fibroblast cell line BJ and four patient-derived 
hiPSC lines: JOM-iPSC, MMC-iPSC and HPS1-iPSC were derived from patient 
fibroblasts and PB3-iPS cells from peripheral blood mononuclear cells (PBMCs) 
(Goh, Caxaria et al. 2013). In brief, hPSCs were added in small clumps on an over-
confluent OP9 stromal cell layer and cells were cultured over a period of 9 days 
(Figure 3.1).  Typical morphological changes could be observed within all hPSC 
cultures (Figure 3.2). Stem cell colonies started to expand on the stromal cell layer 
by day 1, the centre and edges began to differentiate within the first four to six days 
of differentiation. This developmental stage is believed to be the equivalent to the 
haemangioblast, a mesenchymal structure described in early development (Choi, 
Kennedy et al. 1998). After about eight days of co-culture, distinct radial sac-like 
structures were formed.   
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Figure 3.1 Experimental layout of OP9 co-culture differentiation protocol. 
hiPSCs are seeded in small colonies on an overgrown OP9 cell layer. On day 9, a 
heterogeneous cell population is collected for characterisation, CD34+ cell 
enrichment and further differentiation. 
 
Figure 3.2 Morphological changes in OP9 co-culture at days 0, 6 and 9.  
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3.2.2 CD34+ cells can be generated from hPSCs 
All cell lines tested were capable of generating haematopoietic progenitor cells 
assessed by the expression of CD34 (Figure 3.3). The efficiency of 4,4 ± 1,8% 
CD34+ of the control hESC line H1 was lower compared to published data of 12,8 ± 
4,7%, achieved using the same protocol (Vodyanik, Bork et al. 2005). The 
differences in efficiency may be due to the use of different starting cell lines and lab 
environment.  
 
Figure 3.3 CD34 efficiencies with OP9 co-culture. (A) CD34+ efficiencies of 
hESC line H1 (4,4 ± 1,8%, n=5), and five different hiPSC lines: PB3 (14 ± 3%, n=3), 
BJ (8,6 ± 4,5%, n=5), JOM (5,5 ± 3,5% , n=2), MMC (8,75 ± 3,5%, n=4) and HPS1 
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(10,5 ± 10,6%, n=2) are shown. (B) The percentage of CD34+ cells is based on flow 
cytometry analysis. The gating strategy is shown on the example of one experiment 
of BJ hiPSCs. Results are presented as Mean±SD, p<0.05(*). Statistical testing was 
performed with one-way analysis of variance (one-way ANOVA) followed by non-
parametric test.  
 
Although the forward differentiation efficiencies varied between experiments, in 
general we observed higher HSC differentiation with hiPSCs when compared to 
hESCs, although this difference is not statistically significant. The fibroblast-derived 
hiPSC lines yielded comparable numbers of CD34+ cells with 8,6 ± 4,5% for BJ 
hiPSCs 5,5 ± 3,5% for JOM hiPSCs, 8,75 ± 3,5% for MMC hiPSCs and 10,5 ± 
10,6% for HPS1 hiPSCs. In contrast, significantly (p=0,0012) higher numbers of 
CD34+ cells were obtained from the PBMC-derived hiPSC line PB3 with 14 ± 3% of 
CD34+ cells.  
3.2.3 Feeder- and serum-free HSC differentiation with APEL medium 
To explore options for clinically applicable feeder- and serum free HSC derivation 
we opted for a protocol based on (Ng, Davis et al. 2008) (Chadwick, Wang et al. 
2003) and their studies on EB formation with addition of haematopoietic cytokines. 
The basal medium was obtained from StemCell Technologies named APEL and the 
components for a more economical variant called BPEL is published in Ng et al. 
(Ng, Davis et al. 2008).  Stem cell colonies remain in 2D culture with APEL medium 
and cytokines for 13 days. The control hES cell line H1 showed consistent 
differentiation efficiency of 20 ± 3% of the resulting population expressing CD34. 
However we observed high variability in CD34 expression in 3 hiPS cell lines used 
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to derive CD34+ cells with this protocol (Fig. 3.4). Notably, the CD34+ expressing 
cell population generated from hESC H1  is greater compared to OP9 co-culture 
derived cells, however, and CD34 expression appears as a shift rather than a 
distinct population.  
 
 
 
Figure 3.4 CD34 efficiencies with serum- and feeder free differentiation. 
(A) CD34 efficiencies before MACS enrichment in serum- and feeder free 
differentiation conditions based on flow cytometry. High variability in two hiPS cell 
lines (MMC and JOM) could be observed. (B) The gating strategy is shown on the 
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example of one experiment of BJ hiPSC differentiation. Results are presented as 
Mean±SD. HESC H1 n=3, hiPSC BJ n=1, hiPSC MMC n=2 and hiPSC JOM n=2. 
 
To assess if any cells remained in a pluripotent state, we stained the differentiated 
cells before MACS enrichment with the pluripotency markers Tra-1-60 and Tra-1-81. 
On day 13 of differentiation, 14 ± 0,6% (n=3) expressed Tra-1-60 and 10 ± 1,2% 
Tra-1-81 (Figure 3.5 A). The hESC H1-derived CD34 expressing cell population 
could be enriched by MACS to 81% (n=1) purity. However, we did not observe co-
expression of the haematopoietic markers CD43 and CD45 (Figure 3.5 B). We 
therefore surmised that the CD34+ cells generated with this protocol most likely 
generated CD34+ cells that were programmed towards either the endothelial or 
mesenchymal lineage. In support of this we did not observe any colonies when 
these feeder and serum-free CD34+ cells were cultured in methyl cellulose. We 
conclude that although higher efficiencies can be achieved with the serum- and 
feeder free approach, the derived cells did not acquire haematopoietic differentiation 
potential in our preliminary results. 
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Figure 3.5 Pluripotency and haematopoietic marker expression. (A) The 
expression of pluripotency markers Tra-1-60 and Tra-1-81 decreased significantly 
during differentiation. Tra-1-60 and Tra-1-81 were still expressed in 14 ± 0,6% and 
10 ± 1,2% of CD34 MACS enriched cells. Blue and red histograms represent the 
isotype control and specific staining, respectively. (B) No co-expression of CD43 
and CD45 could be observed in the serum- and feeder free differentiation approach. 
Histograms and blots are representative of 3 experiments. 
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3.2.4 Embryoid body formation 
Possibly, the differentiation with EB formation provides an environment closer to the 
in vivo development than 2D cultures can provide. EBs could successfully be 
derived from hESCs and hiPSCs and were cultured under 
mesoderm/haematopoietic inducing conditions (see chapter 3.2.3). EBs are very 
compact, three-dimensional aggregates with complex cell-adhesions. In our 
experiments we could not successfully dissociate the EBs into a live single cell 
suspension. Due to this problem we could not analyse the marker expression via 
FACS and could not enrich the haematopoietic precursors with magnetic beads. 
Several enzymes for dissociation were tested, including Accutase, trypsin/EDTA, 
tryPLE and gentle dissociation reagent. To improve the dissociation step in this 
protocol an “Embryoid body dissociation kit” could be tested available from Miltenyi 
Biotec. 
Based on our differentiation studies of hiPSCs to HSCs we decided to conduct 
further characterisation and experiments with OP9 co-culture derived CD34+ cells 
as this method was most robust and showed consistent differentiation efficiencies. 
3.2.5 CD34+ cell enrichment and immunophenotype characterisation  
For further analysis of hiPSC-derived CD34+ cells, a more homogenous cell 
population was obtained by cell enrichment with CD34 magnetic beads using 
magnetic activated cell sorting (MACS) technology. An absolute number of 3,8 ± 
1,7x105 (n=12) CD34+ cells could be isolated from 3x106 PSCs, with a cell purity of 
90 ± 2.6% CD34+ cells. To distinguish murine and human cells within the co-culture, 
cells were co-stained with the pan-human cell marker Tra-1-85. As expected, OP9 
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cells stained negative and hiPSCs positive for Tra-1-85 in the starting cell 
populations. After nine days of co-culture, all CD34+ cells co-expressed Tra-1-85 
which confirmed the human origin of these cells (Figure 3.6).  
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Figure 3.6 Pan human and pluripotency marker expression. (A) The expression 
level of CD34 and the pan-human marker Tra-1-85 in OP9 cells, hiPSCs, after nine 
days of co-culture and after CD34+ cell enrichment. Gates were set with the 
appropriate isotype controls. (B) The expression of pluripotency markers Tra-1-60 
and Tra-1-81 decreased significantly during differentiation and CD34+ sorted cells 
did not show any expression of pluripotency markers. Blue and red histograms 
represent the isotype control and specific staining, respectively. 
 
Although CD34 is a commonly used marker for HSCs, it is also expressed by 
endothelial and mesenchymal cells. To further assess the percentage of cells with 
haematopoietic differentiation potential, we assessed the co-expression of the cell 
surface markers CD43, CD45, CD117 and CD133. Previous studies on hESC 
differentiation with OP9 stromal cells have demonstrated that the early 
haematopoietic progenitors could be identified by the expression of CD43 which 
distinguishes haematopoietic CD34+ cells from endothelial (CD34+ CD31+ CD43- 
KDR+) and mesenchymal (CD34+ CD31- CD43-) cells (Vodyanik, Thomson et al. 
2006).  
We identified the percentage of CD43 co-expression in CD34-enriched cell 
populations and observed a wide variation between experiments with numbers 
ranging from 5-60% (Fig. 3.7A). The acquisition of CD45 occurs later in 
development and CD34+/CD45+ cells were described as a population highly 
enriched in myeloid progenitor cells. In our experiments we observed varying 
expression of CD45 within the enriched CD34+ cell population similar to CD43 
expression (Fig. 3.7B). CD45 is co-expressed on all CD34+ cells of UCB-derived 
HSCs (data not shown) and we observed expression of this marker within the 
CD34dim population of hESC-derived cells. Altogether these data suggest that only a 
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small fraction of isolated hPSC-derived CD34+ cells are committed to the 
haematopoietic lineage. 
 
 
Figure 3.7 CD43 and CD45 co-expression. Percentages of co-expression of 
haematopoietic markers CD43 (A) and CD45 (B) in one hESC and five hiPSC lines 
are shown. FACS plot examples of a BJ hiPSC line are shown. The data represent 
the percentage of CD43, CD45 marker expression in 100% CD34+ cell population. 
Gates were set using the appropriate isotype controls. Results are presented as 
Mean±SD. 
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3.2.6 HiPSC-derived CD34-expressing cells compared to UCB-derived CD34+ 
cells 
To further characterise the CD34+ - enriched cell population derived from hiPSCs, 
we compared cell surface marker expression with hiPSCs and CD34+ cells isolated 
from umbilical cord blood. The haematopoietic markers CD34, CD43 and CD45 
were not expressed in the pluripotent cells at the beginning of differentiation, with 
0,2 ± 0% CD34, 0,3 ± 0% CD43 and 0,1 ± 0% CD45 (n=2) (Figure 3.8). All three 
markers were upregulated within 9 days of OP9 co-culture. After MACS enrichment, 
purities of 98,6 ± 0,6% and 95,7 ± 1,6% CD34 expressing cells can be achieved in 
hiPSC- and UCB-derived cells, respectively. CD43 expression could not be 
detected in UCB-derived CD34+ cells (1,2 ± 0,1%) but is slightly upregulated in 
hiPSC-derived cells with 19,4 ± 0,8%. In contrast, CD45 is expressed in 97,6 ± 
0,8% of UCB-derived CD34+ cells and to a smaller amount in hiPSC-derived cells 
with 24,4 ± 0,6%. The stem cell markers CD117 and CD133 could be detected in 
hiPSCs as well as in the CD34+-enriched cell populations. CD117 was less 
expressed in hiPSC-derived cells with 31,3 ± 0,3% compared to 66 ± 4% observed 
in UCB-derived samples. Downregulation of CD133 could also be observed in 
hiPSC-derived cells with 16,8 ± 2,8% compared to 95,4 ± 0,6% in UCB-derived 
cells. We detected CD56 expression in pluripotent stem cells with 96,1 ± 0,7%, 
which was downregulated to 0,8 ± 0,1% in hiPSC-derived CD34+ cells which is 
comparable to expression levels in UCB-derived CD34+ cells (0,3 ± 0,3%).  
 
104 
 
 
105 
 
 
Figure 3.8 Haematopoietic cell surface marker expression. Comparison of 
marker expression in BJ hiPSCs (n=2), BJ hiPSC-derived CD34+ cells (n=2) and 
UCB-derived CD34+ cells (n=2). FACS histograms represent data from the BJ 
hiPSC line and UCB-derived CD34+ cells. The blue histogram in each plot shows 
the isotype control and red histogram specific staining. 
3.2.7 Assessment of myeloid differentiation potential with colony forming 
unit (CFU) assays 
To assess the in vitro differentiation potential of hPSC-derived CD34+ cells (OP9 co-
culture derived) into multi lineage myeloid progenitors, we performed CFU assays 
with CD34-enriched cells derived from UCB, hiPSC MMC and hESC lines. After 14 
days of culture in a semi-solid methylcellulose medium supplemented with cytokines 
as per the manufacturer’s protocol, we determined the total colony number and 
characterized these colonies by morphology. All hPSC-derived CD34+ cells from 
OP9 co-cultures proliferated and formed colonies (Fig. 3.9 A, B). Progenitor cells of 
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the erythroid lineage were determined as either burst-forming-unit erythrocytes 
(BFU-E) which are typically >200 early erythrocyte progenitor cells in 3-8 densely 
packed clusters or colony-forming-unit erythrocyte (CFU-E) which is defined as a 
packed cluster of 8-200 erythrocyte progenitors. The colour ranged from dark 
red/orange to brown. Staining with May Gruenwald Giemsa (MGG) further 
confirmed that cells changed their morphology towards developing myeloid and 
erythroid cells within our differentiation system. The cells have some features of 
developing myeloid cells including the presence of granules and nuclear 
morphology resembling metamyelocytes and myelocytes (Figure 3.9 C). 
Although all hPSC-derived CD34+ cells could give rise to CFUs, lower colony 
numbers could be observed when compared to UCB-derived CD34+ cells. Limited 
comparative studies showed that hESC-derived CD34+ cells formed 5 ± 1 (n=3) 
colonies. In contrast hiPSC MMC-derived CD34+ cells gave rise to 21 colonies ± 15 
(n=3). We observed lower BFU-E and CFU-E in hPSC-derived CD34+ cells 
compared to UCB-derived HSCs and it was difficult to subcategorise myeloid 
colonies. However, our preliminary data suggest a predominant expansion of 
myeloid CFUs in MMC hiPSC-derived CD34+ cells compared to UCB-CD34+ cells.  
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Figure 3.9 Myeloid and erythroid progenitors form in CFU assays. (A) CFU 
assays with UCB- and (B) hiPSC-derived CD34+ cells after 14 days of culture. (C) 
May-Gruenwald Giemsa stain with 100x oil magnification. (D) A comparison of 
colony numbers shows predominant expansion of myeloid progenitors with limited 
potential of hiPSC-derived cells to form erythroid progenitor colonies. Results are 
presented as Mean±SD. 
 
3.2.8 Transcriptional control during HSC differentiation in OP9 co-culture 
In order to investigate the reason for low efficiencies of CD34+ cell generation, we 
decided to perform gene expression analysis by RT-qPCR. We hypothesised, that 
cells, within the co-culture, differentiate into other lineages than haematopoietic 
progenitors. For this experiment we collected RNA samples at different timepoints of 
differentiation (d0 – d9) and designed primers for genes specific for certain cell 
types and lineages. 
 
3.2.8.1 Genes of the three germ layers 
In the first instance, we investigated the expression levels of markers of the three 
germ layers. We observed high upregulation of the mesodermal marker Brachyury 
from 0,0 ± 0 (n=3) on day 0 to 7,8 ± 1,2 (n=3) relative expression on day 2 (Fig. 3.10 
A). Relative expression significantly decreased again to 1,7 ± 0,3 (n=3) at day 4 and 
stayed down-regulated towards the end of the co-culture. To further investigate if 
early ectoderm or endoderm was induced as well, we followed the expression 
pattern of Nestin and FoxA2, respectively. The relative expression of Nestin was 
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slightly upregulated from 0,2 ± 0,007 (n=3) on day 2 to 0,4 ± 0,07 (n=3) on day 4 of 
differentiation (Fig. 3.10 B). These results indicate that early ectoderm is only 
minimally induced in the OP9 co-culture. No significant upregulation of the 
endodermal marker FoxA2 could be observed at any time point of the differentiation 
(Fig. 3.10 C). These data suggest, that the mesodermal lineage is primarily induced 
in the differentiation with OP9 co-culture. 
 
 
Figure 3.10 Gene expression of the 3 germ layers. The relative expression of (A) 
mesodermal (Brachyury), (B) ectodermal (Nestin) and (C) endodermal (FoxA2) 
marker genes was determined by RT-qPCR on day 0,2,4,7 and 9 of OP9 co-culture. 
Relative expression of Brachyury peaked at day 2 with 7,8 ± 1,2 (n=3), which 
indicates that mainly mesoderm is induced in our differentiation cultures. Results 
are presented as Mean±SD, n=3 technical replicates. 
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3.2.8.2 Haematopoietic genes 
To investigate the kinetics of upregulation of haematopoietic genes on the RNA 
level, we followed the expression levels of haematopoietic-specific genes. The 
relative expression of PU.1 was upregulated from 0,01 ± 0,003 (n=3) on day 4 to 0,4 
± 0,05 (n=3) on day 7 and to 0,6 ± 0,06 (n=3) on day 9 of co-culture (Fig. 3.11 A). 
CD34 was also upregulated from 0,01 ± 0,001 (n=3) on day 4 to 1,1 ± 0,07 (n=3) on 
day 7 and slightly downregulated on day 9 to 0,6 ± 0,07 (n=3) (Fig. 3.11 B). 
The relative expression of CD45 was upregulated towards the end of the co-culture 
from 0,06 ± 0,02 (n=3) on day 4 to 0,3 ± 0,04 (n=3) on day 7 and 1,3 ± 0,6 (n=3) on 
day 9 (Fig. 3.11 C). RT-qPCR data show, that CD34 is most upregulated at day 7 of 
co-culture with lower CD45 co-expression than on day 9. These results suggest that 
the haematopoietic progenitor state might be more immature after 7 days of co-
culture.  
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Figure 3.11 Expression of haematopoietic genes. The relative expression of the 
haematopoietic markers (A) PU.1, (B) CD34 and (C) CD45 was determined by RT-
qPCR on day 0,2,4,7 and 9 of OP9 co-culture. PU.1 expression was upregulated on 
day 7 and peaked on day 9 with 0,6 ± 0,06 (n=3). CD34 relative expression was 
highest on day 7 with 1,1 ± 0,07 (n=3), whereas the relative expression of CD45 
was highest on day 9 with 1,3 ± 0,6 (n=3). Results are presented as Mean±SD, n=3 
technical replicates. 
 
3.2.8.3 Mesenchymal and endothelial genes 
The relative expression of the mesenchymal marker CD10 was steadily upregulated 
from 0,05 ± 0,008 (n=3) on day 4 to 2,9 ± 0,4 (n=3) on day 7 and up to 5,0 ± 0,8 
(n=3) on day 9 of co-culture (Fig. 3.12 A). These results strongly indicate that 
mesodermal precursor cells not only differentiate into the haemotopoietic lineage, 
but also into mesenchymal progenitors. Furthermore, relative expression of the 
112 
 
early endothelial marker Tie2 highly increased from 3,2 ± 0,5 (n=3) on day 4 to 24,5 
± 1,2 (n=3) on day 7 and decreased again to 10,9 ± 1,7 (n=3) on day 9 (Fig. 3.12 B). 
The strong increase in relative expression of the endothelial lineage occurred at the 
same time points (day 7 onwards) as the haemoatopoietic marker up-regulation. 
These results support reports in the literature of parallel development of haemato-
endothelial precursor cells. 
 
Figure 3.12 Expression of mesenchymal and endothelial genes. The relative 
expression of the (A) mesenchymal marker CD10 and (B) early endothelial marker 
Tie2 was determined by RT-qPCR on day 0,2,4,7 and 9 of OP9 co-culture. CD10 
was upregulated from 0,05 ± 0,008 (n=3) on day 4 to 5,0 ± 0,8 (n=3) on day 9. 
Relative expression of the endothelial marker Tie2 peaked at day 7 with 24,5 ± 1,2 
(n=3), suggesting parallel development of endothelial and haematopoietic 
progenitor cells. Results are presented as Mean±SD, n=3 technical replicates. 
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The transcriptional analysis of lineage-specific genes showed a predominant 
mesoderm induction within the first two days of HSC differentiation. The 
upregulation of haematopoietic markers could be confirmed, but also upregulation of 
mesenchymal, endodermal and endothelial genes. These data suggest that the co-
culture on OP9 feeder cells does not only support differentiation towards the 
haematopoietic lineage but into a variety of progenitor cells. This results in a very 
heterogeneous population, including mesenchymal and endothelial cells – which 
can express CD34 on their cell surface.  
 
 
Figure 3.13 A model of lineage differentiation from the pluripotent stem cell 
state. The first specification of haematopoietic development is mesodermal 
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differentiation, followed by the formation of the haemangioblast and haemato-
endothelial progenitors, where haematopoietic stem cells derive from.   
115 
 
 Discussion 3.3
 
In this chapter we investigated if GMP compliant, integration-free hiPS cell lines 
have the potential to differentiate to haematopoietic progenitor cells. Although the 
differentiation of hiPSC to different haematopoietic lineages has been proven in vitro 
in various studies (Ackermann, Liebhaber et al. 2015), the generation of fully 
defined haematopoietic progenitors remains challenging and inefficient. 
Furthermore, HSCs with engraftment and reconstitution potential have not been 
generated with in vitro protocols so far. 
We established a protocol to generate haematopoietic progenitors from hPSCs in 
our lab from scratch. Various differentiation approaches are published in the 
literature and the differentiation with OP9 feeder cells proved to be the most robust 
and reproducible in our hands. We tested four different hiPS cell lines derived from 
fibroblasts, one hiPS cell line derived from PBMCs and the H1 hES cell line. All cell 
lines did undergo typical morphological changes within nine days of OP9 co-culture. 
CD34 expression varied between cell lines and in different experiments with the 
same cell line. Interestingly, we observed slightly higher CD34 efficiencies with 
hiPSCs compared to hESCs. The observation, that hiPSCs derived from PBMCs 
differentiated more efficiently towards the haematopoietic lineage was interesting 
and lead to the question, if the efficiency is significantly influenced by the origin of 
the reprogrammed cells. The epigenetic memory of cells - where DNA methylation 
signature remains present in hiPSCs depending on their somatic origin and 
influences the differentiation ability towards specific lineages - has been described 
in the literature and could explain our observation (Kim, Doi et al. 2010). Although 
the derivation of CD34-expressing cells remained low, our data were comparable to 
what was published in the literature and the protocol was robust and reproducible. 
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The CD34-expressing cell fraction could be enriched with magnetic activated cell 
sorting and was phenotypically compared to UCB-derived CD34+ cells.  
A fraction of derived CD34+ cells co-expressed the haematopoietic markers CD43 
and CD45 to comparable levels in all cell lines. Our data show that after CD34 
enrichment, 90% of cells are of human origin as assessed by Tra-1-85 staining, so 
most OP9 cells are depleted in this enrichment step. The pluripotency markers Tra-
1-60 and Tra-1-81 are downregulated during OP9 co-culture and are not expressed 
after 9 days of differentiation. We further compared the phenotype of hiPSCs, 
enriched hiPSC-derived CD34+ and UCB-derived CD34+ cells by surface marker 
expression with flow cytometry. Interestingly, when we compared 
immunophenotypes of enriched hESC-derived with UCB-CD34+ cells we observed 
distinct CD34dim and CD34bright populations in hESC-derived cells. These findings are 
consistent with reports in the literature, where Dravid et al. identified two 
subpopulations within hESC-derived CD34+ cell compartment with either haemato-
endothelial  (CD34bright) or haematopoietic-restricted (CD34dim) potential (Dravid, Zhu 
et al. 2011). Furthermore, our data suggest that CD43 is co-expressed by CD34dim 
cells, which indicates that this cell population represents cells with haematopoietic 
potential. Further characterisation of the CD34dim and CD34bright populations in 
regards to their haematopoietic differentiation potential would have been of interest. 
CD45 is co-expressed on all CD34+ cells of UCB-derived HSCs (data not shown) 
and we observed expression of this marker within the CD34dim population of hESC-
derived cells. Altogether these data suggest that only a small fraction of isolated 
hPSC-derived CD34+ cells are committed to the haematopoietic lineage.  
CD34, CD43 and CD45 are not expressed in hiPSCs and are upregulated during 
OP9 co-culture. With CD34 MACS enrichment we could achieve purities of more 
than 90%, although in some experiments the purity was significantly lower. 
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Interestingly, CD43 is used as a marker to identify haematopoietic precursors in 
most studies differentiating HSCs from hiPSCs (Knorr, Ni et al. 2013) (Woll, Martin 
et al. 2005) (Vodyanik, Bork et al. 2005) (Choi, Vodyanik et al. 2011). However, 
CD43 is not expressed on UCB-derived CD34+ cells. The pan leukocyte marker 
CD45 is expressed on all UCB-derived CD34+ cells but only in variable fractions in 
hiPSC-derived CD34+ cells. The stem cell markers CD117 and CD133 are 
expressed on hiPSCs and our data suggest downregulation in the enriched CD34+ 
cell population compared to higher expression in UCB-derived CD34+ cells. 
Interestingly, we observed CD56 expression in hiPSCs which is downregulated in 
hiPSC-derived CD34+ cells and not expressed in UCB-derived CD34+ cells. We 
further investigated, if hiPSC-derived CD34+ cells exhibit the ability to differentiate 
into more mature haematopoietic cells in an in vitro colony forming unit assay. The 
enriched CD34+ cells successfully generated myeloid and erythroid progenitors with 
distinct morphological appearance. However, we observed lower colony numbers 
with hiPSC-derived cells compared to UCB-derived cells, especially erythroid 
progenitor colonies. This observation is probably due to lower numbers of actual 
haematopoietic progenitor cells within the hPSC-derived CD34 population 
compared to UCB-derived CD34+ cells. Furthermore, hPSC-derived cells might 
exhibit a more fetal phenotype of HSCs and therefore might not have the same 
differentiation potential. The in vivo engraftment into immunocompromised mice and 
reconstitution of the entire haematopoietic system would be the ultimate functional 
test for hPSC-derived haematopoietic stem cells.  
Beside the OP9 co-culture method, we explored clinically applicable methods using 
a serum- and feeder free approach with APEL medium. Although CD34-expressing 
cells could be generated with this method, the derived CD34+ cells did not co-
express either CD43 or CD45. Furthermore, these cells did not form myeloid or 
erythroid colonies in CFU assays. We further explored differentiation with embryoid 
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body (EB) formation which has been shown to provide an environment closer to the 
in vivo development than 2D cultures, resulting in higher efficiencies of HSCs (Ng, 
Davis et al. 2008) (Knorr, Ni et al. 2013). Although EBs could successfully be 
derived from hESCs and hiPSCs and were cultured under 
mesoderm/haematopoietic–inducing conditions, the dissociation into a live single 
cell suspension could not be achieved in our hands. EBs are very compact, three-
dimensional aggregates with complex cell-adhesions.. Due to this problem we could 
not analyse the marker expression via FACS and could not enrich the 
haematopoietic precursors with magnetic beads. Several enzymes for dissociation 
were tested, including Accutase, trypsin/EDTA, tryPLE and gentle dissociation 
reagent. To improve the dissociation step in this protocol an “Embryoid body 
dissociation kit” could be tested in future experiments available from  Miltenyi 
Biotec. Furthermore, the density of formed EBs can critically affect the successful 
dissociation. For the spin EB method we have used 3000 pluripotent cells/EB where 
cell numbers could be down-scaled to avoid the formation of highly compact EBs, 
although this might have a negative effect differentiation efficiencies. 
 
Further studies with hiPSC-derived CD34+ cells revealed lower haematopoietic 
differentiation potential compared to UCB-derived CD34+ cells, tested in CFU 
assays and NK cell differentiation protocols (discussed in Chapter 4). Although 
CD34 is commonly used as a haematopoietic stem cell marker, it is also expressed 
on endothelial and mesenchymal cells. To address the potential problem that CD34-
expressing cells generated with the established OP9 co-culture are primed towards 
the haematopoietic or other lineages, we performed gene expression analysis with 
cells derived with OP9 co-culture differentiation. 
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Our data suggest that mainly the mesodermal lineage is induced within the first two 
days of differentiation which represents the first specification of haematopoietic 
development from PSCs. The haematopoietic markers PU.1, CD34 and CD45 are 
upregulated during differentiation indicating the successful derivation of 
haematopoietic progenitors within the culture. Interestingly, the mesenchymal 
marker CD10 and endothelial marker Tie2 are highly upregulated beside 
haematopoietic markers. These data suggest that OP9 co-culture does not solitary 
support differentiation towards the haematopoietic lineage, but also generates 
mesenchymal and endothelial progenitor cells. We believe, that this explains the low 
efficiencies in the differentiation to terminal haematopoietic cells. 
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Chapter 4 Generation of hiPSC- derived NK cells and their 
characterisation 
 Introduction 4.1
 
Haematopoietic progenitors are a promising source for the large scale generation of 
functional and pure allogeneic NK cells. Various studies describe the differentiation 
of large numbers of functional NK cells from umbilical cord blood (UCB)-derived 
CD34+ haematopoietic progenitor cells with co-culture systems in combination with 
cytokines (Frias, Porada et al. 2008; Pinho, Punzel et al. 2011; Larbi, Gombert et al. 
2012; Luevano, Madrigal et al. 2012; Luevano, Domogala et al. 2014). Furthermore, 
the generation of allogeneic NK cells without feeder cells and under GMP conditions 
opened doors for clinical trials (Spanholtz, Tordoir et al. 2010; Spanholtz, Preijers et 
al. 2011). These cells have shown efficient killing of bone marrow-residing human 
leukemia cells in NOD/SCID/IL2Rg(null) mice (Cany, van der Waart et al. 2013). 
Further studies with these in vitro culture conditions revealed that the addition of IL-
12 can direct the NK cell differentiation towards more mature NK cells with 
enhanced properties (Lehmann, Spanholtz et al. 2014). 
HPSCs could represent an unlimited source of NK cells enabling administration of 
high cell doses for immunotherapy and supporting the development of a well 
characterized repository of potentially “off the shelf” cells. The differentiation of 
hPSCs into functional NK cells has been described in the literature and although 
varying efficiencies in haematopoietic development can be observed in different 
hESC and hiPSC lines, functional NK cells can be effectively generated (Figure 4.1) 
(Woll, Martin et al. 2005; Knorr, Ni et al. 2013) (Vodyanik, Bork et al. 2005; Woll, 
Morris et al. 2008; Raya, Rodriguez-Piza et al. 2009; Ni, Knorr et al. 2011; Larbi, 
Gombert et al. 2012; Knorr, Bock et al. 2013).  
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Derivation methods are based on a two-step differentiation protocol. The first 
important step is the generation of CD34+ haematopoietic precursors from PSCs, 
discussed in Chapter 3. At this stage most protocols require cell sorting or 
enrichment of HSCs due to low efficiencies in the differentiation process. In the 
second step, PSC-derived HSCs are cultured either on stromal cell lines or in 
differentiation medium supplemented with cytokines to promote NK cell 
differentiation. Woll et al. described the co-culture of hESC-derived CD34+ cells with 
murine fetal liver-derived  AFT024 stromal cells in a medium supplemented with IL-
15, IL-3, IL-7, SCF and fms-like tyrosine kinase receptor-3 ligand (Flt3L) (Woll, 
Martin et al. 2005). After 30 days of culture, cells expressed NK cell maturation 
markers including NCRs, CD16, CD94/NKG2A and KIRs and cells could efficiently 
lyse malignant cells (Woll, Martin et al. 2005). Co-culture on the mouse fetal liver 
cell line EL08.1D2 in combination with IL-3, IL-7, IL-15, SCF and Flt3L has been 
described in the literature and will be discussed in more detail in the result chapter 
below. Another approach utilises the co-culture of CD34+ haematopoietic 
progenitors on OP9 stromal cells in combination with the following cytokines: BMP4, 
VEGF, SCF, FGF, TPO and Flt3L (Raya, Rodriguez-Piza et al. 2009). 
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Figure 4.1 Schematic overview of NK cell derivation methods from hPSCs. 
Figure adapted from (Eguizabal, Zenarruzabeitia et al. 2014).  
 
A clinical-scale derivation protocol of NK cells from hPSCs was published by Knorr 
et al. (Knorr, Ni et al. 2013), generating functional NK cells with the spin EB method 
in the absence of cell sorting and without the support of stromal cell lines, 
suggesting that hPSC-derived progenitors may produce their own stromal support. 
This study reports that NK cells can be generated at high numbers from both, 
hESCs and hiPSCs, achieved by a final expansion on artificial antigen-presenting 
cells (aAPCs) expressing membrane bound IL-21. Generated cells express NK cell-
specific surface markers including CD94, KIR, CD16, NKG2D and NKp46 in 
comparable level to peripheral blood and UCB-derived NK cells. hPSC-derived NK 
cells furthermore show efficient killing of the leukemic cell line K562 in an in vitro 
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killing assay (Knorr, Ni et al. 2013). NK cells generated with this method further 
show efficacy against leukemia, HIV infected cells and ovarian cancer in cellular 
assays and animal models (Ni, Knorr et al. 2011) (Hermanson, Bendzick et al. 
2016). 
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 Results 4.2
4.2.1 NK cell derivation from hPSC-derived CD34+ cells with the mouse fetal 
liver cell line EL08.1D2 co-culture system 
The aim of this study was to test the ability of hPSC-derived CD34+ cells (described 
in chapter 3) to acquire NK cell-specific surface marker expression. We adapted a 
protocol from collaborators at the Royal Free Hospital which facilitates successful 
differentiation of UCB-derived CD34+ cells into functional NK cells (Grzywacz, 
Kataria et al. 2006) (Luevano, Madrigal et al. 2012) (Luevano, Domogala et al. 
2014). The method is based on a co-culture system using the mouse fetal liver cell 
line EL08.1D2 in combination with the following cocktail of cytokines: IL-3 (week one 
only), IL-15, IL-7, SCF in weeks 1-4 and IL-15 only for weeks 5 and 6 (Figure 4.2).  
 
 
 
Figure 4.2 Schematic overview of the EL08.1D2 co-culture protocol for NK cell 
differentiation in vitro. CD34+ cells are co-cultured with the mouse fetal liver cell 
line EL08.1D2 for five to six weeks, supplemented with cytokines to induce NK cell 
differentiation. 
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4.2.2 HPSC-derived CD34+ differentiate into CD56+CD3- NK like cells 
The initial experiment of this study was performed in our collaborators laboratory 
where the protocol was established to generate large numbers of NK cells from 
UCB-derived CD34+ cells. We tested hESC- and hiPSC-derived CD34+ cells 
previously derived with two different methods: OP9 co-culture and APEL 
differentiation (described in chapter 3). CD34+ MACS enriched cells - derived with 
OP9 co-culture - from hESC H1 were used at a purity of 76% CD34+ cells from 
which 16% co-expressed CD43. JOM hiPSC-derived cells were used at a purity of 
67% CD34+ cells with 4% co-expressing CD43 (Figure 4.3 A). CD34+ MACS 
enriched cells derived with the APEL differentiation method were used at a purity of 
85% for H1 hESCs and 81% for JOM hiPSCs (Figure 4.3 B). Co-expression of 
CD43 could not be observed in these cells which correlates with findings discussed 
in Chapter 3. Cells were seeded onto irradiated EL08.1D2 feeder cells at 2000 
cells/96-well. The protocol is optimised to seed 500 UCB-derived CD34+ cells/well 
EL08.1D2 feeder cells which will expand to up to 1x106 NK cells (Grzywacz, Kataria 
et al. 2006; Luevano, Domogala et al. 2014). For this initial experiment we decided 
to plate higher cell numbers/well because of lower purity of CD34-expressing cells. 
Cell numbers limited this experiment to one well for each H1 hESC sample (OP9 
co-culture and APEL derived), two wells for JOM hiPSC APEL derived and two 
wells for JOM hiPSC OP9 co-culture derived. 
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Figure 4.3 hPSC-derived CD34+ cells for NK cell differentiation on EL08.1D2 
co-culture. (A) OP9 co-culture derived H1 hESC-derived CD34+ cells display 76% 
purity with 16% CD43 co-expression. JOM hiPSC-derived CD34+ cells from OP9 co-
culture with 67% purity and 4% CD43 co-expression. (B) APEL derived H1 hESC- 
and JOM hiPSC-derived CD34+ cells display purities of 85% and 81%, respectively 
without CD43 co-expression. 
 
Cells were cultured following the protocol with weekly medium changes 
supplemented with respective cytokines for each week (Figure 4.1). Importantly, on 
day 29 of co-culture, the viability of the cell culture was good and 99% of H1 hESC-
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derived cells (from OP9 co-culture) expressed CD56 in the absence of CD3, which 
characterises the NK cell population (Kiessling, Klein et al. 1975; Lanier, Phillips et 
al. 1986) (Figure 4.4 A). Furthermore, CD56dim and CD56bright sub-populations could 
be observed, with a predominant CD56bright NK cell population generated. Due to low 
cell numbers and the lack of an established multi-colour flow cytometry panel in this 
initial experiment, we could not stain for a range of NK cell-specific surface markers. 
However, the activating receptor NKG2D was expressed in 60% of CD56+ cells.  
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Figure 4.4 Day 29 NK cell differentiation with hPSC-derived CD34+ cells (OP9 
co-culture derived). (A) Primary NK cells isolated from fresh blood with negative 
selection beads. NKG2D expression levels on CD56+CD3- gated NK cells (B) H1 
hESCs display NK cell characteristic expression of 99% CD56, with distinguishable 
CD56dim and CD56bright sub-populations. 60% of CD56+ cells co-expressed the 
activating NK cell marker NKG2D (C) JOM hiPSC display a more granulated 
phenotype in the FSC/SSC profile and only 37% of cells express CD56 with 4% 
NKG2D co-expression. All gates were set based on corresponding isotype controls. 
 
Interestingly, JOM hiPSC-derived cells exhibited a different FSC/SSC profile 
compared to H1 hESC-derived cells on day 29 of co-culture with cells possessing 
higher granularity (Figure 4.4 B). CD56 up-regulation could be observed in 37% of 
cells but no clear separation of CD56dim and CD56bright sub-populations. Expression 
of NKG2D could be observed in 4% of CD56bright expressing cells.  
To investigate if hiPSC-derived cells will up-regulate CD56 to a level resembling the 
H1 hESC-derived NK-like cells, we co-cultured the cells for a further 20 days on 
EL08.1D2 feeder cells. On day 49, cell numbers and viability was low, however, 
84% of JOM hiPSC-derived cells were CD56+CD3- (Figure 4.5). No distinct sub-
populations of CD56dim and CD56bright could be observed. These data could indicate 
the presence of less mature progenitors in the JOM hiPSC-derived cell culture on 
day 29 compared to H1 hESC-derived cells. It might suggest that cells are in a 
different developmental stage from the beginning of the co-culture or hiPSCs might 
not have the same differentiation potential as hESCs. 
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Figure 4.5 Day 49 NK cell differentiation with JOM hiPSC-derived CD34+ cells 
(OP9 co-culture derived). Low cell numbers and viability were observed after 49 
days of EL08.1D2 co-culture, however, 84% of cells were CD56+CD3-. 
 
We further tested the NK cell differentiation potential of APEL derived CD34+ cells. 
The overall viability of APEL derived cells was low after 29 days of EL08.1D2 co-
culture when compared to OP9 co-culture derived cells (Figure 4.6). In the small 
viable cell population we could observe that 75% of H1 hESC-derived cells 
expressed CD56. No CD3 co-expression could be detected and 33% of cells co-
expressed NKG2D (Figure 4.6 A). JOM hiPSC-derived cells revealed a similar 
FSC/SSC profile compared to OP9 co-culture derived JOM hiPSC with more 
granulated cells compared to H1 hESC-derived cells. The viability was very low and 
analysis on the live cell population reveals 42% of cells express CD56 with 11% co-
expressing NKG2D (Figure 4.6 B). Further analysis of CD56 up-regulation at a later 
time point of EL08.1D2 co-culture could not be conducted because of poor cell 
survival. 
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Figure 4.6 Day 29 NK cell differentiation with hPSC-derived CD34+ cells (APEL 
derived). (A) H1 hESCs have a low viability in EL08.1D2 co-culture and display NK 
cell characteristic expression of 75% CD56, with no clear CD56dim and CD56bright 
sub-populations. 33% of CD56+ cells co-expressed the activating NK cell marker 
NKG2D (B) JOM hiPSC display a more granulated phenotype in the FSC/SSC 
profile and only 42% of cells express CD56 with 11% NKG2D co-expression. All 
gates were set based on corresponding isotype controls. 
 
The results of this initial study looked very promising for the prospect to generate 
NK-like cells from hiPSCs which were generated in our laboratory under GMP-
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compliant conditions. Although the overall cell survival and expansion was poor, 
CD56+CD3-NKG2D+ cells could be generated. Data suggest that OP9 co-culture 
derived CD34+ cells are more robust for further NK cell differentiation and we 
decided to conduct further experiments with these cells only.  
4.2.3 Immunophenotypic characterisation of UCB- and hPSC-derived CD34+ 
cells as starting cell population for NK cell differentiation 
We aimed to establish the EL08.1D2 co-culture protocol for NK cell differentiation in 
our laboratory, comparing the NK cell generation potential of UCB-, H1 hESC- and 
MMC hiPSC-derived CD34+ cells. hPSC-derived CD34+ cells were generated with 
OP9 co-culture and CD34+ cells of all three cell sources were enriched with CD34 
MACS technology. The purities of CD34 cultures used in this experiment were 68%, 
92% and 95% for MMC hiPSC-, H1 hESC- and UCB-derived cells respectively 
(Figure 4.7). The purity of MMC hiPSC-derived cells was low and ideally should 
have been enriched further. The CD45 FITC antibody did not work in this 
experiment. However, data for average CD45 expression in CD34 enriched cultures 
are discussed in Chapter 3, Figure 3.8.  
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Figure 4.7 CD34 cell purities for EL08.1D2 NK cell differentiation. 95% UCB-
CD34+, 92% H1 hESC-CD34+ and 68% MMC hiPSC-CD34+ cell purities. hPSC-
CD34+ cells were derived by OP9 co-culture and all cells enriched by CD34 MACS 
technology. CD45 FITC antibody did not give a representative staining in this 
experiment. All gates were set based on corresponding isotype controls. 
 
4.2.4 CD56 is upregulated during differentiation 
We monitored the upregulation of CD56 expression by flow cytometry during NK cell 
generation weekly until day 34 of culture (Figure 4.8). On day 14 of NK cell 
differentiation, upregulation of 6% and 9% of CD56 can be seen in MMC hiPSC- 
and H1 hESC-derived cells, respectively. In UCB-derived cells, upregulation of 4% 
can only be determined a week later on day 21 of culture.  At this time point, MMC 
hiPSC- and H1 hESC-derived cultures express 21% and 18% CD56, respectively. 
MMC hiPSC-derived cells display a clearly separate peak in the histogram, whereas 
H1 hESC-derived cells display a slight shift of CD56 expression. Significant 
upregulation of CD56 occurred in the 4th week of differentiation, with 62%, 76% and 
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83% of cells expressing CD56 in UCB-, MMC hiPSC- and H1 hESC-derived cell 
cultures, respectively. On day 34 of EL08.1D2 co-culture, 66% of UCB-derived cells 
express CD56 and 93% of MMC hiPSC-derived cells. Interestingly, these data 
suggest, that the upregulation of CD56 occurs earlier and more rapid in hPSCs 
compared to UCB-derived cells, resulting in higher percentage of CD56 expression 
on day 34 of NK cell differentiation culture. In the initial study we could observe over 
90% of H1-derived cells expressed CD56 whereas JOM hiPSC-derived cells 
expressed CD56 in only 37% of cells. This could be due to the genetic background 
of the hiPS cell line.  Unfortunately, due to contamination issues, the co-culture with 
H1 hESC cells had to be discarded before day 34 analysis. UCB-derived cells were 
affected by contamination after 5 weeks in culture and MMC hiPSC-derived cells 
were collected for further analysis. 
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Figure 4.8 CD56 upregulation during EL08.1D2 NK cell differentiation. (A) 
Percentage of CD56 expressing cells during differentiation, based on flow cytometry 
analysis of total cells. (B) Flow cytometry data show upregulation of CD56 in UCB-, 
MMC hiPSC- and H1 hESC-derived cells on days 14, 21, 28 and 34. 
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4.2.5 Cell numbers and expansion during NK cell differentiation 
Highly efficient NK cell generation from UCB-derived CD34+ cells is reported with 
the EL08.1D2 co-culture system with up to 1x106 NK cells generated from 500 
CD34+ cells (Grzywacz, Kataria et al. 2006; Luevano, Domogala et al. 2014). We 
aimed to determine the expansion potential of hPSC-derived cells under these 
conditions. Total cells in culture were counted weekly and total fold expansion 
determined (Figure 4.9). In our culture conditions, UCB-derived cells expanded over 
100 fold within the first week and a 700 fold expansion could be observed at day 35 
of EL08.1D2 co-culture. The cell expansion of hPSC-derived cells was extremly low 
to what was observed in UCB-derived cell cultures with less than 10 fold expansion.  
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Figure 4.9 Total fold expansion of cells during EL08.1D2 NK cell 
differentiation. UCB-, H1 hESC and MMC hiPSC-derived cell count was 
determined by trypan blue count. More than 100 fold lower expansion of hPSC-
derived cells could be observed compared to UCB-derived cells. 
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4.2.6 NK cell specific markers are expressed in hPSC-derived cells  
To determine if the generated CD56+ cells expressed NK cell-specific surface 
markers, we analysed UCB- and MMC hiPSC-derived cells on day 34 by flow 
cytometry. Importantly, data showed that cells did not express CD3, excluding the 
presence of T and NKT cells in the culture (Figure 4.10). Sub-populations CD56dim 
and CD56bright cannot be distinguished in either UCB- or MMC hiPSC-derived NK-
like cells.  
Interestingly, CD16 expression was higher on  MMC hiPSC-derived cells with 21% 
CD56+CD16+ cells, compared to 9% CD56+CD16+ cells from UCB-derived cells. 
Compared to NK cells isolated from peripheral blood, where 90% of cells belong to 
the cytotoxic CD56dimCD16+ sub-population. Cells derived from both sources – 
MMC hiPSC and UCB – expressed the activating NK cell marker NKG2D with 95% 
and 63%, respectively. Furthermore, NKp46 expression could be observed in 95% 
and 65% of cells in MMC hiPSC- and UCB-derived cells, respectively. Interestingly, 
these data show higher expression of both NK cell specific markers – NKG2D and 
NKp46 – in MMC hiPSC-derived cells compared to expression levels observed in 
UCB-derived NK cells and PBNKs.  
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Figure 4.10 UCB- and hiPSC-derived NK-like cells on day 34 of NK cell 
differentiation compared to freshly isolated PBNKs. (A) Both MMC hiPSC- and 
UCB-derived cell display NK cell characteristic expression CD56+CD3-, with no 
CD56-CD3+ T cells or CD56+CD3+ NKT cells present in the cultures. 21% and 9% of 
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MMC hiPSC- and UCB-derived cells expressed CD16, respectively. (B) NK cell 
specific markers are expressed in MMC hiPSC-derived cells to 95% NKG2D and 
95% NKp46 and UCB-derived cells express 63% NKG2D and 65% NKp46. 
4.2.7 MMC hiPSC-derived NK-like cells exhibit cytotoxic function against the 
leukemic cell line K562 in CD107a degranulation assay 
To assess the functional activity of MMC hiPSC-derived NK-like cells, we performed 
an in vitro CD107a degranulation assay. NK-like cells were co-cultured 1:1 with 
K562 target cells for 2 hours and the degranulation was assessed by the expression 
of CD107a on the cell surface using flow cytometry. The mean degranulation of 
MMC hiPSC-derived NK-like cells was 14±3.2%, n=3 (Figure 4.11).  
 
Figure 4.11 CD107a degranulation assay MMC-derived NK like cells day 35. 
Controls confirm that neither MMC hiPSC-NK like cells nor K562 target cells 
express CD107a. CD107a is upregulated after co-culture to 14 ± 3.2%, n=3, 
indicating cytotoxic efficiency of hiPSC-derived NK like cells.  
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4.2.8  Serum- and feeder free NK cell differentiation with GBGM medium 
To explore the NK cell differentiation potential in serum- and feeder conditions, we 
used the Glycostem basal growth medium (GBGM) supplemented with a high dose 
of SCF, IL-7, TPO and Flt3L and a low dose of G-CSF, GM-CSF and IL-6. 
Differentiation was induced by replacing TPO with IL-15 on day 10 and Flt3L with IL-
2 on day 14 (Figure 4.12). This method for NK cell differentiation from freshly 
isolated UCB-CD34+ cells is GMP compliant. The initial study reported >15000 fold 
expansion of the ex vivo generated cell product, containing nearly 100% functional 
NK cells (Spanholtz, Preijers et al. 2011).  With gene expression profiling, real-time 
PCR, flow cytometry and functional analysis, this group characterised UCB-derived 
NK cells and compared data to PBNKs (dim and bright) (Lehmann, Spanholtz et al. 
2012). At day 28, the CD56+ NK cell population within the culture reached 50% and 
over 95% at day 35. With gene expression analysis this study shows that relevant 
NK cell receptors and intracellular proteins for NK cell function are expressed in 
UCB-derived NK cells, eg. CD56, CD94, CD16 and cytolytic proteins (granzyme A, 
granzyme B, perforin) (Lehmann, Spanholtz et al. 2012). 
Interestingly, the data suggest that UCB-derived NK cells, differentiated with this 
method cannot, be classified as conventional CD56bright or CD56dim sub-populations 
as seen in PBNKs. Although UCB-derived NK cells display a phenotype similar to 
CD56bright PBNKs, they possess potent cytotoxicity and produce IFN-ƴ upon 
activation. These data demonstrate, that the ex vivo generation of NK cells (from 
UCB CD34+ cells) is a promising approach to generate large numbers of cytotoxic 
lymphocytes for immunotherapy (Lehmann, Spanholtz et al. 2012). HPSC have not 
been used to generate NK cells with this feeder- and serum free method before. We 
aimed to derive NK like cells from hPSCs with comparable cell expansion and 
phenotype as observed in UCB- derived and PBNKs. 
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Figure 4.12 Schematic overview of serum- and feeder free NK cell 
differentiation with GBGM medium. CD34+ cells are cultured in a combination of 
expansion and differentiation media – supplemented with respective cytokines – to 
generate NK cells within 35 days. 
 
4.2.9 Immunophenotypic characterisation of UCB- and hPSC-derived CD34+ 
cells as starting cell population for NK cell differentiation with GBGM 
medium 
We aimed to establish the serum- and feeder free NK cell differentiation protocol 
with GBGM in our laboratory, comparing the NK cell generation potential of UCB-, 
H1 hESC, HPS1 hiPSC- and MMC hiPSC-derived CD34+ cells. hPSC-derived 
CD34+ cells were generated with OP9 co-culture and CD34+ cells of all three cell 
sources were enriched with CD34 MACS technology. The purities of CD34 cultures 
used in this experiment were 96% for H1 hESC-, HPS1 hiPSC- and MMC hiPSC-
derived cells (Figure 4.13). Highest CD45 and CD43 co-expression was observed in 
HPS1 hiPSC-derived CD34+ cells with 43% and 49%, respectively. 16% of H1 
hESC-derived cells co-expressed CD45 and 27% CD43. Co-expression of 25% 
CD45 and 40% CD43 could be detected in MMC hiPSC-derived cells. 
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Figure 4.13 CD34 cell purities for GBGM NK cell differentiation. CD34+ MACS 
enriched cells derived from (A) H1 hESC displayed a purity of 96% CD34 with 16% 
of cells CD34+CD45+ and 27% CD34+CD43+. (B) 96% of HPS1 hiPSC-derived cells 
expressed CD34 with 43% CD34+CD45+ and 49% CD34+CD43+. (C) Enriched cells 
derived from MMC hiPSCs expressed 96% CD34 with 25% CD34+CD45+ and 40% 
CD34+CD43+. All gates were set based on corresponding isotype controls. 
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4.2.10 Cell numbers and expansion during NK cell differentiation 
Highly efficient NK cell generation from UCB-derived CD34+ cells is reported with 
the GBGM culture system (Spanholtz, Tordoir et al. 2010; Spanholtz, Preijers et al. 
2011; Lehmann, Spanholtz et al. 2012). We aimed to determine the expansion 
potential of hPSC-derived cells under these conditions. Total cells in culture were 
counted weekly and total fold expansion was determined (Figure 4.14). In our 
culture conditions, UCB-derived cells expanded 800 fold with highest expansion rate 
within the first three weeks of culture. The cell expansion of hPSC-derived cells was 
very low and comparable what could be observed in EL08.1D2 co-culture. The low 
cell survival and expansion potential of hPSC-derived cells made experimental 
planning and analysis very challenging and we aimed to keep as many cells as 
possible in culture until the last stages for characterisation. 
 
 
Figure 4.14 Total fold expansion of cells during EL08.1D2 NK cell 
differentiation. UCB-, H1 hESC-, HPS1 hiPSC- and MMC hiPSC-derived cell count 
was determined by trypan blue count. 100 fold lower expansions of hPSC-derived 
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cells could be observed compared to UCB-derived cells. Results are presented as 
Mean±SD, n=2. 
 
On day 28 and day 35 of NK cell differentiation, we collected cells and performed 
analysis of surface marker expression by flow cytometry. In HPS1 hiPSC-derived 
cell cultures we could not observe a distinct cell population in the FSC/SSC profile 
(Figure 4.15 A). These data suggest that cell survival was poor. Despite the lack of 
a discrete lymphocyte population, we aimed to gate on the lymphcyte population 
and could observe cell populations expressing 64% CD56 and 9% CD56+CD16+. 
On day 35 of GBGM culture, only cell debris could be observed in HPS1 hiPSC- 
and H1 hESC-derived cells and cultures were lost for further analysis (Figure 4.15 
C). In contrast to HPS1 hiPSC-, MMC hiPSC-derived cells revealed a distinct 
lymphocyte population based on FSC/SSC profiling and interestingly, cells 
expressed the NK cell marker CD56 to 95% on day 28 of differentiation (Figure 4.15 
B) compared to 38% observed in UCB-derived NK cell cultures (Figure 4.16). Cells 
generated from UCB-derived CD34+ cells on day 28 and 35 expressed CD56 in 
38% and 78%, respectively (Figure 4.16 A and B). NK cell specific marker 
expression could be observed to similar levels in week 4 and 5. 
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Figure 4.15 In vitro generated NK cells from hPSC-derived CD34+ cells on day 
28 and 35 of feeder- and serum free GBGM differentiation method. Cells were 
analysed by flow cytometry using antibodies for NK cell specific surface markers. 
(A) HPS1 hiPSC-derived cells on day 28, (B) MMC hiPSC-derived cells on day 28. 
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Figure 4.16 In vitro generated NK cells from UCB-derived CD34+ cells on day 
28 and 35 of feeder- and serum free GBGM differentiation method. Cells were 
analysed by multi-colour flow cytometry using a panel of antibodies for NK cell 
specific surface markers. (A) UCB-derived NK cells on day 28 and (B) day 35 of 
GBGM culture. Cells for surface marker analysis were gated on the CD56+CD3- cell 
population. (C) Expression data in % are summarised in a bar chart, n=1. 
4.2.11 HiPSC-derived NK like cells display surface marker expression close to 
UCB-derived NK cells and freshly isolated PBNKs 
To investigate if hiPSC-derived NK like cells express NK cell specific surface 
makers, to a similar level compared to UCB-derived NK cells and freshly isolated 
PBNKs, we analysed GBGM-derived cells on day 42 by multi-colour flow cytometry 
using a panel of antibodies for NK cell specific surface markers. PBMCs were 
isolated from a healthy donor by density gradient and NK cells were enriched by 
MACS NK cell separation. Cells were gated on the CD56+CD3- NK cell population 
(Figure 4.17). PBNKs displayed the two main subpopulations CD56brightCD16- and 
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CD56dimCD16+ (Figure 4.17 A). Analysis of UCB- and hiPSC-derived NK like cells 
revealed that derived cells cannot be classified as conventional CD56bright or 
CD56dim sub-populations as seen in PBNKs (Figure 4.17 B, C). CD16 expression 
could not be observed in UCB-derived and hiPSC-derived NK like cells. However, 
5% of hiPSC-derived NK like cells expressed panKIR2D on their surface, higher 
compared to 0.8% observed in UCB-derived NK-like cells. Interestingly, we 
observed higher panKIR2D expression on day 28 and day 35 of GBGM 
differentiation in UCB-derived cells (Figure 4.16). CD94 is expressed by 84% of 
MMC hiPSC-derived NK like cells, compared to 77% of UCB-derived NK cells and 
64% PBNKs. NCRs NKp44 is expressed only on 2% of fresh PBNKs, to 58% UCB-
derived and 93% MMC hiPSC-derived NK like cells. NKp30 is expressed in 27% of 
PBNKs, 2% in UCB-derived and 94% hiPSC-derived NK like cells. NKG2D is 
expressed in 96% PBNKs, 74% UCB- and 77% hiPSC-derived NK like cells. NKp46 
and NKG2C could not be analysed in hiPSC-derived cells because FACS panel 
tube 1 and 2 were combined to only 1 tube. 
Surface expression of NKG2A and NKG2C should be linked with CD94 expression 
as NKG2 chains can only be transported to the cell surface with CD94 (Lopez-Botet, 
Bellon et al. 2000). NKG2C is donor dependent in PBNKs (Guma, Cabrera et al. 
2006). 
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Figure 4.17 In vitro generated NK like cells on day 42 of feeder- and serum 
free GBGM differentiation method. Cells were analysed in parallel by multi-colour 
flow cytometry using a panel of antibodies for NK cell specific surface markers. (A) 
Primary NK cells isolated from fresh blood, (B) UCB-derived NK cells day 42 and 
(C) MMC hiPSC-derived NK like cells day 42 of GBGM culture. Cells for surface 
marker analysis were gated on the CD56+CD3- cell population. (C) Expression data 
in % are summarised in a bar chart, n=1. 
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 Discussion 4.3
In this chapter we investigated if hiPSC-derived CD34+ cells (discussed in chapter 
3) have the potential to differentiate to cells with NK cell specific surface marker 
expression and killing capacity. We adapted two different in vitro derivation 
protocols for the generation of NK like cells from hPSC – the co-culture on murine 
fetal liver cells and a feeder-free culture with GBGM medium. The co-culture on 
feeder cells has been described in the literature for NK cell generation from UCB-
derived, hESC- and hiPSC-derived CD34+ cells (Knorr, Ni et al. 2013) (Grzywacz, 
Kataria et al. 2006) (Luevano, Domogala et al. 2014) (Woll, Martin et al. 2005). In 
contrast, the feeder-free in vitro derivation with GBGM medium has so far only been 
described for UCB-derived CD34+ cells (Lehmann, Spanholtz et al. 2012). We 
compared the kinetics of differentiation and phenotype of generated NK like cells to 
those obtained from UCB-derived CD34+ cells and PBNKs.  
The first major observation was that the expansion of hPSC- (both hESC and 
hiPSC) derived cells was significantly lower than what was observed with UCB-
derived CD34+ cells. The cell expansion was lowest with hESC-derived cells and 
was slightly increased with hiPSC-derived cells with less than 10 fold expansion in 
NK cell differentiation medium. In contrast, UCB-derived CD34+ cells expanded up 
to 800 fold. This could be observed in both, co-culture with feeder cells and feeder-
free GBGM culture conditions. Total cell expansion of UCB-derived CD34+ cells with 
EL08.1D2 co-culture was published with 2000 fold (Grzywacz, Kataria et al. 2006). 
Even higher expansion was reported with GBGM culture conditions with over 15000 
fold expansion within five weeks of differentiation (Spanholtz, Tordoir et al. 2010). In 
contrast, the expansion potential of hESC-derived cells is reported to be significantly 
lower. Knorr et al. describe 56.8 fold expansion of hESC-derived cells with 
EL08.1D2 co-culture and 40.4 fold in feeder-free conditions, which is higher than 
what was observed in our study but still significantly lower than UCB-derived cell 
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expansion (Knorr, Ni et al. 2013). This study used the H9 hES cell line compared to 
H1 hESCs used in our study which might exhibit dissimilar differentiation potential. 
Furthermore, haematopoietic progenitors were derived by spin EB method and EBs 
were directly transferred to NK cell differentiation conditions without CD34+ sorting 
(Knorr, Ni et al. 2013). Interestingly, the expansion potential of hiPSC-derived cells 
in in vitro NK cell differentiation is not discussed in this study. A different article 
described 2 log expansion of H9 hESC-derived cells after 3-5 weeks of culture 
(Woll, Martin et al. 2005). This group sorted for CD34+CD45+ progenitor cells 
derived by M210-B4 co-culture. Sorting for the double positive cell population could 
be more specific to haematopoietic progenitors which could explain the increased 
proliferation rate of these cells. 
The low expansion potential could be due to various reasons. Firstly, it could be 
partly because the hPSC-derived CD34+ cell population is heterogeneous and is 
partially primed towards non-haematopoietic lineages. As discussed in Chapter 3, 
our data suggest that the hPSC-derived CD34+ cells might encompass only a small 
fraction of cells with haematopoietic or more specifically lymphocyte or NK cell 
differentiation potential, based on gene expression analysis and colony forming 
ability as assessed in CFU assays. Secondly, hPSC-derived haematopoietic 
progenitors could be less mature or primed towards other haematopoietic lineages 
and they might not express receptors necessary for the induction of NK cell lineage 
differentiation.  
Despite the difficulties observed with cell expansion, our data suggest that 
CD56+CD3- NK-like cells can be generated from both, the H1 hES and the MMC 
patient-derived hiPS cell line (derived from fibroblasts). In EL08.1D2 co-culture, 
CD56 is upregulated in both, hESC and hiPSC-derived cells, to up to 80% within 28 
days of culture. Interestingly, the percentage of CD56 expression is higher in hPSC-
derived cells compared to UCB-derived cells, encompassing 93% and 72% of cells 
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on day 34, respectively. However, interpretation of these results needs to be done 
with caution because data were only collected from one experiment due to low cell 
numbers, time constraints and contamination issues. On day 34 of NK cell 
differentiation, MMC hiPSC-derived NK like cells co-express CD16 slightly higher 
compared to UCB-derived NK cells and no distinct CD56bright and CD56dim sub-
populations can be distinguished, compared to freshly isolated PBNKs with 90% of 
NK cells categorized as CD56dimCD16+. CD56bright NK cells might be in an earlier 
maturation stage and future lines of investigations could test if hiPSC-derived NK 
cells can further mature to CD56dim sub-population. Furthermore, the 
characterisation in regards to cytokine release and comparison to different ILC 
groups would be of interest. Interestingly, hiPSC-derived NK like cells express 
higher NKG2D and NKp46 activation markers compared to UCB-derived NK cells 
and PBNKs. Our data further suggest that EL08.1D2 hiPSC-derived NK like cells 
are capable of killing K562 cells in an in vitro killing assay. Low or absent CD16 
would suggest that hPSC-derived NK cells are not capable of ADCC. It would be 
interesting to investigate this further and what other effector functions might be 
triggered upon target cell recognition. 
We further investigated if NK like cells can be generated in feeder-free conditions. 
Generation of hiPSC-derived NK cells under GMP conditions is of interest for 
clinical application for immunotherapy. Knorr et al. describe feeder-free NK cell 
generation from hiPSCs (Knorr, Ni et al. 2013). In contrast to this study, we used 
hiPSCs derived from fibroblasts under GMP compliable, integration-free conditions. 
Furthermore, the use of GBGM medium – which was shown to efficiently 
differentiate and highly expand UCB-derived haematopoietic stem cells (Spanholtz, 
Tordoir et al. 2010) – was not tested for hPSC-derived NK cell differentiation before. 
Our data suggest that NK like cells can be generated from the MMC hiPSC-derived 
CD34+ cells. Consistent with data from EL08.1D2 co-culture, cell expansion was 
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extremely low during differentiation with over 100 fold less total fold expansion. 
Interestingly, MMC hiPSCs survived and expanded best with almost 10 fold 
expansion, compared to HPS1 hiPSCs and H1 hESCs which could not be cultured 
until the end of the experiment.  
After 42 days of NK cell differentiation, we compared the phenotype by flow 
cytometry of MMC hiPSC-, UCB-derived and peripheral blood NK cells. Based on 
our data, the MMC hiPSC-derived NK cells generated with GBGM medium cannot 
be strictly classified as CD56bright or CD56dim subpopulations on day 42 of culture, 
compared to populations present in PBNK cells. This goes confirm with what has 
been reported in the literature on UCB-derived NK cells (Spanholtz, Tordoir et al. 
2010) (Lehmann, Spanholtz et al. 2012) and what can be observed in our control 
cultures. In contrast to what is published in the literature, UCB-derived NK cells did 
not express CD16 in our experiment.  
MMC hiPSC-derived NK like cells express major NK cell specific markers, including 
KIR2D , CD94, NKp44 and the activating receptor NKG2D to comparable levels with 
UCB-derived and peripheral blood NK cells. Interestingly, we observed higher 
KIR2D and NKp30 expression in MMC hiPSC-derived NK like cells compared to 
UCB-derived cells.  
In summary, our data suggest that NK like cells can be generated from hPSCs 
differentiated with two individual derivation protocols. Derived cells expressed CD56 
in the absence of CD3 and the NK cell-specific marker expression is comparable to 
levels on UCB-derived and peripheral blood NK cells. Furthermore, we show that 
K562 target cells can be lysed in an in vitro degranulation assay. 
The main challenges we observed in this study was low cell expansion and 
contamination issues due to long derivation protocols. Low cell numbers made it 
extremely difficult to rigorously study phenotype and functionality.  
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Chapter 5 Transcription factor-driven NK cell differentiation 
with E4bp4 
 Introduction 5.1
 
In my work so far I have utilized the conventional strategy to generate NK cells from 
hiPSCs via an intermediate differentiation step to CD34+ haematopoietic progenitor 
cells. Although this approach results in functional NK cells phenotypically 
comparable to cord blood-derived NK cells - there are a couple of obstacles: (1) the 
long derivation period of 7 to 8 weeks and (2) low NK cell numbers. To overcome 
these problems we explored the alternative approach of transcription factor-driven 
differentiation. The underlying idea is to identify key transcriptional regulators, 
specific for the desired cell type (NK cells in my study) and to over-express them in 
hiPSCs. Our hypothesis is that this will directly drive the differentiation into the 
lineage of interest and allows bypassing limiting steps in the development. This 
concept has been described in several studies, for example direct induction of the 
haemato-endothelial program in hiPSCs (Elcheva, Brok-Volchanskaya et al. 2014) 
NK cell development and the transcriptional control have been studied well in 
mouse settings. With knock out models the roles of a number of key transcriptional 
regulators have been identified and their phenotypes suggest that they act in 
different time points in NK cell development. Several factors, such as Eomes, Id2, 
MEF and Tox have been reported to regulate NK cell maturation and act relatively 
late in NK cell development (Male, Nisoli et al. 2014).  
In contrast, the transcription factor E4bp4 (Nfil3) has been shown to act early in NK 
cell development. Data suggest a possible role as a lineage commitment factor in 
NK cell development controlling the development of NK cell progenitors (NKPs) 
from common lymphoid progenitors (CLPs) (Gascoyne, Long et al. 2009; Male, 
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Nisoli et al. 2014). The research group led by Hugh Brady further showed that in the 
absence of E4bp4, IL-15-responsive CD122+ NKPs fail to develop (Male, Nisoli et 
al. 2014). This suggests that E4bp4 is required for the expression of IL-15 receptor 
(CD122) and that E4bp4 acts upstream of IL-15 signaling. This has been an 
interesting observation because IL-15 has previously been considered as the 
definitive factor required for NK cell differentiation. Furthermore, this study revealed 
that E4bp4 directly regulates the expression of the transcription factors Eomes and 
Id2, but not T-bet which can also rescue the E4bp4-/- phenotype and might act in a 
different pathway. Over-expression of E4bp4 in murine CLPs enhances NK cell 
production in vitro (Male, Nisoli et al. 2014). The role of E4bp4 in human NK cell 
development has not been studied as extensively as in mouse NK cell development. 
 
We aimed to express E4bp4 at different stages in our in vitro NK cell differentiation 
model. Our hypothesis is that the over-expression of human E4bp4 in cord blood 
and hiPSC-derived CD34+ cells will increase NK cell numbers with improved 
cytotoxic effect in NK cell differentiation with GBGM medium. We further 
hypothesised that the expression of E4bp4 in pluripotent stem cells will directly 
induce the NK cell developmental program which will allow us to bypass the limiting 
HSC stage in our in vitro culture model.  
 
Furthermore, we aimed to explore the strategy of direct lineage reprogramming 
(transdifferentiation) for differentiating functional NK cells from hiPSCs. 
Transdifferentiation describes the reprogramming of one specialised cell type into 
another by either over-expression of lineage-specific transcription factor or adding 
small molecules, micro-RNAs or epigenetic regulators. Various cell types in both, 
mouse and human, have been generated with this approach as summarized in the 
review of Pfaff et al. (Pfaff and Cantz 2013) (Figure 5.1). We hypothesised, that the 
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over-expression of an NK cell-specific transcriptional regulator in somatic cells (eg. 
fibroblasts, endothelial or blood cells) can directly induce the NK cell program. This 
method will not require the intermediate pluripotent stem cell stage and if feasible it 
will generate new sources for the derivation of NK cells. 
 
 
 
 
Figure 5.1 Fibroblast-derived members of the iClub. (Pfaff and Cantz 2013) 
Direct lineage reprogramming of fibroblasts by expression of transcription factors or 
microRNAs (miRNAs) into iPSC (induced pluripotent stem cells), iCM (induces 
cardiomyocytes), iN (induced neurons), iNSC (induced neural stem cells), iHep 
(induced hepatocytes) and iHem (induced haematopoietic cells). 
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 Results 5.2
 
We received the human E4bp4 vector cloned into a lentiviral backbone and the 
mock control plasmid from a collaborator (Hugh Brady lab): pcSGW-IRES-tdtomato 
(0.4µg/ml) and pcSGW-hE4bp4-IRES-tdtomato (0.4µg/ml). Sequences for these 
vectors were not provided, see schematic representation of the plasmids in Figure 
5.2. Both plasmids were transfected into E.coli and plasmid DNA purified by mini- 
and maxi preps. 
 
 
 
 
Figure 5.2 Schematic plasmid map of original lentivirus over-expression 
vectors.  
 
To verify the correct size of the amplified plasmids, a restriction digest with BamHI 
was performed. The correct fragment sizes were confirmed as followed: backbone 
11000bp + 600bp for mock construct (Figure 5.3 a) and 11000bp + 2000bp for 
E4bp4 plasmid (Figure 5.3 b). The described plasmid preps were used for virus 
production. 
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Figure 5.3 Restriction digest with BamHI. Correct sizes of plasmids for virus 
production were confirmed by restriction digest with BamHI. (a) 11000bp + 600bp in 
mock construct and (b) 11000bp + 2000bp in E4bp4 construct. A 1kb DNA ladder 
was used in gel electrophoresis. 
5.2.1 Virus titration  
To determine the lentiviral titer of mock (pcSGW-IRES-tdtomato) and E4bp4 
(pcSGW-hE4bp4-IRES-tdtomato) lentivirus, we transduced HEK293T cells with 
dilutions of lentivirus and measured tdtomato expression on day 3 post-transduction 
(Figure 5.4). 64% of mock transduced cells expressed tdtomato with 1:10 (5µl) and 
13% with 1:100 (0.5 µl) dilution. 34% of E4bp4 transduced cells expressed tdtomato 
with 1:10 (5µl) and 5% with 1:100 (0.5 µl) dilution. Titer was calculated as follows: 
Mock 
0.5µl of viral supernatant lll.13% of 5x104 HEK293T cells 
1000µl of viral supernatant ll..13% of 1x108 HEK293T cells  
            = 1.3x107 infectious units/ml 
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E4bp4 
5µl of viral supernatant llll.34% of 5x104 HEK293T cells 
1000µl of viral supernatant ll..34% of 1x107 HEK293T cells  
            = 3.4x106 infectious units/ml 
 
Virus titer of E4bp4 lentivirus was almost tenfold lower than mock lentiviral prep. 
 
 
Figure 5.4 Virus titration by HEK 293T transduction efficiency. Tdtomato 
expression in cells transduced with varying concentrations of virus was determined 
by flow cytometry. 
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5.2.2 UCB-derived CD34+ cells can be efficiently transduced  
In the initial experiment we aimed to transduce UCB-derived CD34+ cells to assess 
transduction efficiencies and if the expression of the construct can be maintained 
over the period of NK cell differentiation in GBGM medium.  
UCB-derived CD34+ cells were transduced with mock (pcSGW-IRES-tdtomato) and 
E4bp4 (pcSGW-hE4bp4-IRES-tdtomato) lentivirus, respectively, with MOI 5. 
Transduced and untransduced cells were cultured following the GBGM NK cell 
differentiation. On day 6 post-transduction, tdtomoto expression was determined by 
flow cytometry. Transduction with mock lentiviral particles resulted in good efficiency 
of 39% of cells expressing tdtomato, compared to low transduction efficiency with 
4% tdtomato-expressing cells after E4bp4 transduction (Figure 5.5 A). Due to very 
low transduction efficieny with the E4bp4 lentivirus, we decided to sort for tdtomato+ 
cells by FACS on day 13. Mock transduced cells expressed 25% tdtomato on day 
13 pre-sorting which could be enriched to a cell population expressing 94% (Figure 
5.5 B). The E4bp4 transduced cell population expressed tdtomato only in 1.8% of 
cells which could be enriched to 98% post-sorting (Figure 5.5 C). However, due to 
the very low expression rate, the sorted cell population only consisted of 2000 cells 
which made further cell culture challenging. 
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Figure 5.5 Transduction efficiency of UCB-derived CD34+ cells. Tdtomato 
expression was determined by flow cytometry on day 6 post transduction with (A) 
mock vector (left) and E4bp4 vector (right). (B) Tdtomato expression on mock 
transduced cells on day 13 pre-sorting (left) and post-sorting (right) and (C) 
Tdtomato expression on E4bp4 transduced cells on day 13 pre-sorting (left) and 
post-sorting (right). 
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5.2.3 Lentiviral transduced UCB-derived NK cells keep tdtomato expression 
upregulated during NK cell differentiation and surface marker 
expression differs compared to untransduced UCB-derived NK cells  
To investigate if mock and E4bp4 transduced UCB-derived NK cells express NK cell 
specific surface makers to similar levels compared to untransduced UCB-derived 
NK cells, we analysed GBGM-derived cells in parallel by multi-colour flow cytometry 
on day 27. Cells were gated on the CD56+CD3- NK cell population (64%) and 
transduction efficiency is shown in the histogram (Figure 5.6). Untransduced UCB-
derived NK cells on day 27 display CD56bright and CD56dim sub-populations with 11% 
CD16 expressing cells (Figure 5.6 A). Compared to untransduced cells, CD56+CD3- 
NK cell population in mock transduced cells comprised of only 13% (Figure 5.6 B) 
and surprisingly of only 2% in E4bp4 transduced cells (Figure 5.6 C). The low NK 
cell generation could be due to very low cell numbers sorted which could make the 
NK cell differentiation less efficient. On the other side, E4bp4 could exhibit the 
opposite effect as proposed and inhibit NK cell differentiation. 
The analysis of NK cell specific surface markers revealed a general lower 
expression profile in mock transduced cells. 7% of untransduced UCB-derived NK 
cells express KIR2D, compared to no expression in mock transduced cells (Figure 
5.6 A and B). CD94 is expressed in 76% of untransduced and only in 25% of mock 
transduced cells. Lower expression could also be observed in NKp46, NKp30, 
NKG2D and NKG2C in mock transduced cells (Figure 5.6 A and B). NK cell marker 
expression could not be analysed in E4bp4 transduced cells because of low 
CD56+CD3- cell numbers.  
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Figure 5.6 In vitro generated NK cells from UCB-derived CD34+ cells on day 27 
of feeder- and serum free GBGM differentiation method. (A) untransduced and 
(B) mock transduced cells were analysed by multi-colour flow cytometry using a 
panel of antibodies for NK cell specific surface markers. Cells for surface marker 
analysis were gated on the CD56+CD3- cell population. The percentage of GFP 
expressing cells is represented in histograms (C) E4bp4 transduced cells could not 
be analysed for NK cell specific markers due to low CD56+CD3- cell population. All 
gates are set based on corresponding isotype controls. 
 
 
 
  
171 
 
5.2.4 Cloning of new lentiviral vector into pCCL.EF1α.eGFP backbone 
 
Because of the low lentiviral titer achieved with pSGW constructs, we decided to 
clone E4bp4 into a 3rd generation pCCL lentiviral backbone. This construct 
expresses GFP instead of tdtomato under the EF1α promotor (Figure 5.7). 
MP12840.pCCL.EF1α.eGFP was used as mock control. The correct size of the 
cloned and amplified E4bp4 overexpression plasmid was confirmed by restriction 
digest with SmaI and BstBI and expected DNA fragments of 8800bp and 1700bp 
could be observed in DNA from mini preps b-e (Figure 5.8). Lentivirus was 
produced with both the mock control and E4bp4 overexpression plasmid DNA from 
mini prep d. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Plasmid maps of newly cloned lentivirus over-expression vectors. 
 
Mock control 
plasmid 
E4bp4 
overexpression 
plasmid 
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Figure 5.8 Restriction digest of E4bp4 overexpression plasmid DNA with SmaI 
and BstBI. Correct sizes of DNA fragments could be observed in DNA from mini-
preps b-e with 8800bp and 1700bp. Mini-prep d was chosen for further lentivirus 
production. A 1kb DNA ladder was used in gel electrophoresis. 
 
 
The lentiviral titer was determined by transduction of HEK293T cells with various 
concentrations of virus. A higher titer could be achieved with the pCCL lentiviral 
constructs: mock 4.9x109 IU/ml and E4bp4 2x107 IU/ml (data not shown). 
5.2.5 E4bp4 over-expression with pCCL.EF1α.E4bp4.IRES.eGFP can be 
detected on RNA and protein level 
 
To test the upregulation of E4bp4 on RNA and protein level, we transduced Jurkats, 
HEK293T cells and hiPSCs with either mock or E4bp4 over-expression lentivirus. 
Western blot analysis showed the detection of E4bp4 in all three cell lines 
transduced with E4bp4 lentivirus (Figure 5.9 A). E4bp4 is endogenously expressed 
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in Jurkats and HEK293T cells, which was detected in untransduced and mock 
transduced cells. Overexpression could be observed in E4bp4 transduced cells. 
Upregulation could also be detected on RNA level with E4bp4 transduced 
fibroblasts (Figure 5.9 B). 
 
 
 
 
Figure 5.9 Lentivirus construct successfully upregulates E4bp4 in Jurkat 
cells, HEK293T and hiPSCs. (A) E4bp4 (60 kDa) over expression in Western Blot 
with GAPDH loading control and (B) relative expression (normalized to GAPDH) 
determined by RT-qPCR in fibroblasts. Results are presented as Mean±SD, n=3 
technical replicates. 
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5.2.6 Direct differentiation of hiPSCs to NK cells by over-expression of 
E4bp4  
Our initial experiment aimed to over-express E4bp4 in hiPSCs to attempt direct 
differentiation into the NK cell lineage. We transduced MMC hiPSCs with the mock 
(pCCL.EF1α.eGFP) and E4bp4 (pCCL.EF1α.E4bp4.IRES.eGFP) lentivirus, 
respectively. Directly after transduction, cells were transferred into NK cell 
differentiation conditions with GBGM medium and corresponding cytokines. Cell 
morphology and cell numbers were monitored. Cell viability decreased radically 
after a few days in culture and no cell characterization could be performed. 
Haematopoietic, and further NK cell development, is a long process requiring 
sequential acquisition of receptors, important for recognition of maturation signals of 
the environment. We concluded that the expression of a single NK cell-specific TF 
in combination with NK cell differentiation specific culture conditions is not sufficient 
to induce a transcriptional network that facilitates the maturation of NK cells. 
Therefore, we decided to over-express E4bp4 in the established 2-step 
differentiation method to investigate if a combination of cytokine- and TF-driven 
differentiation can improve NK cell differentiation and/or phenotype. 
5.2.7 Can the over-expression of E4bp4 in hiPSCs improve the efficiency of 
NK cell differentiation? 
MMC hiPSCs were transduced with mock (pCCL.EF1α.eGFP) and E4bp4 
(pCCL.EF1α.E4bp4.IRES.eGFP), respectively, with MOI 20. Transduced cells were 
expanded in pluripotent stem cell conditions using mTESR1, differentiated towards 
CD34+ haematopoietic precursors with OP9 co-culture, MACS enriched and 
differentiated to NK cells with GBGM culture conditions (Figure 5.10). 
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Figure 5.10 Schematic overview of experimental layout – E4bp4 
overexpression in 2-step NK cell differentiation from hiPSCs. 
 
5.2.8 Good transduction efficiency of hiPSCs and GFP upregulation is 
maintained during cell expansion in pluripotent culture conditions  
Transduction efficiency was determined by GFP expression with flow cytometry on 
day 3 post-transduction. 46% of mock and 30% of E4bp4 transduced cells 
expressed GFP (Figure 5.11 A). Transduction efficiency with pCCL lentivirus was 
more efficient compared to transductions with the original pcSGW lentivirus. After 3 
passages in pluripotent stem cell conditions with mTESR1, the transduction 
efficiency increased to 57% of GFP expressing cells with mock and 40% GFP 
expressing cells with E4bp4 transductions (Figure 5.11 B). These cells represent 
day 0 of the differentiation experiment. 
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Figure 5.11 MMC hiPSC transduction efficiency. GFP expression was 
determined by flow cytometry on (A) day 3 post-transduction and (B) after 3 
passages, representing day 0 of the differentiation experiment. Cells were kept in 
pluripotent culture conditions with mTESR1. 
5.2.9 CD34+ cell derivation from transduced hiPSCs with OP9 co-culture 
HPSC-derived CD34+ cells were generated with OP9 co-culture with the following 
differentiation efficiencies: untransduced 5.8%, mock transduced 9.8% and E4bp4 
transduced 8.6% CD34+ expressing cells (Figure 5.12). GFP expression slightly 
decreased to 51% in mock and 30.5% in E4bp4 transduced cells. CD34+ cells were 
enriched by CD34 MACS technology. The following purities of CD34+ expressing 
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cells could be achieved: untransduced 95%, mock transduced 96% and E4bp4 
transduced 80% (Figure 5.13).  
 
 
Figure 5.12 CD34 expression efficiency on day 9 of OP9 co-culture 
differentiation. GFP and CD34 expression was determined by flow cytometry in 
hiPSCs untransduced, mock and E4bp4 transduced cells. Blue histograms 
represent the isotype control staining and red histograms the specific staining.  
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Figure 5.13 CD34 MACS enrichment efficiency of OP9 co-culture derived 
CD34+ cells. GFP and CD34 expression was determined by flow cytometry in 
hiPSCs untransduced, mock and E4bp4 transduced cells. Blue histograms 
represent the isotype control staining and red histograms the specific staining. 
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5.2.10 E4bp4 overexpression does not improve cell expansion in NK cell 
differentiation  
To determine any improvements in the cell expansion potential of E4bp4 transdcued 
hiPSCs in GBGM differentiation, we documented total cell counts during in vitro NK 
cell generation (Figure 5.14). Our data suggest a slightly higher expansion of E4bp4 
transduced cells withing the first 10 days of culture when compared to untransduced 
and mock transduced cells (Figure 5.14). However, the maximum expansion did  
not exceed 5 fold with cell numbers decreasing significantly within the last 3 weeks 
of culture. 
 
 
Figure 5.14 Total cell numbers during NK cell differentiation. Total cell numbers 
of untransduced, mock and E4bp4 transduced cells were determined on day 7, 17, 
34 and 51 during differentiation. Day 7 represents the CD34+ HSC stage. 
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5.2.11 E4bp4 is consistently upregulated during NK cell differentiation 
To investigate if E4bp4 is overexpressed in E4bp4 transduced cells during 
differentiation, we collected RNA samples on days 0, 7, 17, 34 and 51 of in vitro NK 
cell generation in GBGM culture conditions. Relative expression of E4bp4 was 
determined by qRT PCR analysis, normalized to GAPDH. E4bp4 was 
overexpressed in E4bp4 transduced cells until day 34 in culture (Figure 5.15).  
 
 
 
Figure 5.15 Relative expression of E4bp4 during in vitro NK cell 
differentiation. The relative expression of E4bp4 and Id2 was determined by RT-
qPCR on day 0, 7, 17, 34 and 51 in cells of a 2-stage NK cell differentiation in vitro. 
Results are presented as Mean±SD, n=3 technical replicates. 
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5.2.12 E4bp4 transduced hiPSC-derived NK like cells differ in surface marker 
expression compared to untransduced and mock transduced cells 
To investigate if E4bp4 transduced hiPSC-derived NK like cells express NK cell 
specific surface makers to similar levels compared to untransduced and mock 
transduced cells, we analysed GBGM-derived cells in parallel by multi-colour flow 
cytometry on day 51. Cells were gated on the CD56+CD3- NK cell population and 
transduction efficiency is shown in histograms (Figure 5.16). Untransduced cells 
comprised of 48% CD56+CD3-, compared to 29% in mock transduced and 18% in 
E4bp4 transduced cells which was generally lower to what was observed in chapter 
4. Distinct CD56bright and CD56dim sub-populations could not be observed in hiPSC-
derived NK like cells. Interestingly, CD16 expression was highest in E4bp4 
transduced cells with 9% compared to 4% and 3% in mock transduced and 
untransduced cells, respectively. Furthermore, higher panKIR2D expression of 10% 
could be observed in E4bp4 transduced NK like cells, compared to 4% and 7% in 
mock transduced and untransduced cells, respectively. In contrast, CD94 
expression was highest in untransduced cells with 84%, 43% of mock transduced 
cells expressed CD94 and only 21% of E4bp4 transduced NK like cells. 
 
The NCR marker NKp44 and NKp30 expression was slightly lower in both mock and 
E4bp4 transduced cells compared to the untransduced control. NKG2D expression 
could be observed to a similar level in all three cell lines (Figure 5.16). 
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Figure 5.16 In vitro generated NK cells from MMC hiPSC-derived CD34+ cells 
on day 51 of feeder- and serum free GBGM differentiation method. (A) 
untransduced, (B) mock transduced, and (C) E4bp4 cells were analysed by multi-
colour flow cytometry using a panel of antibodies for NK cell specific surface 
markers. Cells for surface marker analysis were gated on the CD56+CD3- cell 
population. The percentage of GFP expressing cells is represented in the 
histogram. (C) Expression data in % are summarised in a bar chart, n=1. 
 
5.2.13 Can fibroblasts be driven towards the NK cell lineage by over-
expression of E4bp4 and culture in GBGM NK cell differentiation 
conditions? 
We aimed to investigate if the over-expression of E4bp4 - as master-regulator of the 
transcriptional NK cell program - can induce cells to acquire an NK cell like 
phenotype. To test this hypothesis, we transduced human fibroblasts with 
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pCCL.EF1α.E4bp4.IRES.eGFP lentivirus with MOI 20 and cultured cells in GBGM 
medium containing cytokines supporting NK cell development. Transdifferentiation 
of somatic cells would allow to by-pass the reprogramming to hiPSCs and the 
limiting differentiation step to HSCs (Figure 5.17). 
 
 
Figure 5.17 Schematic overview of transdifferentiation. 
 
Transduction efficiency of fibroblasts was assessed by the expression of GFP with 
flow cytometry 3 days post-transduction, cultured in fibroblast medium. A good 
proportion of cells had been transduced with 37% of cells expressing GFP. CD56 
was not expressed in fibroblasts (Figure 5.18). 
 
 
Figure 5.18 Transduction efficiency day 3 post-transduction of fibroblasts. (A) 
GFP expression (B) CD56 expression. 
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5.2.14 E4bp4 stays upregulated during cell culture  
On day 3 post-transduction, fibroblasts were cultured in conditioned medium 
containing half fibroblast medium and half GBGM Dif1 medium containing SCF, IL-
7, Flt3L, IL-15, G-CSF, GM-CSF and IL-6. On day 6 the medium ratio was changed 
to 25% fibroblast and 75% GBGM Dif1 medium and on day 12 to 100% GBGM 
medium containing SCF, IL-7, IL-15, IL-2, G-CSF, GM-CSF and IL-6. RNA samples 
were collected on days 3, 6, 10, 14 and 19 of culture. E4bp4 over-expression in 
pCCL.EF1α.E4bp4.IRES.eGFP-transduced cells could be observed throughout 
culture when compared to untransduced cells with highest expression on day 3. 
(Figure 5.19). 
To investigate if the transcriptional network is activated by the over-expression of 
E4bp4, we followed the expression levels of Tox and Id2 which have been shown to 
be regulated by E4bp4 (Male, Nisoli et al. 2014). No significant up-regulation of Tox 
or Id2 could be observed when compared to untransduced cells (Figure 5.19). 
These data suggest that the over-expression of E4bp4 is not sufficient to induce the 
NK cell specific transcriptional network in fibroblasts. 
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Figure 5.19 Relative expression of E4bp4, Tox and Id2 in fibroblasts over-
expressing E4bp4 and cultured in NK cell differentiation medium. The relative 
expression of E4bp4, Tox and Id2 was determined by RT-qPCR on day 3, 6, 10, 14 
and 19, normalized to GAPDH. Results are presented as Mean±SD, n=3 technical 
replicates.  
5.2.15 CD56 and IL-15RB are not upregulated in E4bp4 transduced cells 
We further investigated if CD56 and IL-15RB are upregulated in E4pb4 transduced 
cells. IL-15RB is a subunit of the IL-15 receptor and its upregulation is a crucial step 
in the development of early NK cell precursors and makes progenitors responsive to 
IL-15 stimulation. The study of Male et al. suggests, that E4bp4 regulates IL-15RB 
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expression as one of the first steps to induced NK cell progenitors (Male, Nisoli et 
al. 2014). We could not observe either CD56 or IL-15RB upregulation in E4bp4 
transduced (Figure 5.20).  
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Figure 5.20 Relative expression of CD56 and IL-15 RB in fibroblasts over-
expressing E4bp4 and cultured in NK cell differentiation medium. The relative 
expression of CD56 and IL-15 RB was determined by RT-qPCR on day 3, 6, 10, 14 
and 19, normalized to GAPDH. Results are presented as Mean±SD, n=3 technical 
replicates. 
 
To verify the CD56 expression on RNA level, we determined CD56 expression on 
the cell surface by flow cytometry on day 14 of culture. CD56 was expressed on 4% 
of both untransduced and E4bp4 transduced cells (Figure 5.21). These data 
suggest that no significant upregulation of CD56 was induced by E4bp4 
overexpression. 
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Figure 5.21 FACS analysis of GFP- and CD56-expressing cells on day 14 in 
adherent cells. (A) Untransduced and (B) E4bp4 transduced cells. Blue histograms 
represent unstained control and red overlay the specific staining. 
 
In summary our data suggest that the overexpression of E4bp4 does not upregulate 
the expression of Id2, TOX, CD56 and IL-15RB. We conclude that a single 
transcription factor might not be sufficient to induce NK cell lineage specific 
progenitors. 
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 Discussion 5.3
In the first part of this chapter we investigated if the overexpression of the NK cell 
specific transcription factor E4bp4 can drive NK cell differentiation from hiPSCs 
more efficiently. We received the mock and E4bp4 overexpression lentiviral vector 
from a collaborator and produced lentivirus in HEK293T cells. Interestingly, we 
observed low virus titer with both constructs, although the titer with the E4bp4 vector 
was significantly lower than the titer with the mock vector. Despite the low virus titer, 
we could efficiently transduce UCB-derived CD34+ cells with the mock lentivirus. 
Tdtomato reporter gene expression was still upregulated after 27 days of NK cell 
differentiation. However, transduction efficiency with the E4bp4 lentivirus was 
extremely low and the attempted sort did not yield enough transduced cells for 
further analysis. After preparing more virus preps with comparably low titer we 
needed to investigate why tdtomato in the E4bp4 lentivirus is less expressed. We 
believe that the low expression efficiency could be caused by the location of E4bp4 
within the lentivirus plasmid. E4bp4 is located in front of an internal ribosome entry 
site (IRES) followed by tdtomato. IRES sites aim to improve the transcription of 
genes located further away from the promoter, but expression of tdtomato could still 
be hampered in this set up. Based on these observations, we decided to clone 
E4bp4 into the pCCL lentiviral vector backbone. Expression in this vector was 
driven by the EF1α promoter and GFP was included as the reporter gene. Higher 
titers could be achieved with this construct for both, mock and E4bp4, although we 
still observed lower GFP expression with the E4bp4 overexpression virus. Produced 
virus could efficiently transduce Jurkat and HEK293T cells and overexpression of 
E4bp4 could be detected on both RNA and protein level. MMC hiPSCs could be 
efficiently transduced with both, mock and E4bp4 lentivirus, and cells could be 
expanded in their pluripotent state without losing expression from the lenti vector. 
This was an important observation because hiPSCs can be expanded well in the 
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pluripotent state which opens possibilities to bulk, freeze, sort transduced cells or 
even genetically modify further. Transduced MMC hiPSCs were differentiated with 
the established 2-step NK cell differentiation system, including OP9 co-culture, 
CD34 MACS enrichment and further differentiation with GBGM medium and 
cytokines. CD34+ cells could be generated to comparable levels as observed in 
Chapter 3. We noticed lower purity of the CD34+ enriched cell population 
transduced with E4bp4 compared to untransduced and mock transduced cells. This 
is possibly due to a variation in MACS enrichment as CD34 percentages before 
sorting were not significantly lower than observed in mock transduced cells. E4bp4 
did not influence the cell expansion during NK cell differentiation and expansion in 
untransduced, mock transduced and E4bp4 transduced cells did not exceed 5 fold 
with cell numbers decreasing after 17 days of differentiation. E4bp4 upregulation 
could be detected throughout the differentiation on RNA level, although a drop of 
E4bp4 expression could be detected in all cell lines on day 34 and 51. We believe 
that this might be due to limited cell numbers collected for analysis. Despite the poor 
cell expansion we generated enough NK like cells which were analysed by a multi-
colour flow cytometry panel after 51 days of differentiation. Consistent with our 
previous observations, NK like cells could not be classified as classical CD56dim and 
CD56bright sub-populations although interestingly, CD16 and panKIR2D expression 
and was highest in E4bp4 transduced cells. Surprisingly, CD94 expression was 
lower in E4bp4 transduced cells compared to mock transduced cells. I aimed to 
gate on the GFP+ and GFP- populations to identify if transduced cells exhibit a 
different phenotype compared to mock transduced cells. This approach would have 
been extremely helpful to identify differences in marker expression, especially CD16 
and KIR as these were expressed to higher levels in E4bp4 transduced cells. For 
this experiment a higher cell number would have been needed to be acquired as the 
low event count did not allow to perform an accurate analysis of GFP+ or GFP-
194 
 
The percentage of transduced cells on day 51 of differentiation was 17%. Possibly, 
a phenotype is difficult to determine with less than a quarter of cells being 
transduced. For further experiments, cell sorting before differentiation would have 
been an option. In general, the interpretation of these results needs to be done with 
caution as repeated experiments would have been necessary. Unfortunately, due to 
time constraints this was not possible. Furthermore, we questioned if the 
established 2-step NK cell differentiation method was the best platform to study 
transcription factor driven differentiation, because of hurdles with cell numbers and 
expansion. 
 
In the second part of this chapter we investigated if NK cells can be generated 
directly from fibroblasts by overexpression of E4bp4, without the need of 
reprogramming and subsequent forward differentiation. Transdifferentiation with a 
single transcription factor has been an ambitious aim. There are many prove-of-
principle studies published on transdifferentiation into various cell types, reviewed in 
(Pfaff and Cantz 2013). However, in most cases, a combination of several TFs is 
necessary to activate the cell type specific transcriptional network. Since E4bp4 has 
been described as a master regulator acting very early in murine NK cell 
development (Male, Nisoli et al. 2014) and we had functional virus already 
produced, we overexpressed E4bp4 in human fibroblasts and cultured them in NK 
cell differentiation conditions with GBGM. E4bp4 was upregulated on RNA level 
throughout culture of 19 days. Upregulation of the transcription factors Tox and Id2, 
which are regulated by E4bp4 during NK cell development (Male, Nisoli et al. 2014), 
could not be observed. Furthermore, CD56 and IL-15RB were not upregulated 
during culture. These data suggest that the overexpression of E4bp4 alone in 
fibroblasts is not sufficient to activate the NK cell specific transcriptional network.  
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Although our hypotheses could not be confirmed, we have shown that TFs can be 
efficiently overexpressed in hiPSCs by lentiviral transductions and expression can 
be maintained over the long differentiation period of 51 days. This would provide a 
platform for further studies including the overexpression of an array of TFs (e.g. Id2, 
Tox, Eomes, etc).  
We further hypothesized that common lymphoid progenitors (CLPs) would be driven 
towards NK cell progenitors more efficiently by E4bp4 overexpression. We did not 
investigate the percentage of CLPs in the MACS enriched CD34 population, but 
numbers are probably relatively low.  
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Chapter 6 General Discussion and Outlook 
 
Harnessing the body’s own immune system to fight virally infected or cancerous 
cells and even autoimmune disease has enormous clinical potential and has already 
improved the short comes of currently available therapies. The fast moving field of 
immunotherapy encompasses a variety of approaches including therapeutic 
antibodies, antigen-specific redirection of cytotoxic lymphocytes via chimeric antigen 
receptor (CAR) or T cell receptor (TCR) and the adoptive cell transfer of ex vivo 
expanded lymphocytes. NK cell-based immunotherapies have shown great promise 
in the treatment of various malignancies and different applications are under 
investigation. The important role of NK cells in the anti-tumour effect of therapeutic 
antibodies has been well studied, revealing that efficacy occurs via ADCC 
(Muntasell, Ochoa et al. 2017). Other approaches of NK cell-based therapy include 
in vivo expansion with cytokines, autologous or allogeneic NK cell transfer, the use 
of NK cell lines and genetically modified NK cells expressing chimeric antigen 
receptors to improve target cell recognition and cytotoxicity. The need of high 
numbers of pure and functional NK cells for immunotherapy is critical.  
The in vitro derivation of large numbers of functional lymphocytes from hPSC 
sources has huge potential for immunotherapy. In contrast to umbilical cord blood 
HSCs, hiPSCs can be theoretically expanded unlimited whilst remaining their 
pluripotent characteristics. This further provides a platform for genetically modifying 
cells before differentiating them into the lineage of interest whereas genetic 
modifications on UCB-derived CD34+ cells are less efficient. The combination of 
iPSC technology with CRISPR/Cas9-mediated gene editing of autologous cells has 
enormous potential for treatment of haematopoietic diseases (Hendriks, Warren et 
al. 2016). 
197 
 
In addition, NK cell therapy with UCB-derived NK cells is dependent on cord blood 
donations with the desired tissue type. NK cells generated from hPSCs could 
overcome this limitation by establishing a cell database covering all MHC classes 
and providing an off-the-shelf cell therapy. 
In vitro differentiation of haematopoietic precursors from hPSCs has been 
extensively explored in the literature. Although the differentiation of various mature 
haematopoietic cells has been proven, the generation of HSCs, which are able to 
engraft and reconstitute the entire haematopoietic system, remains challenging. 
HiPSCs could provide an alternative cell source for haematopoietic stem cell 
transplantation which is used in a variety of malignant and non-malignant 
haematopoietic disorders. However, these treatments are limited to the amount and 
quality of HSCs and their differentiation potential. The HLA immuno-compatibility of 
donor and recipient remains problematic, limiting the access of HSCs for successful 
therapy. Furthermore, the maturation status of hPSC-derived cells is still a concern. 
Differentiated cells for transfer could retain oncogenic potential and the use of these 
cells remains a safety issue. Non-nucleated hPSC-derived cells like erythrocytes 
and platelets would avoid the risk of tumourigenicity and are therefore extremely 
suitable for hiPSC-derived cell therapies. 
We adopted OP9 co-culture for HSC differentiation from hiPSCs which worked most 
robust and reproducible in our hands. CD34 is not a unique marker for HSCs, but 
also for mesenchymal and endothelial cells. HSCs are often characterized by the 
lack of lineage specific marker and co-expression of CD117, CD133 and CD90. 
These markers are also expressed in hPSCs which makes it difficult to distinguish 
hPSCs and HSCs. The assumption that all CD34-expressing cells have 
haematopoietic differentiation potential – as seen with UCB-derived CD34+ cells – is 
probably misleading. Sorting for CD34+CD45+ or CD34+CD43+ double positive cells 
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could narrow down the HPC fraction. This could have further improved the fold 
expansion in NK cell differentiation, because the starting cell number of “proper” 
HPCs would have been lower. On the other side it might be possible that hiPSC-
derived CD34+ cells are primed towards the myeloid lineage at the time of sorting. 
To address this, cells could be collected at different time points in OP9 co-culture 
differentiation and could be sorted for an earlier developmental stage like 
haemogenic endothelium.  
Studies of HSC generation with the EB method describe higher efficiencies of HPCs 
and mature haematopoietic cells can be generated in the absence of feeder cells, 
serum and cell sorting (Knorr, Ni et al. 2013). Unfortunately, in our hands we could 
not successfully derive HSCs and NK cells using EB method. Although the 
differentiation with OP9 co-culture was most robust in our experience, the 
disadvantage of this method is that the feeder cells and use of serum are non-GMP-
compliant. To potentially take this differentiation method to GMP conditions it is of 
interest to study the mechanism of OP9 co-culture and how haematopoietic 
development is induced. To investigate if differentiation is induced by cell-cell 
interactions, experiments using transwell plates could be explored. These plates 
allow a co-culture of cells - without direct cell-cell contact through a permeable 
membrane – to identify if differentiation is still facilitated without direct contact. If 
cell-cell interactions are necessary, the study of receptors and ligands involved will 
shed light on the mechanism.If secreted factors only play a role, the medium of the 
feeder cells could be analysed for growth factors and cytokines etc. These studies 
will help to mimic the differentiation conditions in a GMP-compliant environment 
without the need of feeder cells. 
In addition to these studies, a better understanding of the niche environment in vivo 
and how to recapitulate it in vitro will provide vital information. Bone marrow is a 
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hypoxic environment and future studies could explore hypoxic conditions for 
differentiation. A better understanding of factors within the bone marrow niche will 
provide important information for replicating the same environment in vitro.  
Furthermore, understanding the intrinsic and extrinsic factors that govern 
haematopoietic development in vivo is necessary to mimic conditions in in vitro 
differentiation. This knowledge will help to improve lineage commitment more 
efficiently by activating certain pathways like Nodal and Wnt signalling or adding 
factors like BMP4 to induce early specifications in haematopoiesis (reviewed in 
(Ackermann, Liebhaber et al. 2015)). 
In addition, hiPSC-derived HSCs could be in a quiescent or dormant state - 
comparable to HSCs residing in the BM in vivo. By activating certain pathways 
these cells can temporarily exit this state and begin to actively divide to provide a 
wider pool of cells for further differentiation. An example is the activation of IFN 
signalling with an acute dose of IFN-α, which has been shown to stimulate the self-
renewal and proliferation of HSCs in vivo (Essers, Offner et al. 2009). Furthermore, 
Notch and Wnt signalling play a fundamental role in haematopoietic self-renewal 
and differentiation. Notch signalling is important for inhibition of differentiation and 
Wnt-mediated signalling for keeping HSCs in their undifferentiated state (Duncan, 
Rattis et al. 2005). Future lines of investigation could include the identification of 
important pathways for self-renewal to activate hPSC-derived HSCs and test if cell 
expansion can be improved by adding factors like IFN-α or Notch ligand Jagged1. 
The comparison of gene expression profiles of hPSC-derived HSCs, UCB-derived 
and bone marrow HSCs (long-term and short-term) with RNA sequencing could give 
insights into differences in transcriptional regulations. A cell proliferation assay (e.g. 
BrdU or CellTrace) could have been helpful to investigate cell proliferation potential. 
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Despite the low cell expansion of hPSC-derived CD34+ cells in NK cell 
differentiation conditions, NK like cells can be generated. It is of importance to note, 
that NK cell differentiation experiments in this project have been conducted with one 
hiPS cell line due to the complexity and time constraints of experiments. 
Importantly, further studies will have to include a variety of hES and hiPS cell lines 
to take variations between different cell lines into account.  Future experiments need 
to explore the functional properties of hiPSC-derived NK cells. These experiments 
could include chromium release assays or degranulation assays to test killing 
efficacy of different tumour cell lines or primary tumour tissue. Furthermore, cytokine 
release upon activation would be of great interest. In our experiments, the cell 
surface marker phenotyping with multi-colour flow cytometry was limited by number 
of fluorochromes in one panel. Future experiments using RNA sequencing will give 
more insights into gene expression levels of a variety of NK cell specific genes and 
perforin and granzyme expression upon activation. Furthermore, a detailed 
comparison of gene expression in hiPSC-derived NK cells compared to UCB-, 
PBNK and possibly tissue specific NK cells would have been interesting. 
To improve cell expansion, future experiments could explore the culture of hPSC-
derived NK cells on IL-21 expressing aAPCs. Knorr et al. reported 1000 fold 
expansion over 70 days of aAPC culture (Knorr, Ni et al. 2013). Taken together, the 
differentiation process, including expansion, would take over 110 days. 
Furthermore, the extremely long culture duration in addition to over-activation of NK 
cells might lead to exhaustion and decreased functional activity of NK cells. 
To overcome limitations of conventional in vitro HSC differentiation directed by 
cytokines and morphogens, direct differentiation with transcription factors has been 
reported in the literature. Doulatov et al. showed that the overexpression of 5 TFs in 
myeloid progenitors - derived with iPSC-EB differentiation – leads to lymphoid 
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generation and myeloid and erythroid engraftment potential in mice (Doulatov, Vo et 
al. 2013). A further study screened a library of 27 TFs to identify candidates able to 
induce the haematopoietic program. This study shows that the over-expression of 
ETV2 and GATA2 can induce myeloid and GATA2 and TAL1 can induce erythro-
megakaryocytic programs in human ESCs and iPSCs (Elcheva, Brok-Volchanskaya 
et al. 2014). 
Transdifferentiation of one somatic cell type to another, without the requirement of 
reprogramming to a pluripotent state, is an alluring option with less safety concerns. 
This powerful technique has been applied to converse a variety of somatic cells to 
other lineages as reviewed in Figure 5.1 (Pfaff and Cantz 2013). This approach 
further allows to by-pass the limiting step of HSC differentiation. Pereira et al. 
transduced mouse embryonic fibroblasts (MEFs), which carried a CD34 reporter 
mechanism, with a library of 18 TFs. Data suggest that Gata2 and Etv6 as well as 
Gfib and Fos are sufficient to induce the haematopoietic lineage (Pereira, Chang et 
al. 2013). Another study overexpressed 6 TFs, including Gata2 and Runx1c, which 
generated haematopoietic progenitors with short-term engraftment in vivo (Batta, 
Florkowska et al. 2014). Transdifferentiation studies have also been performed with 
human somatic cells. Sandler et al. transduced non-hemogenic umbilical cord and 
adult endothelial cells with TFs including Runx1 and Gfi-1. Colony forming potential 
as well as engraftment could be observed in humanized mice after 4 weeks of in 
vitro culture (Sandler, Lis et al. 2014).  
Taken together, these studies show the feasibility of TF-driven differentiation and 
cell fate conversion. Future studies on TF-driven NK cell differentiation will have to 
include a library of TFs of interest which can be narrowed down at a later stage. 
Possibly, a combination of NK cell specific and HSC specific TFs could be used to 
improve lineage specification towards the haematopoietic program.     
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